Community Hospital of the Monterey Peninsula Expands Eclipsys Relationship to Create Enterprise-Wide Electronic Medical Record

Eclipsys Corporation(R), (NASDAQ:ECLP), The Outcomes Company(R), today announced that California-based Community Hospital of the Monterey Peninsula (Community Hospital) will expand its use of Eclipsys solutions by activating Sunrise Ambulatory Care(TM) in outpatient facilities and other settings to create a unified electronic medical record (EMR) across its enterprise. Once complete, the ambulatory initiative will leverage its integration with Community Hospital’s inpatient EMR technology infrastructure to provide all Community Hospital’s caregivers a shared view of information related to the patient’s previous visits in support of enhanced patient experiences and improved care coordination.

“Eclipsys has proven to be a valuable partner to us, facilitating smooth activations and collaborative consultation on leveraging solutions to make a significant and measurable positive impact on our care delivery and our bottom line,” said Steve Packer, MD., Community Hospital chief executive officer. “We look forward to working with them on this new initiative to extend the power of Eclipsys’ EMR solutions to make it much easier for our care providers to make quicker, more informed care decisions that can lead to enhanced patient outcomes.”

The ambulatory initiative builds on Community Hospital’s highly successful, simultaneous enterprise-wide activation of Eclipsys’ Sunrise Clinical Manager (TM) (SCM) suite of clinical solutions and Sunrise Patient Financials(TM). In combination, these applications, which are integrated components of the Sunrise Enterprise(TM) solution suite, have positively impacted Community Hospital’s care quality and financial performance. The hospital has successfully standardized and automated healthcare processes, made vast improvements in inter-disciplinary communications, and streamlined information flow to make patient care more efficient across acute care settings, including critical care and the emergency department.

The integration capabilities of Sunrise Patient Financials has not only enabled Community Hospital to streamline patient financial workflow, improve bill collections and raise its clean-claim submission rate to 90 percent, it played an important part in the community hospital achieving its strategic goals for expansion. Community Hospital’s significant improvement in accounts receivable days outstanding has enhanced cash flow and enabled the hospital to repay, in advance, a large loan for the construction of a new, digital hospital building.

A component of Sunrise Enterprise, Sunrise Ambulatory Care resides within the Eclipsys XA(TM) architecture and offers the advantage of supporting a single enterprise medical record across all settings of care with a single clinical decision support system, as well.

“We are proud of our history and strong relationship with Community Hospital, and we look forward to working with them as they focus to continually improve and extend their healthcare delivery system,” said Jay Deady, Eclipsys executive vice president of Client Solutions. “We believe this partnership is a great example of how our integrated ambulatory solution offers an existing SCM client a tremendous opportunity for clinical and operational outcome achievement.”

About Community Hospital of the Monterey Peninsula

Community Hospital of the Monterey Peninsula, located in Monterey, California, was founded in 1934 and has grown and evolved in direct response to the changing healthcare needs of the people it serves. Today, it is a nonprofit, integrated healthcare delivery system providing a continuum of care from birth to end of life, and every stage in between. It serves the Monterey Peninsula and surrounding communities through 15 locations, including outpatient facilities, satellite laboratories, a mental health clinic, a short-term skilled nursing facility, Hospice of the Central Coast, and business offices.

About Eclipsys

Eclipsys is a leading provider of advanced integrated clinical, revenue cycle and business process improvement software, clinical content and professional services that help healthcare organizations improve clinical, financial and operational outcomes. For more information, see www.eclipsys.com or email [email protected].

Statements in this news release concerning the timing of features and benefits provided by Eclipsys software, content and implementation services are forward-looking statements and actual results may differ from those projected due to a variety of risks and uncertainties. Implementation and customization of Eclipsys software is complex and time-consuming. Results depend upon a variety of factors and can vary by client. Each client’s circumstances are unique and may include unforeseen issues that make it more difficult than anticipated to implement or derive benefit from software, content or services. The success and timeliness of the company’s services will depend at least in part upon client involvement, which can be difficult to control. Eclipsys is required to meet specified performance standards, and the contract can be terminated or its scope reduced under certain circumstances. More information about company risks is available in recent Form 10-Q and 10-K filings made by Eclipsys from time to time with the Securities and Exchange Commission. Special attention is directed to the portions of those documents entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Eclipsys Corporation and The Outcomes Company are registered trademarks of Eclipsys Corporation. Sunrise Ambulatory Care, Sunrise Clinical Manager, Sunrise Patient Financials, Sunrise Enterprise and Eclipsys XA are trademarks of Eclipsys Corporation. Other product and company names in this news release are or may be trademarks and/or registered trademarks of their respective companies.

Members Sue National SEIU Officers

OAKLAND, Calif., Sept. 18 /PRNewswire-USNewswire/ — Twenty-eight elected rank-and-file members of SEIU United Healthcare Workers-West (UHW) filed a lawsuit against SEIU President Andy Stern and Secretary-Treasurer Anna Burger charging the two national officers violated SEIU members’ right to free speech and equal participation in their union, guaranteed by Title I of the U.S. Labor Management Reporting and Disclosure Act.

The lawsuit filed Wednesday charges that Stern “has engaged in a relentless and pervasive campaign that … intimidated and chilled dissent and criticism of his policies, decisions and actions.” Further, the suit charges that Stern used millions of dollars of SEIU members’ dues money to finance this internal war aimed at orchestrating the “implosion” of the 150,000-member healthcare union.

“A union is supposed to be a way for workers to strengthen our own voices by joining together,” said Michael Torres, a respiratory therapist at USC University Hospital in Los Angeles and a plaintiff in the suit. “It’s unbelievable that Andy Stern and Anna Burger would go to these extremes to weaken our union and silence SEIU members. These attacks are worse than what we’ve seen from even our worst anti-union employer.”

[Read the lawsuit: http://www.seiuvoice.org/downloads/FILED_COMPLAINT.pdf]

The lawsuit cites a private email from national SEIU official Bill Regan to other top SEIU officials including Stephen Lerner, Thomas Debruin, Kirk Adams, Denise Poloyac and counsel Edgar James. The email does not mention concerns about UHW’s finances or any other legitimate grounds for trusteeship. Instead, the email reveals that the goal of the effort was to remove UHW’s elected leaders for political reasons.

It outlines a secret plan by top SEIU officials to use whatever means necessary to remove UHW’s elected leaders, including orchestrating the “implosion” of UHW, dismembering the union by abusing SEIU’s power over local union jurisdiction, exploiting “pockets of dissatisfaction” among UHW members, recruiting away key local union staff, filing lawsuits against UHW, initiating regulatory actions against UHW with the U.S. Department of Labor, and taking control of UHW through a trusteeship. SEIU has scheduled a trusteeship hearing for UHW next week.

   SEIU members' lawsuit charges that Andy Stern and Anna Burger:    --  sought a trusteeship of UHW for political purposes and in violation of       requirements set out in federal law and in SEIU's Constitution;    --  spread lies about UHW's elected leaders among UHW members - using       mailings leaflets and recorded phone calls - seeking to undermine       members' confidence in their elected leaders, and among SEIU locals to       remind all members and officers of the consequences of dissent;    --  collaborated with anti-union employers to undermine UHW's organizing       and collective bargaining efforts;    --  knowingly filed a frivolous lawsuit as a public relations handle for       attacking UHW's elected leaders;    --  "carpet-bombed" the entire SEIU leadership nationwide with negative       publicity, attacks and threats of retaliation aimed at UHW, sending an       unmistakable message that any dissent would be met with an iron fist.   

The suit notes that Stern and Burger sought to weaken UHW by forcing 65,000 long-term care members into SEIU Local 6434, whose president, Stern protege Tyrone Freeman, is now under investigation for possible fraud.

UHW’s more than 80 rank-and-file executive board members work in hospitals, homecare, and nursing homes across California, and are elected by their co-workers to lead the union. A trusteeship would replace them with one appointed trustee accountable only to Stern and Burger in Washington, D.C.

With more than 150,000 members, SEIU United Healthcare Workers-West is the fastest-growing healthcare union in the United States. We represent healthcare workers in all job classifications and all healthcare settings, including hospitals, homecare, nursing homes and clinics. Our mission is to achieve high-quality healthcare for all.

Contact Sadie Crabtree, 323-365-2083

SEIU United Healthcare Workers-West

CONTACT: Sadie Crabtree of SEIU United Healthcare Workers-West,+1-323-365-2083

Web Site: http://www.seiu-uhw.org/http://www.seiuvoice.org/

James R. Thomas Appointed President of South Atlantic Division

NASHVILLE, Tenn., Sept. 18 /PRNewswire/ — HCA today announced James R. Thomas has been appointed President of HCA’s South Atlantic Division in Charleston, S.C., effective September 1.

As President of the newly-formed division, Thomas, 56, is responsible for HCA’s seven hospitals and seven ambulatory surgery centers in Charleston, Myrtle Beach and Jacksonville, Fla. These hospitals had previously been part of HCA’s Carolina Market and Jacksonville Market.

“Jamie is a 28-year veteran of healthcare administration and is well-respected,” said Chuck Hall, President of HCA’s Eastern Group. “Under his leadership and with the new division support, our South Atlantic Division hospitals are positioned for continued success.”

Most recently, Thomas was CEO of HCA’s North Florida Regional Medical Center in Gainesville, Fla. He joined HCA in 1992 as Vice President of Operations at Coliseum Medical Center in Macon, Ga. He later served as CEO of other HCA facilities, including Redmond Regional Medical Center in Rome, Ga.

Before joining HCA, Thomas served as Senior Vice President – Operations at Charter Medical Corporation, managing 25 behavioral health hospitals in six southeastern states, among other leadership roles with the company.

Thomas obtained his master’s in health administration and master’s degree in teaching from Duke University and a bachelor’s degree in religion from the University of North Carolina in Chapel Hill, N.C. He is an active board member of the United Way of Alachua County and the Gainesville Chamber of Commerce and a trustee of the Florida Hospital Association. He and his wife, Emily, have two sons, John and William.

HCA also announced Rodney VanPelt, 52, has been named the South Atlantic Division’s Chief Financial Officer.

Most recently, VanPelt served as CFO of the Jacksonville Market and simultaneously as CFO of Memorial Hospital Jacksonville. He began his career with HCA in 1976 as a staff auditor in the company’s internal audit department. After serving as CFO for several HCA hospitals, he became CFO of HCA’s Wichita Division in 1994 and later the Group CFO for HCA’s Western Psychiatric Group including 26 hospitals. After a brief stint away from the company, he returned to HCA as CFO of Memorial Hospital in 1999. He holds a bachelor of science in business administration from Florida State University and is a certified public accountant. VanPelt and his wife, LuAnn, have a daughter, Laurie, and a son, Andrew.

All references to “Company” and “HCA” as used throughout this document refer to HCA Inc and its affiliates.

HCA

CONTACT: Investors, Mark Kimbrough, +1-615-344-2688; Media, Ed Fishbough,+1-615-344-2810, both for HCA

Web site: http://www.hcahealthcare.com/

Mission Hospital Contracts With Best Upon Request to Provide Concierge Services As a Patient Benefit

Mission Hospital patients and their families now have access to an on-site concierge service provided by Cincinnati-based Best Upon Request to help reduce the stress associated with being a hospital guest. The complimentary concierge service is available to assist with making special arrangements for visitors, food requests, personal errand-running and more.

“Imagine being admitted to the hospital unexpectedly and not having time to make arrangements for your time away,” said Peter F. Bastone, president and chief executive officer of Mission Hospital. “Through our partnership with Best Upon Request, patients and their families have the benefit of a personal concierge to take care of the little things that make a patient’s stay more comfortable.”

Tillie Hidalgo Lima, president/CEO of Best Upon Request said, “We are committed to reducing the demands and stresses of patients during their time in the hospital so they can focus on healing. Our partnership with Mission Hospital is a testament to their mission of improving the quality of life of people in the community they serve.”

Mission Hospital is committed to providing a high level of care to the community, a critical component to being a compassionate leader in patient- and family-centered care. Best Upon Request concierge services are provided free of charge; patients only pay costs for goods and services, and mileage over 10 miles.

About Mission Hospital

Mission Hospital is a 301-bed acute care, full-service facility serving all of south Orange County and houses the region’s designated trauma center, one of only three in the county. Located in Mission Viejo, Mission Hospital offers a complete array of top-quality healthcare services including Mission Regional Trauma Center and 24-hour emergency care; Mission Imaging Center offering the most advanced diagnostic care, Mission Heart Center providing cardiac rehabilitation and chest pain center; Mission Maternity Center including special care for high risk pregnancy; Mission Women’s Wellness Center offering comprehensive breast, heart and pelvic care; and Mission Stroke Center, offering the region’s most comprehensive neurological care and is a certified Primary Stroke Center. Mission Hospital also offers the highest level of care in orthopedics, rehabilitation, cancer, spine and vascular services. A member of the St. Joseph Health System, the hospital is one of 14 not-for-profit hospitals sponsored by the Sisters of St. Joseph of Orange. Children’s Hospital of Orange County (CHOC) at Mission, a separately licensed pediatric hospital representing a unique partnership with Mission Hospital and CHOC, is located on the top floor of Mission Hospital’s patient tower.

About Best Upon Request

Established in 1989, Best Upon Request is a national certified Minority and Women Business Enterprise offering on-site concierge services as an innovative approach to holistic, patient-focused care, as well as a viable and highly utilized employee benefit. Best Upon Request’s clients view concierge services as a critically advantageous component to being Employer of Choice and increasing patient satisfaction.

Visit Best Upon Request online at www.bestuponrequest.com

Family Donates Another $2 Million to AAMC

By SCOTT DAUGHERTY Staff Writer

When a Davidsonville family gave Anne Arundel Medical Center $3 million in 2003 to help fund a cancer institute, it was the largest private donation in the 106-year-old hospital’s history.

But that wasn’t enough for the DeCesaris family.

JoAnn DeCesaris, the matriarch of the family, announced a $2 million donation yesterday to support a new Pediatric Emergency Department and Inpatient Unit.

“AAMC’s vision to gear this new unit toward children and children only is really what prompted our family’s second gift to the medical center,” she said in a prepared statement. “Children need specialized care, especially in an emergency room, and when you think of the number of regional families that will need access to this kind of care, this unit just makes sense.”

According to the hospital, nearly 15,000 children visited the AAMC emergency room last year. In all, the emergency room handled more than 72,000 visits.

Justin Paquette, spokesman for AAMC, said the new pediatric emergency room and inpatient unit will allow doctors to treat children separate from adult patients. The unit will be located on the first floor of AAMC’s new patient tower, a $153 million project expected to open in 2010.

“The new emergency department will be the only such location in Anne Arundel County designed specifically to care for sick and injured infants, children, and teenagers,” said Dr. Michael Clemmens, an AAMC pediatrician.

Mr. Paquette described the DeCesaris family as “a pillar of AAMC.”

After Mrs. DeCesaris and her husband, Geaton, donated $3 million to AAMC in 2003, the hospital named its new cancer institute in their honor. Mr. Paquette said the Geaton and JoAnn DeCesaris Cancer Institute now has more than 22,000 treatment visits a year.

Mr. DeCesaris, former president and CEO of Washington Homes and later president of the Hovnanian Land Investment Group, died in April 2006 of non-smoker’s lung cancer. He was 50 and left behind five daughters, two sons-in-law and five grandchildren.

Mr. DeCesaris, a Washington, D.C., native, was diagnosed with cancer six weeks before he made the $3 million donation. In the months that followed his diagnosis, he underwent chemotherapy and major thoracic surgery, which included the removal of the lining of the lung.

His family credited a pre-surgery pilgrimage to holy sites in Fatima, Portugal, and Lourdes, France, with stymieing the illness.

Mrs. DeCesaris said the latest donation was made in the spirit of her late husband.

“I think this gift would fall right in with ways he envisioned helping the people in the region, many of them new parents,” she said.

Before his death, Mr. DeCesaris talked about how he’d like to help the AAMC emergency room, she said.

“He talked about how to positively impact the care of an entirely different patient population than those helped in the cancer institute. This donation will help make that impact a positive reality,” Mrs. DeCesaris said.

Lisa Hillman, executive director of the AAMC Foundation, credits the DeCesaris family with bringing more to the hospital than their $5 million in donations.

“The DeCesaris family is tremendous in their recognition of the needs of this region,” she said. “They are more than donors; they are really partners in helping AAMC deliver care. Our hospital is extremely fortunate to have their support.” {Corrections:} {Status:}

DECESARIS GIFT WILL HELP BUILD PEDIATRIC EMERGENCY ROOM

(c) 2008 Capital (Annapolis). Provided by ProQuest LLC. All rights Reserved.

Researchers Say Some Antibiotic Use Linked To Cerebral Palsy

British researchers said on Thursday a once-used practice of giving antibiotics to some women at risk of premature birth may have increased the odds their children will develop cerebral palsy and other problems.

The study looked at women at risk of premature labor who had no signs of infection. Doctors now recommend antibiotics only for women whose waters have broken prematurely or have an obvious infection.

Sara Kenyon, a researcher at the University of Leicester who led the study, said the findings reaffirm that doctors should not use antibiotics for premature labor when the mother’s water is intact and if there is no infection.

The researchers believe cerebral palsy is unlikely to be a direct effect of the antibiotic but rather due to factors involved in prolonging a pregnancy that might otherwise have delivered early.

“We don’t think it is the antibiotics themselves but rather the situation the antibiotics are given in,” she said. “These findings mean doctors do not need to give antibiotics if a woman’s water hasn’t broken unless she has an infection.”

Kenyon said smoking, alcohol use and weight problems can increase the chances of premature labor. While it was known children born prematurely are more prone to functional problems later in life, the link to cerebral palsy was unexpected.

The researchers followed up 9,000 children from the original trial at age 7 and used a health questionnaire and national school results to gauge the children’s health.

Data showed that children whose mothers were given the antibiotic erythromycin had an 18 percent higher risk of mainly mild functional problems that also included struggles with day-to-day problem solving compared to those whose mothers did not receive the drug.

The other antibiotic, co-amoxiclav, did not appear to raise such risk.

The researchers wrote in the report that the risk of cerebral palsy was increased by either anti-biotic, although the overall risk of this condition was low.

But for women whose water did not break and who got both antibiotics together, the chance their children would develop cerebral palsy nearly tripled.

However, the overall risk was low and researchers do not know why the combination of antibiotics and an intact membrane in women whose water did not burst appeared to affect some children.

Cerebral palsy can cause physical impairments and mobility problems and results from the failure of a part of the brain to develop before birth or in early childhood or brain damage and affects one in 400 births.

On the Net:

Competitive Technologies Signs Agreement for Distribution of Pain Management Device

FAIRFIELD, Conn., Sept. 18, 2008 (GLOBE NEWSWIRE) — Competitive Technologies, Inc. (AMEX:CTT) announced today that it has signed an agreement with Biogene Pharma Limited granting them exclusive distribution rights in Bangladesh for CTT’s pain management therapy device. CTT is in the process of selecting distributors from a targeted list of companies representing the U.S. and global markets in Europe, Asia and Latin America. The device is a non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. CTT will share in revenue derived from sales of the device to Biogene.

Biogene, based in Dhaka, Bangladesh, provides medical devices and equipment, and pharmaceutical and healthcare services to medical facilities and organizations throughout their country.

“Biogene provides CTT with a strategic partner in Bangladesh,” said Aris D. Despo, CTT’s Executive VP, Business Development. “Their population of over 150 million people represents a key market for our innovative pain management technology. Bangladesh benefits from the committed activities of both international and national organizations to improve private and public health care systems throughout the country.”

Dr. Shafaitul Islam, Biogene’s Chairman, commented, “We are very pleased to work with CTT to bring this important device to the people of Bangladesh. It is our goal to improve the well-being of our community, and to strengthen and improve the medical capabilities of our country’s healthcare facilities.”

John B. Nano, CTT’s Chairman, President and CEO, noted, “We believe that our revenue and profits from the pain management technology will dramatically exceed those produced by any other technology in CTT’s 40-year history. CTT is aware of the needs expressed worldwide for treatment of pain, and is pleased to be a part of the solution as we aggressively market the device to meet those needs. There is exciting potential for the success of this device in the global pain management market; a market estimated to reach $40 billion by 2010.”

Developed in Italy by CTT’s client, Prof. Giuseppe Marineo, the device was brought to CTT through the efforts of Prof. Giancarlo Elia Valori of the Italian business development group, Sviluppo Lazio S.p.A., and assistance from the Zangani Investor Community(tm). The device, with a biophysical rather than a biochemical approach, uses a multi-processor able to simultaneously treat multiple pain areas by applying surface electrodes to the skin. CTT has exclusive worldwide rights to the therapy device. CTT partner GEOMC Co., Ltd. of Korea, is producing the device commercially for worldwide distribution.

The device has been used on over 2,300 patients in seven hospitals in Europe, including the Pain Management Center at Tor-Vergata University Medical Center in Rome (http://www.ptvonline.it/uo_ter_ant_ing.asp).

CTT has exclusive worldwide rights to the device. An earlier agreement gave Excel Life Sciences, Inc. exclusive distribution rights for the device in India. CTT is working with the FDA for 510(k) approval for sales of the device in the U.S. market. The device has Medical Device CE certification from the European Union allowing European sales.

About Biogene Pharma Limited

Biogene, formed in 2003, is a Bangladesh-based provider of comprehensive pharmaceuticals, and medical nutraceuticals, devices and equipment. Their objective is to develop a professionally managed healthcare organization to bring innovative products and services from both international and local manufacturers to benefit patients in Bangladesh. Biogene markets products from the U.S., Europe and Asia throughout Bangladesh.

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT’s website: www.competitivetech.net

Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2007, filed with the SEC on October 29, 2007, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

This news release was distributed by GlobeNewswire, www.globenewswire.com

 CONTACT: IR Services, LLC          Johnnie D. Johnson          860 434 2465          [email protected] 

Adult Relatives of Homicide Victims Get Mental-Health Help

By Amanda Milkovits

By removing one word from an existing law, sponsors succeed in extending a benefit already available to children.

PROVIDENCE — After Cynthia McKenna was killed in February 2007, her grieving daughters needed someone to talk to.

Alicia, 27, didn’t have health insurance and couldn’t afford to see a counselor on her own. Jackie, 22, had health insurance through her job, but it limited the number of mental-health visits.

While the state crime victim compensation fund pays for the mental-health expenses for the children and siblings of homicide victims, by law it only covers those who are minors.

The odd cut-off seemed to say that mourning ends at age 18. But the pain of the McKenna sisters led to action at the General Assembly and an amended law that will make sure all children and siblings of murder victims will find help no matter their age.

Yesterday, the McKenna sisters and the bill’s sponsors joined state General Treasurer Frank Caprio at a news conference announcing the change in the law. As Jackie McKenna spoke, a silver heart pendant engraved with the word “Mom” and the date of her mother’s death shone against her neck. “A child never outgrows a need for her mother,” she said in a trembling voice. “I believe a child’s bond to a mother is endless at any age.”

The sisters were overwhelmed with mourning their mother, suddenly planning her funeral and dealing with an ongoing criminal investigation. Unable to afford counseling, they found help instead at the Victims Support Center run by The Institute for the Study and Practice of Nonviolence, which advocates and offers free support for victims and survivors.

Sheila Cardente, the director of the victims support center, listened as the women told her about their search for help. Children have access to RIte Care, but adults who are uninsured or underinsured are on their own to pay for mental-health counseling, Cardente said.

Carol Peloquin, an intern at the institute working on her master’s degree in social work from Rhode Island College, decided to study the law and see what other states offered for adult siblings and children of crime victims. “I saw that other states do this. Why can’t we?” Peloquin said.

The crime victim compensation program is financed by Victims of Crime Assistance grants, court receipts, and the criminals themselves, who pay into the fund as part of their sentences. Victims of violent crimes and survivors can apply for assistance under the program, which pays expenses not covered by insurance, such as medical costs, funeral expenses, loss of earnings and the costs for mental-health visits.

The program is administered by the state treasurer’s office and currently has about $4.55 million in the account. The assistance is capped at $25,000 for each claim, though the average claim is $3,800, according to the treasurer’s office. During the period of Oct. 1, 2006, to Sept. 30, 2007, the fund paid $82,217 for a total of 293 approved claims.

By striking the word “minor,” the law will allow the adult children and siblings of victims of violent crime to seek funding for expenses of psychiatric and mental-health counseling.

Rep. Joanne Giannini, D-Providence, and Sen. Josh Miller, D- Cranston, both agreed to sponsor legislation to amend the law. “When it came into committee [House Judiciary], we talked about ‘What is the difference between 18, 19, 20 years old and to lose a mother like that?’ ” Giannini said afterward. “When we talked about the need that was there, the age didn’t matter.”

Representatives from the treasurer’s office also testified at the House and Senate to clarify that there was no fiscal impact, “and how important it was economically and ethically,” Miller said. Governor Carcieri signed the legislation, which took effect in July.

“The people who are skeptical of government can see how simple it can be — you remove one word in legislation and affect so many lives,” Miller said. [email protected] / (401) 277-7213

Originally published by Amanda Milkovits, Journal Staff Writer.

(c) 2008 Providence Journal. Provided by ProQuest LLC. All rights Reserved.

Mt. Diablo Region YMCA Names Judith Parker As Vice President of Financial Development

PLEASANT HILL, Calif., Sept. 18 /PRNewswire/ — The Mt. Diablo Region YMCA announced today it has named Judith Parker as Vice President of Financial Development. Ms. Parker’s addition comes as the YMCA nears completion of its capital campaign that will allow for the charity to add two new branch facilities in the Alamo and Oakley communities and remodel the Irvin Deutscher Family YMCA in Pleasant Hill. Ms. Parker’s long-standing relationships in the community, strong expertise in donor cultivation and planned giving, along with her proven ability to develop major gifting opportunities provides the YMCA with an important resource as it secures the final million dollars of a $9.1 million campaign. In her new role at the YMCA, Parker will support the successful completion of this capital campaign and build programs for planned giving and corporate grants.

“Judith is a welcome addition to the management team as we enter the home stretch of our capital campaign. Her proven track record of generating needed funding for charitable organizations is very important to ensure we can afford the substantial infrastructure expansion and the subsequent maintenance of these new facilities,” said Michael F. Erwin, President and CEO of the Mt. Diablo Region YMCA. “We are now $1 million away from our goal to fund the infrastructure expansion, which we believe is critical to the burgeoning communities within Contra Costa County. Judith will play a key role in helping us reach our goal.”

Parker has dedicated nearly a decade to managing fundraising campaigns and major donor programs that support impressive charitable organizations including the California Symphony and The Wellness Community. Since 2000, Parker has demonstrably increased charitable revenue comprising both corporate sponsorships as well as individual gifting. Prior to joining the YMCA, Parker held the position of Development Director of the California Symphony where she increased revenue by 18 percent over three years and expanded corporate sponsorship by 30 percent. Before joining the Symphony, Parker was Director of Development for The Wellness Community and Vice President of Development for the Center for Leadership Excellence. In each of these roles, she posted double-digit improvements in revenue and donor activity.

Infrastructure Expansion Supports Growing Contra Costa County Communities

The Mt. Diablo Region YMCA plans two new facilities in Alamo (on which they have already broken ground for the bridge required for the new facility) and in Oakley. Additionally the YMCA will remodel the Irvin Deutscher YMCA in Pleasant Hill with state-of-the-art equipment and a sports court. The new facilities will follow “green” guidelines and support growing needs of the Danville / San Ramon and Discovery Bay regions. Features of these new facilities include: a community center, a health and wellness center, a Cyber Cafe, meeting rooms, an indoor warm-water therapeutic pool, an outdoor lap pool, a family splash zone, aerobics/cardiovascular and strength-training facility, cutting-edge health and fitness center, aquatics center, multi-generational technology center and community gathering place, a demonstration/nutritional teaching kitchen, a special needs playground, and on-site child care.

The Mt. Diablo Region YMCA currently supports more than 40,000 members of the community and with these new facilities, this number will likely double over the next decade.

About the Mt. Diablo Region YMCA

The Mt. Diablo Region YMCA has served the greater Contra Costa County area for 50 years. With four branches (Concord/Clayton YMCA in Clayton, the Delta Family YMCA in Oakley, the Irvin Deutscher Family YMCA in Pleasant Hill, and the San Ramon Valley YMCA in Alamo), 23 school-age child-care sites at local elementary schools, and four preschools, the organization is continuing to grow and expand its network to meet the ever-changing needs of the local community. The Mt. Diablo Region YMCA provides program services for more than 40,000 members of the community, from toddlers to seniors. The organization is dedicated to enriching the lives of all people through programs that strengthen spirit, mind and body. Financial assistance is available to all individuals who demonstrate proven need. For more information, visit mdrymca.org.

All product and company names herein may be trademarks of their registered owners.

The Mt. Diablo Region YMCA

CONTACT: Shannon Magill of Trainer Communications, +1-925-463-4844,[email protected], for The Mt. Diablo Region YMCA

Web site: http://www.mdrymca.org/

Prescription Solutions Receives TIPPS(SM) Certification For Pharmacy Benefits Transparency Standards

Prescription Solutions, a leading pharmacy benefits management (PBM) organization and a UnitedHealth Group (NYSE:UNH) company, today announced that it received Transparency in Pharmaceutical Purchasing Solutions (TIPPS) certification from the HR Policy Association (HR Policy) Pharmaceutical Coalition. TIPPS certification enables Prescription Solutions to offer PBM services to members of the Coalition, which currently includes 58 companies representing more than five million people and collective annual drug expenditures of approximately $5 billion.

HR Policy developed the TIPPS certification process to achieve a more cost-effective and transparent model for purchasing pharmaceutical benefits for employees, retirees and their dependents. Certification is bestowed only upon PBMs that are willing to meet the Coalition’s rigorous transparency standards and agree to provide Coalition members with audit rights to validate compliance. This simplifies the negotiation process for Coalition members because they can work with a pre-screened group of PBMs and be confident that these companies will adhere to high transparency standards.

“TIPPS certification validates Prescription Solutions’ long-standing commitment to transparent business practices. Our programs allow employers to achieve a meaningful cost advantage and provide their members with access to quality, affordable pharmacy benefits,” said Dr. Edward M. Feaver, Pharm.D., president of Prescription Solutions. “We align ourselves with our customers’ goals by providing innovative and cost-efficient services and by helping their members use their drug benefits more effectively and live healthier lives.”

About Prescription Solutions

Prescription Solutions is an innovative pharmacy benefit management company managing the prescription drug benefit of commercial, Medicare and other governmental health plans, as well as those of employers and unions. A UnitedHealth Group company, Prescription Solutions serves members through a national network of 60,000 community pharmacies and state-of-the-art mail service pharmacies in Carlsbad, California, and Overland Park, Kansas, which have both earned the prestigious Verified Internet Pharmacy Practice Sites(TM) (VIPPS(R)) accreditation by the National Association of Boards of Pharmacy(R) (NABP(R)). The company was recently named by WilsonRx(R) as the #1 National Top-Tier PBM, and #1 National Mail Order Pharmacy for customer satisfaction two years in a row. Prescription Solutions also won URAC’s 2008 Best Practices for Consumer Empowerment and Protection Award in the PBM category. Additional information can be found at www.rxsolutions.com.

About UnitedHealth Group

UnitedHealth Group (NYSE:UNH) is a diversified health and well-being company dedicated to making health care work better. Headquartered in Minneapolis, Minn., UnitedHealth Group offers a broad spectrum of products and services through seven operating businesses: UnitedHealthcare, Ovations, AmeriChoice, OptumHealth, Ingenix, and Prescription Solutions. Through its family of businesses, UnitedHealth Group serves more than 70 million individuals nationwide.

About HR Policy Association

HR Policy Association is a public policy advocacy organization representing the senior human resource executives of 250 leading employers doing business in the United States. Collectively, its members employ over 12 percent of the U.S. private sector workforce or some 19 million Americans. Due to extreme concern over skyrocketing health care costs in the United States and deficiencies in efficiency and quality, the Association has been working through its public policy agenda and market reform initiatives to address the problems that plague our nation’s health care system.

Research and Markets: Gain a Strong Understanding of the In Vitro Diagnostics Devices Market in Canada With Analysis and Forecasts to 2012

Research and Markets (http://www.researchandmarkets.com/research/7774c4/canada_in_vitro_di) has announced the addition of the “Canada In Vitro Diagnostics Investment Opportunities Analysis and Forecasts to 2012” report to their offering.

This report is an essential source for in-depth information and data relating to the Canada In vitro diagnostic devices market. It also offers detailed and comprehensive coverage of market revenue, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the In vitro diagnostic devices in Canada

Scope

– The report provides in vitro diagnostics information broken down into detailed categories and segments in Canada.

– Total revenues, end users

– Market shares of all the key competitors.

– Key pipeline products that are set to shape the market, broken down by sector.

– Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis.

– Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.

– Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.

– Key mergers and acquisitions, partnerships, private equity investments and IPOs.

– Customer, hospitals and physicians data.

Reasons to buy

– Gain a strong understanding of the in vitro diagnostics devices market in Canada.

– Evaluate and compare the attractiveness of the market in the country.

– Identify growth segments and opportunities in each industry sector within the country.

– Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.

– Analyze the competitiveness of the market in the country and identify hotspots.

– Develop strategies based on the latest product, brand, expansion and research and development news in the country.

– Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.

– Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

Key Topics Covered:

1 Table Of Contents

2 Introduction

2.1 What Is This Report About?

3 Definitions of Markets Covered in the Report

3.1 In Vitro Diagnostics Devices

3.2 Clinical Chemistry Test Reagents

3.2.1 Laboratory Reagents

3.2.2 Clinical Chemistry Calibrators and Controls

3.2.3 Clinical Chemistry Rapid Tests

3.3 Immunochemistry Test Reagents

3.3.1 Disease Specific Markers

3.3.2 Disease Specific Test Reagents

3.3.3 Drug Related Testing Reagents

3.3.4 Hormone Related Testing Reagents

3.3.5 Immunochemistry Calibrators and Controls

3.3.6 Immunochemistry Rapid Tests

3.4 Blood Test Reagents

3.4.1 Hematology Test Reagents

3.4.2 Hemostasis Test Reagents

3.4.3 Tissue Typing Reagents

3.4.4 Monoclonal Antibodies

3.4.5 Cytokines and Immunomodulators

3.4.6 Histology and Cytology Reagents

3.5 Microbiology Test Reagents

3.5.1 Bacteriology Test Reagents

3.5.2 Microbiology Calibrators and Controls

3.5.3 Microbiology Rapid Tests

3.6 Infectious Immunology Test Reagents

3.6.1 Bacteriology

3.6.2 Virology

3.6.3 Parasitology

3.6.4 Infectious Immunology Calibrators and Controls

3.6.5 Infectious Immunology Rapid Tests

3.7 Genetic Test Reagents

3.8 Self Testing

3.9 Instruments

4 Healthcare Sector Review

4.1 Healthcare Expenditure

4.2 Healthcare Infrastructure

4.3 Healthcare Policy

4.4 Canada Healthcare Trade Statistics

5 Regulation System

5.1 Medical Equipment Approval Process

5.1.1 Classification

5.1.2 Conformity Assessment

5.1.3 License Fee

5.1.4 License Application Processing Duration

5.2 Labeling and Packaging

5.3 Post-Market Surveillance

6 Pricing and Reimbursement

7 Distribution Structure

7.1 Distribution Structure

8 Canada Medical Equipment Cross Market Comparison

9 In Vitro Diagnostics In Canada

9.1 In Vitro Diagnostics Cross Country Comparison (2000-2012)

9.2 In Vitro Diagnostics, Canada, Overall Revenues, 2000-201

9.3 In Vitro Diagnostics, Canada, Company Share (2006-2007)

10 Blood Test Reagents In Canada

10.1 Blood Test Reagents Overall Revenue (2000-2012)

10.1.1 Haematology Test Reagents Revenue (2000-2012)

10.1.2 Hemostasis Test Reagents Revenue (2000-2012)

10.2 Blood Test Reagents Distribution Share (2006-2007)

10.3 Blood Test Reagents, Canada, Company Share (2006-2007)

11 Clinical Chemistry Test Reagents In Canada

11.1 Clinical Chemistry Test Reagents Overall Revenue (2000-2012)

11.2 Clinical Chemistry Test Reagents Distribution Share (2006-2007)

11.3 Clinical Chemistry Test Reagents, Canada, Company Share (2006-2007)

12 Genetic Test Reagents In Canada

12.1 Genetic Test Reagents Overall Revenue (2000-2012)

12.2 Genetic Test Reagents Distribution Share (2006-2007)

12.3 Genetic Test Reagents, Canada, Company Share (2006-2007)

13 Immunochemistry Test Reagents In Canada

13.1 Immunochemistry Test Reagents Overall Revenue (2000-2012)

13.1.1 Disease Specific Markers Revenue (2000-2012)

13.1.2 Disease Specific Test Reagents Revenue (2000-2012)

13.1.3 Drug Related Testing Reagents Revenue (2000-2012)

13.1.4 Hormone Related Testing Reagents Revenue (2000-2012)

13.2 Immunochemistry Test Reagents Distribution Share (2006-2007)

13.3 Immunochemistry Test Reagents, Canada, Company Share (2006-2007)

14 Infectious Immunology Test Reagents In Canada

14.1 Infectious Immunology Test Reagents Overall Revenue (2000-2012)

14.1.1 Virology Revenue (2000-2012)

14.2 Infectious Immunology Test Reagents Distribution Share (2006-2007)

14.3 Infectious Immunology Test Reagents, Canada, Company Share (2006-2007)

15 Instruments In Canada

15.1 Instruments Overall Revenue (2000-2012)

15.2 Instruments Distribution Share (2006-2007)

15.3 Instruments, Canada, Company Share (2006-2007)

16 Microbiology Test Reagents In Canada

16.1 Microbiology Test Reagents Overall Revenue (2000-2012)

16.1.1 Bacteriology Test Reagents Revenue (2000-2012)

16.2 Microbiology Test Reagents Distribution Share (2006-2007)

16.3 Microbiology Test Reagents, Canada, Company Share (2006-2007)

17 Self Testing In Canada

17.1 Self Testing Overall Revenue (2000-2012)

17.2 Self Testing Distribution Share (2006-2007)

17.3 Self Testing, Canada, Company Share (2006-2007)

18 F. Hoffmann-La Roche Ltd. Company Profile

18.1 Company Overview

18.2 Value Chain Analysis

18.2.1 Manufacturing

18.2.2 Product Development

18.2.3 Sales and Marketing

19 Beckman Coulter, Inc. Company Profile

19.1 Company Overview

19.2 Value Chain Analysis

19.2.1 Manufacturing

19.2.2 Product Development

19.2.3 Sales and Marketing

19.3 Beckman Coulter, Inc. Pipeline Products

19.3.1 Beckman Coulter, Inc. Pipeline Products by Equipment Type

19.3.2 Beckman Coulter, Inc. Pipeline Products by Development Stage

19.3.3 Beckman Coulter, Inc. Pipeline Products by Therapy Area

19.3.4 Beckman Coulter, Inc. Pipeline Products by News Summary

20 Dade Behring Holdings, Inc. Company Profile

20.1 Company Overview

20.2 Dade Behring Holdings, Inc. Pipeline Products

20.2.1 Dade Behring Holdings, Inc. Pipeline Products by Equipment Type

20.2.2 Dade Behring Holdings, Inc. Pipeline Products by Development Stage

20.2.3 Dade Behring Holdings, Inc. Pipeline Products by Therapy Area

20.2.4 Dade Behring Holdings, Inc. Pipeline Products by News Summary

21 Abbott Laboratories Company Profile

21.1 Company Overview

21.2 Value Chain Analysis

21.2.1 Manufacturing

21.2.2 Product Development

21.2.3 Sales and Marketing

21.3 Abbott Laboratories Pipeline Products

21.3.1 Abbott Laboratories Pipeline Products by Equipment Type

21.3.2 Abbott Laboratories Pipeline Products by Development Stage

21.3.3 Abbott Laboratories Pipeline Products by Therapy Area

21.3.4 Abbott Laboratories Pipeline Products by Clinical Trials

21.3.5 Abbott Laboratories Pipeline Products by News Summary

22 Siemens Medical Solutions Company Profile

22.1 Company Overview

22.2 Value Chain Analysis

22.2.1 Manufacturing

22.2.2 Product Development

22.2.3 Sales and Marketing

22.3 Siemens Medical Solutions Pipeline Products

22.3.1 Siemens Medical Solutions Pipeline Products by Equipment Type

22.3.2 Siemens Medical Solutions Pipeline Products by Development Stage

22.3.3 Siemens Medical Solutions Pipeline Products by Therapy Area

22.3.4 Siemens Medical Solutions Pipeline Products by News Summary

23 bioMerieux S.A. Company Profile

23.1 Company Overview

23.2 Value Chain Analysis

23.2.1 Manufacturing

23.2.2 Product Development

23.2.3 Sales and Marketing

24 Affinity Biologicals Incorporated Company Profile

24.1 Company Overview

25 Biocore Systems Inc. Company Profile

25.1 Company Overview

26 bioLytical Laboratories Inc. Company Profile

26.1 Company Overview

26.2 bioLytical Laboratories Inc. Pipeline Products

26.2.1 bioLytical Laboratories Inc. Pipeline Products by Equipment Type

26.2.2 bioLytical Laboratories Inc. Pipeline Products by Development Stage

26.2.3 bioLytical Laboratories Inc. Pipeline Products By Therapy Area

26.2.4 bioLytical Laboratories Inc. Pipeline Products By Clinical Trials

26.2.5 bioLytical Laboratories Inc. Pipeline Products By News Summary

27 Biomedica Diagnostics Inc. Company Profile

27.1 Company Overview

28 Cedarlane Laboratories Limited Company Profile

28.1 Company Overview

29 Diagnostics Chemicals Limited Company Profile

29.1 Company Overview

30 DRAXIMAGE Company Profile

30.1 Company Overview

31 Medicorp Inc. Company Profile

31.1 Company Overview

32 Medmira Inc. Company Profile

32.1 Company Overview

33 Financial Deals Landscape

33.1 Acquisition

33.1.1 Roche To Acquire ARIUS Research

33.2 Venture Financing

33.2.1 Adnavance Technologies Secures $5.47 Million In Series B Financing

34 Recent Developments

34.1 Strategy and Business Planning

34.1.1 Mar 04, 2008: Biotage And McMaster Sign Two Year Extension To Molecular Imaging Development Agreement

35 APPENDIX

35.1 Global Markets Direct Research Methodology

35.2 Coverage

35.3 Secondary Research

35.4 Primary Research

35.5 Models

35.6 Forecasts

35.7 Expert Panels

35.8 Currency Conversion

35.9 Contact Us

35.10 Disclaimer

1.1 List of Tables

1.2 List of Figures

Companies Mentioned:

F. Hoffmann-La Roche Ltd.

Beckman Coulter, Inc.

Dade Behring Holdings, Inc.

Abbott Laboratories

Siemens Medical Solutions

bioMerieux S.A.

Affinity Biologicals Incorporated

Biocore Systems Inc.

bioLytical Laboratories Inc.

Biomedica Diagnostics Inc.

Cedarlane Laboratories Limited

Diagnostics Chemicals Limited

DRAXIMAGE

Medicorp Inc.

Medmira Inc.

For more information visit http://www.researchandmarkets.com/research/7774c4/canada_in_vitro_di

Source: Global Markets Direct

Three Rivers Pharmaceuticals Signs Licensing Agreement With Amgen

Three Rivers Pharmaceuticals, a privately held company that focuses on specialized therapies including hepatitis C therapies, has signed a definitive licensing agreement with Amgen to expand its commercial rights to the hepatitis C drug Infergen.

Three Rivers Pharmaceuticals will obtain commercial rights to Infergen in all markets except Japan. In addition, Three Rivers Pharmaceuticals will obtain commercial rights to China, effective March 31, 2009. Three Rivers Pharmaceuticals currently has commercial rights to Infergen in the US and Canada.

Three Rivers Pharmaceuticals will seek marketing partners to assist with the commercialization of Infergen outside of the US.

Infergen is indicated for the treatment of chronic hepatitis C virus (HCV)infection in patients 18 years of age or older with compensated liver disease who have anti-HCV serum antibodies or the presence of HCV RNA.

Patrick Kerrish, executive vice president of business development at Three Rivers Pharmaceuticals, said: “The expansion of commercial rights to Infergen compliments Three Rivers Pharmaceuticals strategy to continue to grow its hepatitis C franchise.”

Celprogen Introduces Stem Cells in Syringes for in Vivo Applications

Celprogen Inc., a Global leader in the Stem Cell Research and Therapeutics industry for development of stem cell technologies in regenerative medicine, today announced that they have successfully validated shipment of embryonic and adult stem cells at room temperature within United States research facilities for in vivo applications. These Stems including progenitor cells were derived from the following species mouse, rat and human.

Celprogen’s stem cells and progenitor cells in the syringes are available for basic science research and drug discovery. The stem cells validated in syringe shipment are as follows: Hepatocytes, Neuronal, Pancreatic, Gastric, Cardiomyocytes, Colon, Lung and Keratinocytes. These stem cells in their syringes are able to maintain their stem-ness and are able to engraft at their organ specific sites once injected within 3 to 5 days from the date shipped. Celprogen has successfully shipped stem cells globally at room temperature in Tissue culture flasks to Asia, Europe and United Kingdom.

Celprogen provides Stem Cell Tissue culture system which includes cells, pre-coated flasks with extracellular matrix and Medium for growth and proliferation of these cells. The stem cell culture system includes stem cell differentiation, expansion and maintaining stem cells in their undifferentiated stage.

About Celprogen Inc.

Celprogen Inc. is a global Stem Cell Research & Therapeutics company which is developing proprietary portfolio of unique cancer therapeutics products and life science research tools that includes stem cell technologies for regenerative medicine, as well as bio-engineering products for tissue & organ transplants. Headquartered in San Pedro, California, Celprogen is committed to the research, development, and manufacture of quality Stem Cell products to serve our global community. Additional information about Celprogen is available at http://www.celprogen.com.

The National Labor Office of the Blue Cross and Blue Shield Association Selects Best Doctors As a Strategic Alliance

Best Doctors(R) Inc., the trusted medical resource for ensuring individuals with serious illnesses and injuries have the right diagnosis and the right treatment, today announced a strategic alliance with the National Labor Office (NLO) of the Blue Cross and Blue Shield Association. This alliance will allow Best Doctors to explore opportunities with the labor trust funds, labor unions and independent Blue Cross and Blue Shield companies served by the National Labor Office. In doing so, Best Doctors will be able to offer its unique medical diagnosis evaluation service to an even larger population of union members, ensuring that these employee members can get the answers they need when faced with questions about their diagnosis and treatment.

The Blue Cross and Blue Shield Association (BCBSA) is a national federation of 39 independent, community-based and locally operated Blue Cross and Blue Shield companies. These Blue Cross and Blue Shield companies provide health benefits for more union workers, retirees, and their families than any other national carrier. Union contracts account for approximately 20 million Blue Cross and Blue Shield company members — almost one-fifth of the Blue System’s national enrollment. BCBSA established the National Labor Office in 1965 to demonstrate its strong commitment to building successful partnerships with organized labor.

The Best Doctors unique diagnosis evaluation service is sold as a benefit to employers, trusts, labor unions and health plans. With Best Doctors, eligible employees and family members who are uncertain about a serious diagnosis or have questions about their treatment plan can receive answers from world-renowned doctors, selected from a database of 40,000 specialists. Through Best Doctors, an expert specialist conducts a thorough analysis of the member’s case based on all medical records and tests. The member and his/her treating physician receive a comprehensive, easy-to-understand report summarizing the findings that they can use to ensure the right diagnosis and best course of treatment.

“The NLO is committed to seeking out, developing and managing strategic alliance relationships with only select best-in-class services like Best Doctors to enhance Blue Cross and Blue Shield company product and service offerings for our union customers,” said Bonnie Summers, NLO executive director. “With their large populations and specific medical concerns, unions often present health challenges that drive the need for unique medical benefits that can truly provide a positive impact on the standard of care for their members. We believe that Best Doctors offers a powerful benefit that can have a significant impact on the quality of care for our union clients.”

“As today’s healthcare system becomes more complex, the National Labor Office helps union representatives understand new options and gain access to critical information that satisfy the needs of labor, management and health plans alike,” said David Seligman, CEO of Best Doctors. “We are very pleased to align with the NLO and intend to be active allies in the ongoing quest by the Blues and the labor community to identify new tools that help individuals get the right care.”

About Best Doctors

Best Doctors(R) is the trusted medical resource for ensuring individuals have the right diagnosis and the right treatment. The Company serves employers, insurers and health plans by dramatically improving the quality of healthcare at the point of treatment for individuals with serious illnesses and injuries. Founded in 1989 by two Harvard Medical School professors, Best Doctors serves more than 260 insurers, employers and health plans, touching 10 million people in 30 countries. For more information, visit www.bestdoctors.com or call 1-800-223-5003.

 Contacts: Jon Siegal/Christian T. Potts Schwartz Communications 781-684-0770 [email protected]

SOURCE: Boston Software

Braintree Should Have Say on Hospital Land’s Future

OUR OPINION

Ever since Norfolk County took 98 acres of prime land in Braintree near the Holbrook line 91 years ago to build a tuberculosis hospital, the town and its residents have had numerous promises broken and been left out of the loop as the property has fallen into private ownership hands.

Now, the latest owner of the hospital, Kindred Healthcare Inc., of Lexington, Ky., has announced it will purchase the land around the facility for $22.3 million from the Ohio real estate holding company that owns it and sell the whole kit and caboodle to the highest bidder.

In a town like Braintree where open space is at a premium with little available parkland, we hope the town with the state’s assistance looks into ways the land can remain in an undeveloped state.

There are many problems with this sale, the least of which is Kindred never gave Braintree Mayor Joseph Sullivan or other officials the courtesy of a phone call, let alone input. Company officials notified Sullivan by fax roughly the same time company executives put out a press release and statement declaring they were closing the unprofitable long-term care facility and would move the scores of patients.

Nothing was said about what would happen to the 217 workers at the hospital.

There’s also a question, asked many times but never answered in Braintree, over whether land that was taken by eminent domain can be sold by a private entity for private development.

For seven decades, the county ran a hospital for the care of tuberculosis patients until the demand ebbed with the near- eradication of the disease in this country. It was switched to a chronic care facility and, in 1984, a jail facility was added. The town successfully sued to stop housing prisoners although officials reached an agreement that was updated every two years that allowed prisoners at the alternative center until 2000.

When the county sold the hospital to a private healthcare company in 1997, the buyers agreed in writing to place a conservation restriction on the land in exchange for the necessary permits for Olympus to buy the hospital and forego the town’s right of first refusal.

But when the owners filed a plan with the town to subdivide the property in 2002, Braintree’s attorneys could not find any such restriction ever having been filed.

As the saying goes, fool me once, shame on me; fool me twice. . .

With the care and treatment of its patients as the first priority, the state needs to ensure Kindred lives up to its obligations and patients are found beds in facilities where they and their families are comfortable.

There also needs to be a hard look at the original deed when the land was first taken by eminent domain. Under the state constitution and even the most generous court interpretations, land takings are for the sole purpose of “public use.” It’s hard to imagine a development being “public use” and we hope the town presses the issue.

But perhaps the best solution here is for Kindred to open communication with Sullivan and other Braintree officials to bring them into the loop and ensure the town’s needs are not the bottom of the priority list. After nearly a century, it’s about time for Braintree residents to have a voice in the land’s future.

(c) 2008 Patriot Ledger, The; Quincy, Mass.. Provided by ProQuest LLC. All rights Reserved.

National Survey Reveals Impact of ADHD in Adults

TITUSVILLE, N.J., Sept. 18 /PRNewswire/ — Adults diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) say that having ADHD significantly impacts their ability to focus at work, as well as their responsibilities at home and their relationships. These findings were according to a national survey including more than 1,000 adults across the United States diagnosed with the condition.

McNeil Pediatrics(TM), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, sponsored the survey as part of its commitment to the ADHD community’s 2008 National ADHD Awareness Day.

ADHD is thought to affect about 9 million adults in the United States, and research on the life span of the condition notes the disorder can impair academic, social and occupational functioning, and is often associated with academic underachievement, conduct problems, underemployment, motor vehicle safety and difficulties with personal relationships.

“Findings from today’s survey underscore the impact ADHD can have for adults who are struggling to cope with and manage this condition at work, at home and in their relationships,” said Dr. Edward Hallowell, a practicing psychiatrist and founder of the Hallowell Center for Cognitive and Emotional Health in Sudbury, Mass. “As a psychiatrist who has treated adults with the condition for more than 25 years, and as an adult who was diagnosed with ADHD at age 31, I know firsthand the importance of working with a healthcare professional to identify strategies that may be effective in controlling ADHD symptoms, such as behavioral modifications and medication.”

The survey findings on adults with ADHD reinforce previous findings from a recent World Health Organization (WHO) report, which concluded ADHD is a relatively common condition among working adults and is associated with impairment and work performance. The WHO survey also found that only a small number of employed adults with ADHD are being treated for the condition, even though evidence shows medication can be effective in improving ADHD symptoms, and that on average, adult workers with ADHD miss more than three weeks a year in workplace productivity.

Adult ADHD Survey Findings

Conducted by Harris Interactive on behalf of McNeil Pediatrics(TM), key survey findings included a variety of participant perspectives, including:

   -- Most adults with ADHD agree that having the condition strongly affects      their performance in multiple areas of their lives, including:      - Their responsibilities at home (65 percent)      - Their relationships with family and friends (57 percent)      - Their ability to succeed at work (56 percent of those employed)   -- Up to half (50 percent) of those employed worry ADHD symptoms affect      opportunities for promotion, and the majority feel they have to work      harder (65 percent) and/or longer (47 percent) than their co-workers to      accomplish similar work.   -- Three-quarters of respondents said their ADHD symptoms strongly affect      their ability to stay on task at work (75 percent), while others listed      challenges such as:      - Concentrating on what others were saying (70 percent)      - Wrapping up projects (61 percent)      - Following through on tasks (61 percent)      - Sitting still in meetings (60 percent)      - Organizing projects (59 percent)   -- Just as their needs differ, adults with ADHD report divergent goals in      managing ADHD symptoms. In selecting their top three goals for managing      the condition, half cited being able to finish projects and tasks (51      percent), and getting their household more organized (51 percent).      Other top-three goals included:      - Feeling less irritable and upset (38 percent)      - Getting personal finances more organized (28 percent)      - Improving personal relationships (26 percent)      - Feeling calmer and to feel less need to always be moving (22        percent)      - Getting along better with others in social situations (20 percent)   -- One-third (36 percent) feel their ADHD symptoms are not under control,      and many more (58 percent) are not satisfied with their ability to      handle stress.      - Of those whom symptoms are not under control, 54 percent feel like a        failure for it.   -- One-third (37 percent) get depressed thinking about how hard ADHD is to      deal with.    

Adults with ADHD who participated in the survey also reported utilizing a variety of techniques to help manage their symptoms. Four out of five have used visual reminders, such as post-it notes, to help manage their ADHD symptoms. Those in the survey also reported:

   -- Taking prescription medication (82 percent)   -- Listening to music (75 percent)   -- Using a planner or organizer (71 percent)   -- Exercising (69 percent)    

Of those adults on medication, four out of five (81 percent) reported that not taking medication negatively impacts their work or home performance. Patients on medication said they are focused primarily on goals of symptom control and improving performance at work (74 percent), at home (69 percent) and in relationships (62 percent).

“I was diagnosed two years ago after I realized that some of the stress I felt from trying to keep up with my career, home and family might be more than stress,” said Natalie Knochenhauer, a former public defender, non-profit executive and founder of the Metro Philadelphia Chapter of Children and Adults with Attention Deficit Hyperactivity Disorder (CHADD), and advocacy chair of Pennsylvania CHADD. “After my diagnosis, I felt like I had extra hours in every day to accomplish what I needed to get done. Because of the clear benefits I have experienced, I work closely with my doctor to manage my condition, which enables me to perform better in all aspects of my life.”

About Dr. Edward Hallowell

Dr. Edward (Ned) Hallowell is a practicing psychiatrist and founder of the Hallowell Center for Cognitive and Emotional Health in Sudbury, Mass. A former instructor at Harvard Medical School, he is the author of 10 books, including the bestsellers on ADHD: “Driven to Distraction,””Delivered from Distraction” and, most recently, “CrazyBusy.” Dr. Hallowell has ADHD himself. He is a paid consultant for McNeil Pediatrics(TM).

About Natalie Knochenhauer

Natalie Knochenhauer is the founder of the Metro Philadelphia Chapter of Children and Adults with Attention Deficit Hyperactivity Disorder (CHADD), and is advocacy chair of Pennsylvania CHADD. With four children who also have ADHD, Natalie realizes that adults with ADHD have issues at work with deadlines and procrastination and that like children with ADHD, adults need to have systems and accommodations in place to succeed. She is a paid consultant for McNeil Pediatrics(TM).

About the Survey

On behalf of McNeil Pediatrics(TM), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, data for this survey were collected by the Harris Interactive Service Bureau (HISB) on behalf of Richard Day Research (RDR). HISB was responsible for the data collected and RDR was responsible for all survey design, data analysis and data reporting. Data were collected online between July 28 and August 8. The sample included 1,007 U.S. adults who have been diagnosed with ADHD.

About McNeil Pediatrics(TM)

McNeil Pediatrics(TM), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, is committed to meeting the needs of pediatric medicine through the development of therapies specifically formulated for children. McNeil Pediatrics(TM) markets CONCERTA(R) for the treatment of children, adolescents and adults with ADHD in the United States. McNeil Pediatrics(TM) continues to explore other new therapies to meet the needs of children and the pediatric community. McNeil Pediatrics(TM) markets the most recently approved treatment for adults with ADHD, CONCERTA(R) (methylphenidate HCl). Visit http://www.mcneilpediatrics.net/ for more information.

About CONCERTA(R)

CONCERTA(R) is approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as part of a total treatment program that may include counseling or other therapies.

IMPORTANT SAFETY INFORMATION

Talk to your healthcare professional for a proper diagnosis and treatment of ADHD. Only a healthcare professional can decide whether medication is right for you or your child.

CONCERTA(R) should not be taken by patients who have: allergies to methylphenidate or other ingredients in CONCERTA(R); significant anxiety, tension, or agitation; glaucoma; tics, Tourette’s syndrome, or family history of Tourette’s syndrome; current or past use of monoamine oxidase inhibitor (MAOI); esophagus, stomach, or intestinal narrowing. Children under six years of age should not take CONCERTA(R).

Abuse of methylphenidate may lead to dependence. Tell your healthcare professional if you or your child has had problems with alcohol or drugs; has had any heart problems, heart defects, high blood pressure, or a family history of these problems; has had depression, abnormal thoughts or visions, bipolar disorder, or seizure. Contact your healthcare professional immediately if you or your child: develops abnormal thinking or hallucinations, abnormal or extreme moods and/or excessive activity; or if aggressive behavior or hostility develops or worsens while taking CONCERTA(R).

Stimulants may impair the ability of the patient to operate potentially hazardous machinery or vehicles. Caution should be used accordingly until you are reasonably certain that CONCERTA(R) does not adversely affect your ability to engage in such activities.

The most common adverse reaction (> 5%) reported in children and adolescents was upper abdominal pain. The most common adverse reactions (>10%) reported in adults were dry mouth, nausea, decreased appetite, headache, and insomnia.

Visit http://www.concerta.net/concerta/pages/full.jsp for full Prescribing Information.

    Tricia Geoghegan    McNeil Pediatrics    (609) 730-3746    [email protected]     Rebekah Sinzheimer    GolinHarris    (312) 729-4239    [email protected]  

McNeil Pediatrics(TM), Division of Ortho-McNeil-Janssen

CONTACT: Tricia Geoghegan of McNeil Pediatrics, +1-609-730-3746,[email protected]; or Rebekah Sinzheimer of GolinHarris, +1-312-729-4239,[email protected], for McNeil Pediatrics(TM), Division ofOrtho-McNeil-Janssen Pharmaceuticals, Inc

Web site: http://www.mcneilpediatrics.net/

Xoft to Launch Axxent(R) Xpress(TM) Transportable Electronic Brachytherapy Vehicles at ASTRO Meeting

BOSTON, Sept. 18 /PRNewswire/ — Xoft, Inc., developer of the Axxent(R) Electronic Brachytherapy System (eBx), which delivers non-radioactive, X-ray-based radiation treatment directly to cancer sites with minimal exposure to surrounding healthy tissue, announced that it will launch the Axxent Xpress(TM) Mobile Electronic Brachytherapy Vehicles to expand and improve access to critical radiation therapy. The announcement was made in advance of the 49th American Society for Therapeutic Radiology and Oncology (ASTRO) Meeting, September 21-24.

Xoft also announced that it has collaborated with Medical Coaches Inc., a leading manufacturer of custom mobile medical and specialty vehicles, to design and manufacture the specialized medical vehicles, as well as complete the extensive Department of Transportation (DOT) certification process. Xoft and Medical Coaches will showcase an Axxent Xpress Mobile Electronic Brachytherapy Van in a dedicated booth at the ASTRO Meeting.

“Eliminating the need to deliver treatment in heavily shielded vaults, Electronic Brachytherapy was designed to help radiation oncologists improve access to critical cancer care and make it available to patients across geography and socioeconomic levels,” said Michael Klein, president and CEO of Xoft. “Adding the ability to provide mobile radiation therapy services is a natural progression; one we hope will further improve access for the tens of thousands of breast cancer patients who do not comply with their prescribed radiation treatment or otherwise would not receive it. Studies presented at the recent ASCO Breast Cancer Symposium support prior findings that much of this problem is based on inability to access therapy because of distance, fear, or difficulty with the logistics of getting to traditional radiation centers — issues that are addressed with electronic brachytherapy.”

Commercially available for accelerated treatment of early stage breast cancer and endometrial and rectal indications, the Axxent Electronic Brachytherapy System is also cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated. Designed to deliver electronic, X-ray-based radiation treatment, the proprietary Axxent treatment platform can be used in many clinical settings under the supervision of a radiation oncologist, without the need for a shielded room. As a platform technology, the Axxent System addresses a variety of oncological and non-oncological indications and is designed to deliver non-radioactive therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue.

In its treatment of early stage breast cancer, the Axxent Electronic Brachytherapy System provides the opportunity to reduce the therapy time required from seven weeks (for external radiation therapy) down to five days. As a result, tens of thousands of patients will have greater access to therapy that is delivered more easily and conveniently. This may accelerate patient choice of breast sparing lumpectomy surgery with adjuvant radiation therapy over the alternative of a full mastectomy.

“Medical Coaches has worked with some of the largest medical companies for decades bringing critical diagnostic and therapeutic equipment to where patients need it most,” said Geoff Smith, president of Medical Coaches. “We are very proud to be working with Xoft on the Axxent Xpress vehicles to help improve access to radiation therapy in outlying and underserved areas.”

The new Axxent Xpress Mobile van has been custom designed by experts from both Xoft and Medical Coaches. The van will be able to carry up to three Axxent System HDR controllers. The controllers will ride on an easy to drive sprinter van modified to provide the safest transport environment. Modifications include ride softening shock absorbers and rear heating and cooling to insure equipment is ready to operate at delivery. A specially built easy to use equipment lift is installed at the rear doors for un-loading and loading sensitive medical equipment. Custom built cabinets and work counters are also supplied for transport of accessories needed to support mobile electronic brachytherapy treatment delivery.

Xoft products will be on display in Booth 1427 in the ASTRO Exhibition Hall and an Axxent Xpress van will be available for viewing in Booth 1457. Xoft will also host an educational symposium in conjunction with the ASTRO Meeting on September 22, where results from its Phase IV study will be presented as well as updates on new electronic brachytherapy applications.

About Medical Coaches

Medical Coaches Inc, http://www.medcoach.com/, is a privately held business that has manufactured more than 20,000 highly specialized mobile medical units located in more than 110 countries since the 1940’s. They have been working together with Siemens Medical Systems, GE Healthcare, and Philips Medical for more than twenty years delivering many mobile MRI, CT, PET and PET/CT coaches to customers throughout the United States. Medical Coaches unique design approach allows them to build the best strength-to-weight ratios in the mobile industry. Each new coach has passed the rigorous testing required by many of the major medical manufacturers to conform to their standards.

About Xoft Inc.

Xoft, founded in 1998, develops Electronic Brachytherapy (eBx) systems based upon miniaturized X-ray tube technology for the practice of radiation oncology in virtually any clinical setting, eliminating the need for heavily shielded environments. Xoft provides a “point of care model” that is patient centric and accessible to a broader spectrum of patients and their physicians. The Axxent treatment platform provides a therapeutic dose of radiation directly to the region at risk with minimal radiation exposure to surrounding healthy tissue and without the complex handling, resource logistics and costs associated with using radioactive isotopes. Xoft aligns with the Nuclear Regulatory Commission’s (NRC) directive to seek alternatives for radioactive medical isotopes. Commercially available for accelerated treatment of early stage breast cancer and endometrial and rectal indications, the Axxent(R) Electronic Brachytherapy System is also cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated. As a platform technology, the Axxent System addresses a variety of oncological and non-oncological indications. For more information, visit http://www.xoftinc.com/.

Axxent is a registered trademark of Xoft, Inc.

Xoft, Inc.

CONTACT: Chad Smith of Medical Coaches, +1-607-432-1333, ext. 125,[email protected]; or Chris K. Joseph of Xoft Inc., +1-510-339-2293,[email protected]

Web site: http://www.xoftinc.com/http://www.medcoach.com/

Jeffrey Modell Foundation and Talecris Biotherapeutics, Inc. Expand Diagnostic Services for Primary Immunodeficiencies at Children’s Hospital Boston

The Jeffrey Modell Foundation (JMF) and Talecris Biotherapeutics, Inc. have donated $150,000 to Children’s Hospital Boston, the primary pediatric teaching affiliate of Harvard Medical School, to expand clinical care and outreach for children with primary immunodeficiency (PI), the two organizations announced today.

PI is a term that encompasses more than 150 diseases caused by an immune system that does not function properly. The program at Children’s Hospital Boston, one of 39 worldwide supported by the JMF, focuses on the diagnosis, care and treatment of those suffering from PI.

“Early recognition and diagnosis of PI can save lives and improve health outcomes for children,” said Raif Geha, M.D., Chief of the Division of Immunology at Children’s Hospital Boston and James Gamble Professor of Pediatrics at Harvard Medical School. “The educational and diagnostic programs made possible through this support will improve care for patients with PI, and will also generate cutting edge research opportunities,” said Dr. Geha, who is also director of the Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies at Children’s Hospital Boston.

“It is especially gratifying that this diagnostic and research center, together with today’s dedication of the Jeffrey Modell Endowed Chair in Pediatric Immunology Research and the establishment of the newly constructed Jeffrey Modell Immunology Center at Harvard Medical School, creates an infrastructure in immunology that is second to none in the world,” said Fred Modell, co-founder of the JMF. “Talecris’ generous contribution for this diagnostic and research center is in addition to the previously committed $1,000,000 toward support of the Jeffrey Modell Immunology Center at Harvard Medical School. This is a tremendous commitment by Talecris.”

Vicki Modell, co-founder of the JMF, noted that “a large, undiagnosed population of children and young adults continues to suffer from these diseases, which keep them from enjoying a full life. For example, they often miss 30 or 40 days of school every year. Their illness interrupts their activities, detours their plans and shatters their dreams.”

PI affects males and females of all ages, but the most severe forms are frequently detected in childhood. PI often can present in the form of common illnesses such as sinus infections, pneumonia, ear infections and bronchitis. For this reason, families and doctors are often unaware that the troubling conditions that they are dealing with are actually rooted in a defect in the immune system, and may treat the symptoms rather than addressing the underlying cause. Failure to diagnose and treat PI can lead to serious chronic illness, permanent organ damage or even death.

“The JMF’s unwavering dedication to the early diagnosis and treatment of PI is evident through its many very successful endeavors, the most recent being the expansion of diagnostic services and outreach at Children’s Hospital Boston,” said Larry Stern, chairman and CEO of Talecris Biotherapeutics. “Talecris’ collaboration with the JMF and Children’s Hospital Boston demonstrates our ongoing commitment to improving the lives of those with PI.”

Talecris and the JMF are long-standing partners in the effort to raise awareness and increase diagnosis of PI globally. In addition to establishing diagnostic centers around the world, Talecris and the JMF have collaborated on programs to raise PI awareness in the U.S. and Europe.

About Jeffrey Modell Foundation

The Jeffrey Modell Foundation (JMF) was established in 1987 by Vicki and Fred Modell in memory of their son, Jeffrey, who died at the age of 15 of a PI disease. The Foundation is dedicated to early and precise diagnosis, meaningful treatments, and ultimately cures of PI. Today there are 39 Jeffrey Modell Research and Diagnostic Centers and more than 200 Referral Centers worldwide. The Jeffrey Modell Immunology Center at Harvard Medical School was dedicated in November 2007, and serves as a unique graduate facility for the study of immunology. More information about PI can be found at www.info4pi.org, or by contacting the JMF at (212) 819-0200 or [email protected].

About Talecris

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology and hemostasis. Talecris is proudly building upon a 60-year legacy of innovation and a commitment to improving the lives of people who rely on its therapeutic products. With an emphasis on scientific inquiry and technological excellence, Talecris is expanding its current portfolio of products, programs, and services through its own world-class product development organization as well as through strategic initiatives that leverage its strengths with those of its partners.

Talecris, with revenues of approximately $1.2 billion in 2007, is headquartered in biotech hub Research Triangle Park, N.C., and employs more than 4,500 talented people worldwide. To learn more about Talecris and how its employees are making a difference in the lives of patients and the healthcare community, visit www.talecris.com.

About Children’s Hospital Boston

Children’s Hospital Boston is home to the world’s largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults since 1869. More than 500 scientists, including eight members of the National Academy of Sciences, 11 members of the Institute of Medicine and 12 members of the Howard Hughes Medical Institute comprise Children’s research community. Founded as a 20-bed hospital for children, Children’s Hospital Boston today is a 397-bed comprehensive center for pediatric and adolescent health care grounded in the values of excellence in patient care and sensitivity to the complex needs and diversity of children and families. Children’s also is the primary pediatric teaching affiliate of Harvard Medical School. For more information about the hospital and its research visit: www.childrenshospital.org/newsroom.

Incyte’s Topical JAK Inhibitor Demonstrates Positive Proof-of-Concept Results in Patients With Mild to Moderate Psoriasis

Incyte Corporation (Nasdaq:INCY) reported positive results from two 28-day Phase IIa clinical trials of topical INCB18424, a selective janus-associated kinase (JAK) inhibitor, in patients with mild to moderate psoriasis. Results from the first study (Study 201), a Phase IIa dose-escalation trial involving 28 patients, demonstrated that INCB18424 was well tolerated at all doses and significantly improved overall total lesion score and each component of the total lesion score (thickness, erythema and scaling) as compared to vehicle. In this trial, INCB18424 at 1.5% twice daily also showed improvements in total lesion scores that were similar to the currently approved therapies, Dovenex(R) and Diprolene(R).

The second study (Study 202) is an ongoing open-label sub-total inunction 28-day Phase IIa trial designed to evaluate the safety and pharmacokinetics of INCB18424 at increasing coverage levels of total body surface area (BSA). Results from Study 202 demonstrated that INCB18424 was well tolerated in the first cohort of patients involving five subjects who applied the compound to not less than 2% or more than 7% of their BSA. Data from the first cohort of this trial also showed that INCB18424 improved lesion thickness, erythema and scaling, and reduced overall treated lesion area as compared to the overall untreated lesions.

Alice Gottlieb, M.D. Ph.D., Chair of Dermatology and Dermatologist-in-Chief at Tufts Medical Center and Harvey B. Ansell Professor of Dermatology at Tufts University School of Medicine and Senior Author stated, “In addition to the these encouraging safety and efficacy results seen with 28-days of treatment with INCB18424, transcriptional profiling data demonstrate that topical INCB18424 inhibits two key pathways, Th1 and Th17, that play important roles in the pathogenesis of psoriasis. Highly efficacious injectable anti-TNF agents inhibit many of the same pathways. While we lack long-term data, a topical JAK inhibitor may prove to be effective in patients with mild to moderate psoriasis.”

These findings were presented as a poster, “Initial Efficacy and Safety of Topical INCB018424 Cream, a Selective Janus Kinase 1&2 (JAK1&2) Inhibitor in Psoriasis”, at the 17th Congress of European Academy of Dermatology and Venereology currently being held in Paris.

To access a copy of the poster go to: http://investor.incyte.com/phoenix.zhtml?c=69764&p=irol-presentations

About the Phase IIa Clinical Trials

Study 201: A 28-day dose-escalating proof-of-concept trial designed to evaluate the preliminary efficacy, pharmacokinetics and safety of 0.5%, 1.0% and 1.5% once- or twice-daily topical formulations of INCB18424 versus vehicle or active comparators in patients with limited plaque psoriasis. Each cohort consisted of 5 or 6 subjects and each subject served as his or her own control with INCB18424 or vehicle applied to paired lesions separated by at least 15 cm in patients with active but stable plaque psoriasis.

Results from this study demonstrated that:

— the 1% once-daily dose and the 1.5% twice-daily dose decreased mean total lesion scores by 53% and 54%, respectively, compared with 32% and 27% reduction with vehicle treatment on day 28 (pless than or equal to 0.05);

— improvements were seen in each component of total lesion scores (lesion thickness, erythema and scaling); and,

— mean total lesion scores for the 1.5% twice-daily dose of INCB18424 decreased on day 28 by 46% as compared to 40 % for Dovonex(R) and 58% as compared to 44% for Diprolene(R)AF.

INCB18424 was well tolerated at all doses; no significant adverse effects were noted and no laboratory or ECG abnormalities were seen.

Study 202: This is an ongoing 28-day open-label sub-total inunction study to evaluate the safety and pharmacokinetics of INCB18424 in patients who apply the compound to as much as 20% of their BSA. Results from the first cohort of patients using the 1.5% twice-daily dose over 2-7% of their BSA demonstrated that INCB18424 improved lesion thickness, erythema and scaling and also reduced the overall treated lesion area as compared to the overall untreated lesions. In this study, INCB18424 was well tolerated with no serious adverse effects observed. Additionally, transcriptional profiling data in these patients confirmed that topical INCB18424 treatment inhibits two pathways, Th1 and Th17, which are considered to be central drivers of psoriasis. These effects correlated with clinically relevant improvements in total lesion scores.

Current Status of Topical INCB18424

A three-month Phase IIb trial involving approximately 300 psoriasis patients with mild to moderate disease is scheduled to begin in October. The Phase IIb trial will evaluate three doses of topical INCB18424 applied once-daily as compared to vehicle. The primary endpoints for the trial include change in total lesion score (erythema + scaling + thickness) of all psoriatic lesions, and safety and tolerability as assessed by monitoring signs and symptoms and through collection of clinical laboratory and blood samples. Secondary endpoints include change in individual lesion scores (erythema, scaling, and thickness) of all psoriatic lesions, the mean change in Physicians Global Assessment (PGA) in INCB18424 treated subjects compared to placebo subjects, the percentage of subjects achieving clear (0) and almost clear (1) on PGA, the percentage of subjects achieving improvements in their Psoriasis Area Severity Index (PASI) (PASI 50, PASI 75 and PASI 90 improvement), and trough plasma concentrations of INCB18424 prior to application at steady state.

About Psoriasis

Psoriasis is a chronic immune-mediated inflammatory skin disorder of unknown origin. The hallmarks of the disease are thick red skin lesions that are often itchy, sometimes painful and covered by silvery scales. According to the World Psoriasis Day consortium, psoriasis affects approximately 125 million people worldwide. The National Institutes of Health estimates that between 5.8 and 7.5 million Americans have psoriasis. It is estimated that over 85% of psoriasis patients have mild to moderate disease in which up to 10% of a patient’s total body surface area is affected.

Treatment of psoriasis is based on severity of the disease, with first-line therapy consisting of topical medications followed by ultraviolet light treatment (phototherapy) and systemic drugs. While drug treatments and phototherapies may clear lesions and relieve uncomfortable symptoms, many patients experience one or more exacerbations (flare ups) or relapses per year. Exacerbations occur when drug therapy is discontinued because of side effects and/or patient noncompliance, or tolerance to therapy develops.

About the Incyte JAK Inhibitor Program

There are four known JAK enzymes: JAK1, 2, 3 and TYK2. These enzymes are critical components of signaling mechanisms utilized by a number of cytokines and growth factors, including those that are elevated in psoriasis, rheumatoid arthritis and myeloproliferative disorders. Pathways triggered by the JAKs are dysregulated in inflammation, myeloproliferative diseases, and other liquid and solid cancers.

INCB18424 is Incyte’s lead internally developed JAK 1&2 inhibitor. The compound is a potent JAK inhibitor that is greater than100 fold selective against a broad panel of kinases and is being developed as a topical treatment for psoriasis, and as an oral treatment for rheumatoid arthritis, myelofibrosis, polycythemia vera, essential thrombocythemia, multiple myeloma, and hormone refractory prostate cancer.

Incyte has discovered multiple potent, selective and orally bioavailable JAK inhibitors from multiple distinct chemical scaffolds. A follow-on compound has completed single- and multiple-dose Phase I trials.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based drug discovery and development company focused on developing proprietary small molecule drugs to treat serious unmet medical needs. Incyte’s pipeline includes multiple compounds in Phase I and Phase II development for oncology, inflammation and diabetes. For additional information on Incyte, visit the Company’s web site at: www.incyte.com.

Forward Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements with respect to the potential for Incyte’s JAK inhibitor INCB18424 to be effective in longer-term studies, and plans to begin a three-month Phase IIb trial for INCB18424 involving 300 psoriasis patients in October are all forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the high degree of risk associated with drug development and clinical trials, the uncertainty of the FDA approval process, results of further research and development, the impact of competition and of technological advances and the ability of Incyte to compete against parties with greater financial or other resources, Incyte’s ability to enroll a sufficient number of patients for its clinical trials, and other risks detailed from time to time in Incyte’s filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2008. Incyte disclaims any intent or obligation to update these forward-looking statements.

Mayor Sacked Over of China Milk Powder Scandal

Text of report in English by official Chinese news agency Xinhua (New China News Agency)

[Xinhua: “1st Ld-Writethru: Mayor of Shijiazhuang Sacked Over Tainted Milk Powder Scandal”]

Shijiazhuang, Sept. 18 (Xinhua) – The mayor of Shijiazhuang, capital of north China’s Hebei Province, was sacked here on Thursday over a tainted milk powder scandal.

The dismissal of Ji Chuntang was made at the local legislature, one day after Ji was removed from his post as vice secretary of the Shijiazhuang Municipal Committee of the Chinese Communist Party (CCP).

The dairy giant Sanlu Group, based in Shijiazhuang, was the first company exposed in the scandal. More than 6,200 infants across the country had developed kidney stones after drinking Sanlu’s tainted baby formula, including three who have died.

Four officials in Shijiazhuang had been fired before Ji Chuntang. They included vice mayor in charge of agricultural production, head of animal husbandry and fishery bureau, director of food and drug administration and head of quality supervision bureau.

Hebei police have so far arrested 18 suspects connected to the baby milk powder scandal. Six of them allegedly sold the industrial chemical melamine to milk dealers, while the other 12 were milk dealers who added the chemical to milk and sold the tainted milk to dairy companies.

Originally published by Xinhua news agency, Beijing, in English 0604 18 Sep 08.

(c) 2008 BBC Monitoring Asia Pacific. Provided by ProQuest LLC. All rights Reserved.

US Refinery Investments Align With Oil Sands Supplies to 2015

By Sword, Lindsay

Supply of Canadian oil sands products will increase by 2 million b/d between 2007 and 2015; half of this growth will be in Canadian heavy crude blends. A recent study shows that the export pipeline infrastructure and US refinery capacity will be able to handle forecast additional supplies of Canadian crude during 2007-15. Planned export pipeline infrastructure should keep pace with forecast additional supply of oil sands products to 2015; export pipeline capacity will increase by 2.1 million b/d. Current capacity tightness should be resolved once expected new pipelines start up in 2008 and 2009. By the end of 2015, spare capacity will reduce, suggesting the need for additional export capacity shortly after 2015. Refinery projects targeting Canadian heavy blends that we expect to proceed are aligned with our forecast of additional supply: Canadian heavy blends supply will increase by 1 million b/d by 2015, and projects that are planning on processing heavy blends will increase by 1.1 million b/d.

Flexibility in Canadian heavy blends supply vs. refinery capacity will be available only after commissioning of the proposed Texas Access pipeline to the US Gulf Coast (post 2012). At that point, heavy-oil capacity in the region could be used to process Western Canadian blends if projects do not progress as planned in US Petroleum Administration for Defense District (PADD) 2.

Currently disclosed project costs reveal that pipeline companies and US refiners plan to invest more than $31 billion by 2015 to export and distribute oil sands products as well as process them in the US refining system. This figure excludes any investments in internal pipelines in Alberta, the Canadian refining and upgrading system, and undisclosed refining investments.

Our study shows that pipeline availability will largely determine the actual allocation of crude supplies by 2015:

* Canadian heavy blends. Most additional Canadian heavy blends will be refined in PADD 2 by 2015, with remaining supplies processed in new markets of the US Gulf Coast or supplied from Cushing, Okla.

* Synthetic crude oil. Most additional SCO will be shipped to the US Pacific Coast by 2015; pipeline constraints will limit transfers to PADDs 2 and 3. SCO that will make its way to the Midcontinent will be run in PADD 2 and US Gulf Coast refineries.

This study uses Wood Mackenzie’s refinery evaluation model, which provides independent appraisal of global refinery competitive position.

Canadian crude

Canada ranks as having one of the world’s largest oil reserves, after only Saudi Arabia and potentially Venezuela. The Albertan oils sands deposit has inplace resources of about 1.75 trillion bbl, of which about 10% are recoverable with current technologies.

Projected growth of Alberta’s oil sands output is triggering investments in US midstream and downstream sectors in anticipation of the new production. In Canada, oil producers have announced production projects as well as upgraders that will supply growing volumes of bitumen and SCO.

This has encouraged Canadian and US pipeline companies to propose new midstream infrastructure to deliver the production to market. US refiners have announced projects in preparation for the incoming flows from Western Canada.

This article analyzes the effect of pipeline and refinery investments during 2008-15, focusing on:

* Who is expected to invest and where?

* How will the projects fit together?

* How will the medium term look?

Upstream outlook

Strong growth in oil sands production during the past few years has been an important contributor to global supply and provided the US with the prospect of a secure source of supply from Canada. Bitumen production from Alberta’s oil sands during 2007-15 will increase to 3.1 million b/d from 1.2 million b/d.

This outlook is based on an assessment of individual projects that are currently in production or likely to come on stream. It also anticipates delays to projected start-up dates and less than full utilization rates due to anticipated technical problems.

A significant portion of bitumen production will be upgraded to SCO. Currently there are four upgraders in Alberta and Saskatchewan, operated by Suncor, Syncrude, Husky Energy, and the Athabasca Oil Sand Project. Canadian Natural Resources Ltd. and OPTI-Nexen have invested in new upgraders, scheduled for start-up in 2008. Lq addition, another 11 upgraders and one refinery conversion have been announced, projected to begin operating before 2015.

In reality, several of these projects including proposed expansions of existing upgraders are likely to be delayed, rescaled, or canceled due to increased cost, complexity of regulatory requirements, engineering and construction material shortages, as well as revisions to forecasts for bitumen output.

Nonupgraded bitumen is blended with diluents, synthetic oils, and conventional crude to reduce its viscosity before being pumped to the refineries. Resulting Canadian heavy blends and SCO supply will grow to 3.7 million b/d by 2015 from 1.7 million b/d in 2007.

Existing pipelines

The existing pipeline infrastructure to deliver oil sands crude to foreign markets consists of export pipelines and the internal distribution network in the US (Fig. 1). Most of the Canadian crude is exported to US markets through four major trunk-line systems:

* Enbridge-Lakehead system is the main route for Western Canadian crude exports to the US. It links Alberta with PADD 2 and also with Ontario. This system connects to downstream pipelines in Illinois, which extend to Cushing and the US Gulf Coast.

* Express-Platte system links Alberta with PADD 4 and, in a limited way, to PADD 2.

*; Western Corridor connects the Rangeland and Cenex pipelines in Western Canada with PADD 4.

* Trans Mountain pipeline is the only system that links Alberta with the Pacific Coast (Vancouver in Canada and Anacortes in the US).

These trunk lines transported about 1.7 million b/d of Canadian crude, including both conventional crude and oil-sands products, to the US in 2007. They are unable, however, to accommodate the projected increase in heavy oil supply from Western Canada.

New pipeline investments

There are many proposals to expand and extend the pipeline infrastructure to meet growing supplies from Western Canada in the short and medium term. In many cases, the decision to invest will be subject to support from pipeline users and regulatory approval, leaving considerable potentials for delay.

Fig. 1 shows the existing and proposed pipelines to export and distribute Canadian crude.

Enbridge is investing the most in pipeline infrastructure. Its projects with disclosed cost information total more than $8.5 billion. Other companies including Kinder Morgan and ConocoPhillips- TransCanada have announced investments totaling more than $7.3 billion, and there are three substantial projects proposed for after 2010 with undisclosed costs.

New and incremental export pipeline projects will provide an additional 2.1 million b/d of capacity between 2008 and 2015. The downstream distribution pipelines most likely to proceed will add 250,000 b/d of additional capacity to Eastern PADD 2, 65,000 b/d to Cushing, Okla., and 450,000 b/d to the US Gulf Coast during 2008- 15.

Expansion of the pipeline infrastructure will focus on PADD 2 in the short term. Expansions will not allow significant oil sands products to reach the US Gulf and Pacific Coasts until after 2012.

Downstream

Fig. 2 shows an indicative allocation of additional oil sands products by 2015.

It also shows that, assuming Canadian heavy blends’ intake into PADD 2 reach maximum capacity by 2015, only small volumes of oil sands products would reach the US Gulf Coast (PADD 3) by yearend 2015.

This raises a question regarding the future supply of additional heavy crude in PADD 3, given the significant number of projects that are planning to upgrade heavy oils in this region, and may lead to some strong price competition for Canadian heavy blends that could affect the various flows in Fig. 2.

Canadian heavy blends

The growth of heavy oil sands production and the attractive price differential vs. conventional light crudes has encouraged proposed refinery investments in the US targeted at processing heavy blends.

Refiners that lead the investment in refinery expansions and upgrading to run Canadian heavy blends are BP PLC (including its partnership with Husky Energy), ConocoPhillips (by means of its WRB Refining joint venture with EnCana), and Marathon Petroleum Corp. These three companies and their partners currently plan to invest $13 billion to add about 850,000 b/d of heavy blends processing capacity by 2015.

Other refiners have announced refinery projects that will require investments exceeding $1.7 billion to process an additional 205,000 b/d of oil sands blends by 2015.

The investment climate is changing quickly; increasing project costs, availability of raw materials and labor, as well as reductions in refinery margins are delaying and could lead to cancellation of several proposed projects.

Most of the announced capacity will be built in PADD 2 areas already supplied by Western Canadian crude and only 250,000 b/d in southern markets. In addition to the investments listed in the accompanying table, there are several expansion and upgrading projects that will increase heavy oil processing, most of them on the US Gulf Coast but not necessarily planned exclusively for Canadian heavy blends feedstocks. Synthetic crude oil

There have been no announcements of new capacity in the US specifically for processing SCO. SCO can replace light sweet conventional crude in most refineries. The sensitivity of each refinery to the weak point of SCO-poor quality of the distillates- determines how much each refinery can process. Ln most cases, dilution in the crude slate is sufficient to overcome this.

Wood Mackenzie assumes that SCO will compete with both domestic and foreign light crude oil in the US. Canadian SCO penetration will redistribute domestic light crude flows within the US. This will likely result in less domestic crude from the US Gulf Coast and Texas transferring to PADD 2. PADD 3 refineries will instead process this crude.

The net effect of increased SCO intake by US refineries will be the replacement of foreign crude in the US market.

Lindsay Sword

Wood Mackenzie

Edinburg

The author

Lindsay Sword ([email protected]) is product manager, global refinery view for Wood Mackenzie, Edinburg. She has worked for Wood Mackenzie since 1996 in both research and consulting, focusing on the downstream industry with a particular emphasis on refining. Sword has been involved in detailed analysis of refinery supply, product quality, oil product pricing, and refinery economics, as well as product trade. She has worked on a range of downstream consulting assignments including market analyses and pricing studies in Europe, the US, and Asia Pacific. Sword moved from consulting to research in 2006 to develop the global refinery view research offering.

Copyright PennWell Corporation Aug 18, 2008

(c) 2008 Oil & Gas Journal. Provided by ProQuest LLC. All rights Reserved.

Assessment and General Education: Resisting Reductionism Without Resisting Responsibility

By Katz, Stanley N

GENERALIZATIONS about longitudinal collegiate assessment are difficult to make, and they are often problematic. For one thing, there is an incredible range of institutional types. Even if we were to stipulate a primary interest in fouryear liberal arts institutions, we would find that almost all colleges and universities lay claimhowever plausibly-to this designation. And apart from their differing educational structures and missions, institutions also differ in terms of access to resources, geographical location, faculty, and much else. Further, there is no modal student in American higher education. Public discussions frequently imagine student bodies composed of recent high school graduates, mostly native-born, who attend school full time, graduate in roughly four years, live on or near campus, and seek a liberal education. Yet the majority of college students are part-time, and many attend two or even three institutions before gaining a degree. Liberal education is not a personal goal for most of these students. If we cannot readily generalize about the universe we would like to assess, then how can we even begin to think about the problem of longitudinal assessment? We could take a deep breath and assert that, regardless of the institutional differences, the relevant group in each institution is the students; students are the constant, and student learning is what we need to measure. Or we could throw up our hands and say that, because both students and institutions differ so widely, there is no point in making comparisons that are inevitably artificial or even meaningless. We might still conclude, however, that such objections do not hold for intrainstitutional assessment or, perhaps, assessment within peer groups of institutions.

Any attempt at institutional assessment is likely to provoke objections like those raised in reaction to the Spellings Commission, which, in the name of educational accountability, touted mandatory national outcomes assessment through standardized tests as the reform of the future. Although the commission ultimately backed off this extreme and ill-considered recommendation, the specter of a Spellings future has turned many educators into adamant opponents of outcomes assessment per se. The rationale for these objections needs to be taken seriously. Moreover, there seems to be something inherent in liberal education itself that is hostile to formal assessment. From this point of view, students are works of art in progress; we cannot know whether they have truly been liberally educated until many years after graduation-if ever.

While I strongly believe that we must attempt to assess the effectiveness of liberal education, I recognize that “liberal education” means different things to different people and that different sorts of institutions have quite different formal duties of accountability. I refuse to accept the consumerist assumptions that Chairman Charles Miller of the Spellings Commission and many others apply to higher education, but I also reject the notion that the higher education community as a whole does not share important values and goals. I am not yet convinced that there is any adequate way to assess across this vast universe, hut my mind is open on the subject. I do, however, feel fairly sure that we can assess across comparable groups of institutions and that both the community as a whole and individual institutions would benefit from the effort.

Institutional self-assessment

Individual institutions can and should attempt to determine how much and how well their students have learned, but it is not clear how best that could be done. Every institution has a responsibility, both to itself and to the broader educational community, to learn the extent to which it is meeting its educational goals. Therefore, institutional self-accountability is what matters most. As faculty members and administrators, we need to be able to say to ourselves that we are clear about both what our objectives are and whether we are achieving them. From this point of view, the most important use of assessment is in the reevaluation of curriculum, cocurriculum, and anything else relevant to the student learning experience.

Measurable proxies for the student educational experience are clearly needed to provide fixed points of comparison over time, and in order to enable comparisons across institutions, these proxies would have to exist across all forms of liberal education. The more subjective the proxies are-and, thus, more difficult to measure with a high degree of confidence-the less useful they would be. The more objective and easily measured the proxies are, the less subtle and meaningful they may be. The specification of fixed points to measure is the most significant challenge.

Most advocates of liberal education deny that a primarily content- based evaluation of what seniors have learned represents an assessment of the totality of the educational experience. Obviously, the graduating history or biology major should be able to demonstrate considerably greater subject-matter competence than the student just entering the major. Nor do we accept the senior’s comparably broader general knowledge, beyond his or her field of concentration, as a proxy for liberal education. Yet these are the aspects of student learning that are most easily and objectively measured, and they are the ones usually assessed.

The unwillingness to accept these fairly objective proxies is rooted in a commitment to the notion that liberal learning has more to do with the cultivation of qualities of the mind than with the mastery of any quantum of information. What the liberal educator seeks to develop is the capacity to recognize meaningful problems and to identify the information and modes of analysis necessary to address them as well as the instinct to bring these to bear in problem solving. These capacities are much more difficult to measure, although a variety of tests and other assessment exercises have been constructed to try to assess them with some level of precision.

Many right-minded skeptics assert that the very attempt to measure learning outcomes is likely to stifle student creativity, since the forms of assessment create incentives for students to mimic what they assume the assessors seek. This is not a trivial problem, and it is the reason many stress the need for culminating demonstrations of knowledge in the senior year. Having directed senior theses for many years, I am very sympathetic to this view; but senior theses are not enough. Liberal educators should seek more adequate means of both culminating and longitudinal assessment of undergraduate learning. Over the past decade there have been a number of serious attempts to do just that.

National assessment Instruments

A wide variety of institutional assessment instruments are now available. Some address institution-specific student experiences, others are topic specific, and still others portray national information relating to higher education. The two instruments currently thought to hold the greatest promise are the National Survey of Student Engagement (NSSE) and the Collegiate Learning Assessment (CLA).

NSSE and CLA are, however, very different sorts of assessment instruments. NSSE is designed to obtain from large numbers of colleges and universities, on an annual basis, information about participation in programs and activities provided for student learning and personal development. NSSE inquires about institutional actions and behavior, student behavior inside and outside the classroom, and student reactions to their own collegiate experiences. CLA, on the other hand, is an approach to assessing an institution’s contribution to student learning by measuring the outcomes of simulations of complex, ambiguous situations that students may face after graduation. CLA attempts to measute critical thinking, analytical reasoning, written communication, and problem solving through the use of “performance tasks” and “analytical writing tasks.”

Both of these assessment projects result from substantial financial investment and research, and both are serious efforts to create quantifiable measures of the outcomes of liberal education for samples of college students. The proxies each uses for learning outcomes are very different, as are their assessment strategies. Nonetheless, the general project to collect meaningful institutional data represents a good-faith effort to respond to national calls for accountability, and NSSE and CLA provide such data. We are in the early days of this movement, however, and are not yet capable of confidently assessing the assessments.

The more interesting question is, what can and should be done with these data? Some clearly hope that cross-institutional comparisons based on them will provide for a quality ranking of institutions that is more reliable than the faux-scientific rankings currently offered in popular magazines. If one takes a consumerist view of higher education, this makes sense; it would give prospective college students (and their parents) more objective information about the respective educational merits of different colleges and universities. Yet many of the institutional participants in these new assessment exercises will not release the findings, and even if they did, it is not altogether clear that what is being measured would provide satisfactory purchasing signals to prospective students. To the extent that making the findings available can genuinely facilitate informed college selection, however, all responsible educators should favor it. But we are not there yet, and so we will just have to live with U.S. News & World Report for the foreseeable future-doing our best to be noncooperative and noncomplicit in a deeply flawed and poorly motivated process. More consequentially, we will also have to live with continuing Spellings-like demands for accountability in higher education. This, I suspect, is why the Association of American Colleges and Universities (AAC&.U) has collaborated with the Council for Higher Education Accreditation to issue the recent report New Leadership for Student Learning and Accountability (2008). Most striking about this report is what, in contrast to the Spellings Commission report, it does not include-namely, a demand for standardized metrics of outcomes assessment that would permit systematic comparison across institutions of higher education. Instead, the report emphasizes the responsibility of colleges and universities to “develop ambitious, specific, and clearly stated goals for student learning” appropriate to their “mission, resources, tradition, student body, and community setting” in order to “achiev[e] excellence.”

Each college and university should gather evidence about how well students in various programs are achieving learning goals across the curriculum and about the ability of its graduates to succeed in a challenging and rapidly changing world. The evidence gathered … should be used by each institution and its faculty to develop coherent, effective strategies for educational improvement. (2)

I agree with almost all of this-and why not, since the statement so carefully avoids endorsing cross-institutional comparisons? Yet I am concerned by the double bottom line: ( 1 ) the assessment of the achievement of “learning goals across the curriculum” and (2) the assessment of “the ability of graduates to succeed.” Are we really responsible for the future success of our graduates in the same way that we are responsible for their learning while in college? Can we really assess future success in ways that do not privilege income and social status as measures of accomplishment? I doubt it, and I firmly oppose such a commitment.

Individual colleges and universities themselves might be able to make creative use of data from institutional assessment instruments in order to determine what works in their own learning programs, and what does not. The one certainty that emerges from the rather tedious ongoing debate about accountability is that each institution has a duty to itself rigorously to evaluate the effectiveness of the student learning it facilitates. And it follows that we owe this duty to our students, to their parents, to the faculty, and to our (public and private) donors.

Public institutions have additional responsibilities to external stakeholders, not least their state legislatures. In response to the special political pressures for accountability on public institutions, the National Association of State Universities and Land-Grant Colleges and the American Association of State Colleges and Universities have created the Voluntary System of Accountability (VSA), a highly objective and potentially comparable crossinstitutional database. Setting aside such a project as unlikely for all of higher education, and acknowledging that the noncompliance of the University of California system does not bode well for the VSA, it seems to me that American educational pluralism dictates that each institution must think through its own standards of accountability. In doing so, an institution should involve all of its many stakeholders.

It seems quite reasonable for colleges and universities to avail themselves of national assessment instruments that at least provide significant benchmarks for evaluating the success of student learning. Depending upon the open availability of data, it may also be possible for institutions to compare themselves to one another. Yet many institutions will not consider these instruments to be sufficient or, perhaps, adequate. But in that case, the burden should fall on that college or university to develop its own internal modes of assessment.

Lessons from history

Conscientious institutions are careful in constructing curricula. We devote time and human resources to designing both general education and field of concentration curricula. We take evaluation of student performance in courses seriously. We are increasingly concerned to support new types of learning experiences, from freshman seminars and undergraduate research to service learning and study abroad. We are experimenting with the potential of information technology and new media to enhance student learning. We are steadily making new fields of knowledge, most of them interdisciplinary, available to our students. These are exciting days in American higher education. But do we really know whether and why we are successful in promoting student learning, if we are?

In a new report, the Education Testing Service advocates a seven- step approach to creating “an evidence-based accountability system for student learning outcomes.” The penultimate step is to determine “What Institutional Changes Need to be Made to Address Learning Shortfalls and Ensure Continued Success.” The report recommends communicating the results of data analysis, “using the internal decision-making processes of the institution [to determine] the meaning of the successes and the shortfalls,” and then making educational policy decisions based on this analysis (Millett et al. 2008, 17). The double assumption here is that the data analysis will lead to clear policy decisions and that the institution will have the will and capacity to shift educational policies accordingly. Is it too cynical to suggest that few institutions are fully capable of carrying out step six?

The history of higher education in this regard is not encouraging. We have been worrying about just these sorts of problems for more than a century. In 1933, for example, the American Association of University Professors (AAUP) addressed many of the same questions that vex us today. That year, the AAUP Committee on College and University Teaching issued a report that begins by noting the very problem that remains at the core of our assessment challenge: “The college classroom is the professor’s castle. He does not object to the invasion of it by his own colleagues who understand his problems and difficulties, but he reacts against the intrusion of anyone outside that circle who undertakes to scrutinize and appraise his work” (7). The report then picks up on what is today one of the leading criticisms: “Does the college teacher, as such, have a clear conception of what he is trying to do, or indeed of what his institution is seeking to do?” (36). And its assumption of what constitutes good teaching is one that still commands respect. Good teaching “is the kind of teaching which inspires the student to take an active part in the educational process, in other words inspires him to educate himself rather than to expect that someone else will do it for him” (36). The report goes on to assert that “any teacher who gains the desired end, who induces self- education on the part of his students, is an effective teacher no matter what his methods or personal attributes may be” (36). It then asserts that “the main function of the teacher is to stimulate critical thinking, to train his students in methods of reasoning and to carry them back to the sources of the facts, as well as to encourage them to form their own conclusions” (95).

Reading the 1933 AAUP report is an unsettling experience; it might well have been written last year. It notes that many of our difficulties “are connected with the great expansion in college enrollment which has taken place during the past twenty years” (39). And the bottom line is devastatingly reminiscent of our current assessment debates:

There is reason to feel that the general standards of college teaching in the United States have been, on the whole commendably high. Unfortunately, when any one takes issue with this assertion, there is no convincing way of substantiating it. For college teachers have as yet devised no systematic means of having the results of their own work fairly evaluated. They have worked out no objective way of determining whether their work is good or bad.

The college teacher plans his own course and gives his own instruction; at the end of the term he prepares his own examinations, tests his own students, and renders his own verdicat upon what he has accomplished. He looks on his handiwork and says that it is good. This self-appraisal of results is not checked by anyone else. (41)

Taking away the current student evaluation system, a very partial reform at best, can we claim much more today in most colleges and universities? The AAUP concluded that “if even a small portion of the ingenuity and persistence which are now being expended on research of the usual type in American colleges and universities could be deflected … toward research into the results of their own teaching, the improvement in the general standards of collegiate instruction might be considerable” (68). These words were written eighty-five years ago!

The AAUP report is disturbing for another, more important, reason. Its authors were propagandists for “general education” in the same way that AAC&U currently advocates for “liberal education.” But the history of higher education in the last century suggests that, in fact, “general education” was a weak idea with little unifying or binding power either within or across institutions. If that is correct, then how likely is it that switching from “general” to “liberal” is going to solve the problem? If we are to have meaningful assessment, is it possible that we will need to assess something more precise than “liberal education” and broader than student performance in courses? The courage to assess, and the capacity to assess, is dependent upon the courage of an institution to do something other than to put the pea under a different shell. This is the real issue, and resolving it will take a massive effort of educational re imagination. Conclusion

The present utility of institutional assessment lies in its potential capacity to enable us to begin to understand what we are doing, and to plan for educational change. If we truly can measure student learning at the levels of sophistication necessary to know whether we are achieving the outcomes we strive for, then assessment data should enable us to begin to make informed judgments about what we are doing wrong, and what we are doing right. And then we can adjust our learning strategies accordingly. Or at least we can have a more meaningful debate about our goals and strategies. Right now, we too often fail to see beyond tactics.

Many thoughtful critics of outcomes assessment warn that a Spellings-like mandate would violate the educational self- determination of institutions and move higher education in the direction of robotic self-imitation. That is indeed a terrible prospect. secretary Spellings herself has moved away from such an approach, however, and I do not think we ought to behave like Chicken Little. It is possible for us to assess ourselves in ways that will not only help institutions improve student learning, but might also create the norms and benchmarks that will enable us to move ahead nationally in our quest to improve the quality of undergraduate education.

To respond to this article, e-mail [email protected], with the author’s name on the subject line.

I feel fairly sure that we can assess across comparable groups of institutions and that both the community as a whole and individual institutions would benefit from the effort

The specter of a Spellings future has turned many educators into adamant opponents of outcomes assessment per se

The general project to collect meaningful institutional data represents a good-faith effort to respond to national calls for accountabiity

Is it possible that we will need to assess something more precise than “liberal education” and broader than student performance in courses?

REFERENCES

American Association of University Professots. 1933. Repott of the committee on college and university teaching. AAUP Bulletin 19 (5, section 2): 7-122.

Association of American Colleges and Universities and the Council for Higher Education Accreditation. 2008. New leadership for student learning and accountability. Washington, DC: Association of American Colleges and Universities.

Millett, C. M., D. G. Payne, C. A. Dwyer, L. M. Stickler, and J. J. Alexiou. 2008. A culture of evidence: An evidence-centered approach to accountability for student learning outcomes. Princeton, NJ: Educational Testing Service.

STANLEY N. KATZ is lecturer with the rank of professor in public and inrernatiorui/ affairs, faculty chair of the undergraduate program, and director of the Center for Arts and Cultural Policy Studies at Princeton University. This article is adapted from the plenary address at “integralitive Designs for General Education and Assessment,” an AAC&U Network for Academic Renewal conference held in February 2008.

Copyright Association of American Colleges and Universities Summer 2008

(c) 2008 Liberal Education. Provided by ProQuest LLC. All rights Reserved.

Oceanography Isn’t the Same As Marine Biology

When I attend a middle school or high school career day, I often have a student tell me, “I want to be an oceanographer.” But as we talk more, I realize that what the student really wants to be is a marine biologist. Or sometimes it’s the other way around – the student says “marine biology” when he or she is thinking of oceanography. What’s the difference? Basically, it comes down to this – an oceanographer studies the oceans, a marine biologist studies marine life.

Oceanography is the study of the oceans. Since most of our planet is covered by oceans, that’s a pretty big subject. So oceanographers usually study one of the four basic areas of oceanography:

– Chemical oceanography is the study of seawater composition. This covers how it changes from one area of the ocean to another and what chemical elements and compounds are present that should or should not be there.

– Physical oceanography is the study of the movements of the ocean brought about by wind, tides, waves, currents, and temperature and salinity differences.

– Geological oceanography is the study of the sea floor. It covers the sediments and rocks on the bottom of the ocean, as well as the undersea mountain ranges, sea mounts, volcanoes, earthquakes, hydrothermal vents and other events that take place as the ocean’s crust moves.

– Biological oceanography is the study of the interaction of the plants and animals of the ocean with their environment. This also can be a part of marine biology. However, the biological oceanographer focuses more on how the interaction affects the ocean than the individual organism.

Biological oceanography is the most interdisciplinary area of oceanography. Biological oceanographers want to describe the diversity of marine life, especially in habitats such as the deep sea where so much is still unknown. They use submersibles and remotely operated vehicles.

They also use oceanographic vessels equipped with sonar, GPS, dredges, corers, trawls, plankton nets and other samplers to collect ocean organisms and information on the physical, chemical and geological factors that control their lives.

If you are curious about the natural world, like to solve puzzles, think three-dimensionally and try to figure out how things work, you might want to become an oceanographer.

If you also like to be outdoors (especially at sea) and if you can write clearly (all scientists must write up their research and publish it to make it known to others), you should consider working in this field.

To be in charge of a research project, you will have to go to college and graduate school to get a doctorate in oceanography. As a college or graduate student, you will start going on oceanographic cruises to help your professors with their projects.

There are other careers in oceanography, too. There are opportunities that do not require as many years of school, such as in the Navy and Coast Guard, or as a crew member or technician on a research ship.

Virginia science Standards of Learning: 3.5; 3.6; 4.5; 5.6; LS.7; ES.11.

On the Web

Neptune’s Web: Get the facts on oceanography at this fun site full of information, quizzes and links to related sites.

(http://www.navmetoccom.navy.mil/educate/neptune/neptune.htm)

National Oceanic and Atmospheric Administration Ocean Explorer: This is an educational site for you to learn about, discover, and virtually explore the ocean. (http://oceanexplorer.noaa.gov/)

Marine Bio: Explore the depths of Marine Bio to find out more about marine species, ocean conservation, research and lots more.

(http://marinebio.org/)

Judith Winston is curator of marine biology at the Virginia Museum of Natural History in Martinsville.

MEMO: Sci-Kids

Originally published by WINSTON; Special Correspondent.

(c) 2008 Richmond Times – Dispatch. Provided by ProQuest LLC. All rights Reserved.

Coining and Defining Novel Nursing Terminology. Part 1: Critical Incident Nursing Diagnosis

By Wong, Elizabeth

PURPOSE. In the first of a three-part series, a novel nursing terminology is introduced and proposed for inclusion in the North American Nursing Diagnosis Association (NANDA) International ClassificationCritical incident nursing diagnosis (CIND)-defined as the recognition of an acute life-threatening event that occurs as a result of disease, surgery, treatment, or medication. DATA SOURCES. The literature, research studies, and meta-analyses from a variety of disciplines, and personal clinical experience serve as the data sources for this article.

DATA SYNTHESIS. The current nursing diagnoses in the NANDA International Classification are inaccurate or inadequate for describing nursing care during lifethreatening situations. The lack of standardized nursing terminology creates a barrier that may impede critical communication and patient care during life- threatening situations.

CONCLUSIONS. Coining and defining a novel nursing terminology, CIND, for patient care during life-threatening situations are important and fill the gap in the current standardized nursing terminology.

IMPLICATIONS FOR NURSING PRACTICE. Refining the NANDA International Classification will permit nursing researchers, among others, to conduct studies on nursing diagnoses in conjunction with the proposed novel nursing terminology: CIND. Parts 2 and 3 of this series will propose additional nursing terminology: critical incident nursing intervention and critical incident control, respectively.

Search terms: Critical incident nursing diagnosis, definition principles, NANDA International Classification, nursing diagnosis, standardized nursing terminology

Introduction

Coining and defining novel nursing terminology to record nursing behaviors inherent in the practice and experience of critical care registered nurses (CCRN) can be a challenging task. The initial impetus for this endeavor was the realization that the current standardized nursing terminology contained in the NANDA International Classification is inadequate or inaccurate for describing nursing diagnoses that may be required during the course of patient care during life-threatening situations. The lack of standardized nursing terminology creates a barrier that may impede critical communication to other registered nurses (RNs), the public, and other healthcare professionals.

Historical Overview of Standardized Nursing Terminology

The first nursing textbook written by Nightingale (1969/1860), Notes on Nursing: What It Is and What It Is Not, contains keen, accurate descriptions of nursing behaviors or treatments responsible for returning a patient to wellness. Note that all of the words Nightingale used to define the term observation are different, yet they describe the same nursing behavior. The use of different terms to describe nursing behavior prohibits the clear categorization of these nursing behaviors for purposes of the systematic study, teaching, application, and research of nurses’ contribution to patient care. What was ultimately needed was a standard classification system for nursing practice.

The organization of standardized nursing diagnosis terminology was pioneered in the 1970s by Gebbie and Lavin (1974) in their seminal article “Classifying Nursing Diagnoses.” A prominent group of nurse theorists joined the First Task Force to Name and Classify Nursing Diagnoses in 1977 in order to further develop the work that Gebbie and Lavin began (NANDA International, 2007). The development and construction of the nursing diagnosis classification eventually led to the formation of NANDA in 1982 (NANDA International). As a result of widespread research, testing, acceptance, and expansion of the term nursing diagnosis, NANDA has gained international status and is now known as NANDA International; the NANDA International Classification was accepted by the American Nurses Association in 1987 and the International Council of Nurses in 1989 as the definitive source for nursing diagnoses (Carpenito, 1997).

A literature search was conducted using the keyword “nursing diagnosis.” Over the past three decades 3,412 articles (U.S. National Library of Medicine, 2008) have been written that scrutinize the ability of standardized nursing diagnosis terminology to benefit the practice of nursing. Most recently, Muller-Staub, Lavin, Needham, and van Achterberg (2006) conducted a meta-analysis of 48 nursing articles that specifically examine the effect of nursing diagnoses on the documentation of the quality of nursing assessment; the quality, frequency, accuracy, and completeness of nursing diagnoses; and the coherence among nursing diagnosis, interventions, and outcomes. The conclusion of this meta-analysis was that the use of nursing diagnostics improved the documentation of nursing assessment, the quality of reporting nursing interventions, and the outcomes attained; conversely, deficits were noted in the reporting of signs, symptoms, and etiology. In short, what is apparent from a review of the history of the development of standardized nursing terminology is that such a system is greatly needed, investigation of its accuracy and relevance is ongoing, it has been accepted internationally by the nursing community, it is documented in nursing textbooks, and, finally, it is used to advance the profession of nursing globally for the betterment of patient care.

Some confusion may exist between the terms medical diagnosis, which is defined as “the entire process of identifying the cause of the patient’s illness or discomfort” (Thomas, 1993, p. 531), versus nursing diagnosis, which is defined as “a clinical judgment about individual, family, or community responses to actual or potential health problems/life processes. A nursing diagnosis provides the basis for selection of nursing interventions to achieve outcomes for which the nurse is accountable” (Neal, 2007, p. 332). Both medicine and nursing use data collection and data analysis to arrive at a standardized label for a particular cause of the patient’s illness or discomfort. The difference between a medical diagnosis (e.g., congestive heart failure, diabetes mellitus, hypertension) and a nursing diagnosis (e.g., Risk for Falls, Readiness for Enhanced Comfort, or Bathing/Hygiene Self-care Deficit) lies in the object or primary focus of the investigation, the tools and methods of the investigation, and the nature of the conclusion reached (Kelly, 1985).

NANDA International Classification: Evidence of Work in Progress

Retrospective reviews have been written by researchers attempting to classify nursing behaviors from documented descriptions. Meyer and Lavin (2005) examined Nightingale’s observations of nursing behavior and indicate that Nightingale is describing the term vigilance. They maintain that vigilance is the essence of nursing care and define it as “attention to and identification of clinically significant observations, signals, cues; calculation of risk inherent in nursing practice situations; and readiness to act appropriately and efficiently to minimize risks and to respond to threats” (p. 2). Vigilance, the authors contend, is practiced by modern RNs also. A recommendation by the authors has been made that the NANDA International Classification should be expanded to include the novel nursing terminology vigilance under a novel nursing diagnostic label: Surveillance Nursing Diagnosis. Nursing Diagnoses: Definitions and Classification 20072008 contains an entire section outlining the procedure for submitting new nursing diagnoses in article or outline format for review by the NANDA International Diagnostic Review Committee (Neal, 2007).

Principles of Definition

Words or terms may have several meanings and may be confusing to readers and users of those words or terms. Thus, definitions have been developed for each word or term to clarify the meaning to the reader and user. A definition of a word or term is a fundamental means of organizing information. The goal of a definition is to develop a statement that gives an outline and boundaries for the usage of the word or term. Several rules for the development of a definition exist. The word or term being defined, or definiendum, is written followed by the defining expression, or definiens. The definiens has the same or equivalent meaning as the definiendum. Thus, the standard format for a definition is that X means Y and/or Y means X (Bulechek & McCloskey, 1992; Mills, 1991; Snyder, Egan, & Nojima, 1996). The word or term is capitalized when it is used as a proper noun in a sentence.

The development of a term or concept for standardized nursing terminology begins with the nursing diagnosis as the foundation for nursing interventions and nursing outcomes. Lunney (1990, 1998) stresses that accuracy is absolutely essential so that the RN is able to use the nursing diagnostic term to help interpret human behavior and responses in order to guide patient care. Characteristics of the accuracy of a nursing diagnosis encompass the use of patient cues to support the nursing diagnosis. “Accuracy exists when a diagnosis matches the real or true state of the patient, and accuracy reflects a specific state of existence, therefore, diagnoses that do not reflect this state of existence are inaccurate” (Lunney, p. 13). Every effort was made to follow these principles for defining terms when suggesting a novel term to be included in the NANDA International Classification that is the focus of Part 1 of this three-part series. The importance of developing accurate, standardized nursing terminology cannot be overstressed. Safar (1974) reminds us that “investigators at all levels should communicate with each other using the same terminology” (p. 543). Critical Incident Nursing Diagnosis

Registered nurses have been identifying life-saving nursing diagnoses since the advent of modern nursing. Descriptions of patient care scenarios are often used to convey nursing diagnoses and nursing interventions that made the difference between life and death for a patient. In the following example, an RN recounts her ability to recognize important life and death cues and to intervene appropriately:

An elderly patient was transported to the intensive care unit (ICU) from the operating room after undergoing a 4-hr intracranial neurosurgical procedure followed by successful extubation of the trachea. The patient was quietly spontaneously breathing eight breaths per minute while wearing an oxygen mask during transport.

Arrival at the ICU is a hectic period in which the patient is disconnected from the transport monitors and reconnected to the bedside monitors. During this time the elderly patient became apneic due to having a poor respiratory drive with resultant airway obstruction. The CCRN noticed this serious incident. The CCRN stopped what she was doing, reached over, strategically placed her index finger under the patient’s chin, and lifted it. This painful maneuver stimulated the patient and opened the patient’s obstructed airway, hence his breathing resumed.

In the above scenario, the primary and most important nursing diagnosis for this patient was the NANDA International-approved nursing diagnosis: Impaired Spontaneous Ventilation. The NANDA International textbook format of Domain, Class, Nursing Diagnosis, Defining Characteristics, and Related Factors for Impaired Spontaneous Ventilation are shown in Table 1 (Neal, 2007). The Activity/Rest Domain is defined as “the production, conservation, expenditure, or balance of energy resources” (p. 273), while the Cardiovascular/Pulmonary Responses Class is defined as “cardiopulmonary mechanisms that support activity/ rest” (Neal, p. 274). By definition this Domain and Class may be appropriate for certain nursing diagnoses such as Activity Intolerance or Risk for Activity Intolerance, but it may not be a good fit for a nursing diagnosis such as Impaired Spontaneous Ventilation. In the example shown in Table 1 NANDA International classifies non-life- threatening nursing diagnoses along with life-threatening nursing diagnoses. Would an RN, or any outside group, looking up a standardized nursing term to designate or chart a life-threatening event such as apnea consult the Activity/Rest Domain for the appropriate nursing diagnosis? As will be explained in greater detail later, non-life-threatening nursing diagnoses or routine nursing diagnoses are completely separate in importance and priority when compared to life-threatening nursing diagnoses.

Even the definition of Impaired Spontaneous Ventilation does not appear to be accurate or adequate, as NANDA International defines the standardized nursing term impaired as “damaged or weakened” (Neal, 2007, p. 260). Weak ventilations may not necessarily be life- threatening, and the standardized nursing term “damaged ventilations” does not make sense. The label does not appear to be an intuitive good fit for the definition. Life-threatening nursing diagnoses require their specific designation so that they may be researched, taught, and applied clinically. Thus, the novel nursing terminology, CIND, defined as the recognition of an acute life- threatening event that occurs as a result of disease, surgery, treatment, or medication, should be included in the NANDA International Classification.

Proposal for the Inclusion of CIND in the NANDA International Classification

Lash (1978) conducted a review of the definitions of nursing diagnoses in journals published from 1956 through 1978 and determined that there were six common characteristics:

1. A nursing diagnosis is made by a professional nurse.

2. A nursing diagnosis is a summary statement.

3. A nursing diagnosis is derived from patient data.

4. A nursing diagnosis is about health problems.

5. A nursing diagnosis is about a therapeutic decision amenable to a nursing intervention.

6. A nursing diagnosis is the necessary base for nursing care. (p. 334).

The novel term, CIND, fulfills all six characteristics outlined by Lash. For example, the RN recognizes a life-threatening situation as a result of disease, surgery, treatment, or medication, using clinical assessment skills derived from patient data. Following the nursing diagnosis, the RN makes a therapeutic decision that results in a nursing intervention that attempts to reverse the life- threatening situation. In addition, life-threatening nursing diagnoses should be separated from non-lifethreatening or routine nursing diagnoses, with the placement of life-threatening nursing diagnoses in the Safety/Protection Domain. The current Safety/ Protection Domain is shown in Table 2, and the proposed novel Safety/ Protection Domain is shown in Table 3.

Implications

The issue of improving the quality of care that RNs deliver has gained national momentum. In 2007, the Joint Commission and Accreditation of Healthcare Organizations launched a research project aimed at collecting data on 12 nursing-sensitive performance measures (Joint Commission, 2008). The first nursingsensitive performance measure is “death among surgical in-patients with treatable serious complications; failure-to-rescue.” Unfortunately, the research project does not stipulate which are “treatable serious complications.” Being able to recognize or conduct a nursing diagnosis of a “treatable serious complication” is an important first step for an RN to perform in this schema and a critical example of where standardized nursing terminology is required. Including the novel nursing terminology, CIND, in the NANDA International Classification would be an aid in this research.

Summary

Maas, Hardy, and Craft (1990) stated that “for the science of a practice discipline to progress, the concepts that describe subject matter of the field must be identified, defined, and empirically validated” (p. 24). This article has presented the initial steps in this process, which are identifying and defining an important concept, CIND, and its inclusion in NANDA International Classification is urged. Refining the NANDA International Classification will permit nursing researchers, among others, to conduct studies on nursing diagnoses in conjunction with the proposed novel term: CIND.

Acknowledgment. The author would like to thank Jennifer Briseno, RN, BSN, Lynne M. Scott, RN, MSN, CCRN, CCNS, Cecelia L. Crawford, RN, MSN, Raoul J. Burchette, MA, MS, and Lorys Oddi, EdD, RN, Distinguished Teaching Professor Emerita, Northern Illinois University, for their advice and critique during the preparation of this manuscript.

Table 1. NANDA International-Approved Diagnosis: Impaired Spontaneous Ventilation ((c)NANDA International)

Domain: Activity/Rest: The production, conservation, expenditure, or balance of energy resources

Class: Cardiovascular/Pulmonary Responses: Cardiopulmonary mechanisms that support activity/rest Approved Nursing Diagnoses:

Decreased Cardiac Output

Impaired Spontaneous Ventilation

Ineffective Breathing Pattern

Activity Intolerance

Risk for Activity Intolerance

Dysfunctional Ventilatory Weaning Response

Ineffective Tissue Perfusion (specify type: renal, cerebral, Cardiopulmonary, gastrointestinal, peripheral)

Approved Nursing Diagnosis:

Impaired Spontaneous Ventilation: Decreased energy reserves result in an individual’s inability to maintain breathing adequate to support life.

Defining Characteristics:

Apprehension

Decreased cooperation

Decreased dissolved oxygen

Decreased oxygen saturation

Decreased tidal volume

Dyspnea

Increased heart rate

Increased metabolic rate

Increased dissolved carbon dioxide

Increased restlessness

Increased use of accessory muscles

Related Factors:

Metabolic factors

Respiratory muscle fatigue

Table 2. Current Structure of Safety/Protection Domain ((c) NANDA International)

Domain: Safety/Protection: Freedom from danger, physical injury, or immune system damage; preservation from loss; and protection of safety and security

Class 1: Infection

Class 2: Physical Injury

Class 3: Violence

Class 4: Environmental Hazards

Class 5: Defensive Processes

Class 6: Thermoregulation

Table 3. Proposed Novel Safety/Protection Domain With Altered Definition, Life-Threatening Event Class, and Critical Incident Nursing Diagnoses Included

Domain: Safety/Protection: Freedom from danger, physical injury, or immune system damage; preservation from loss of life; and protection of safety and security

Class 1: Life-threatening events

Class 2: Infection

Class 3: Physical Injury

Class 4: Violence

Class 5: Environmental Hazards

Class 6: Defensive Processes

Class 7: Thermoregulation

Class 1: Life-threatening Events: Any acute change in physiology that threatens life and results in a critical incident

Critical Incident Nursing Diagnosis: an acute lifethreatening event that occurs as a result of disease, surgery, treatment, or medication

Defining Characteristics:

Airway-Obstruction

Regurgitation and aspiration

Breathing-All respiratory arrests

Respiratory rate

Respiratory rate > 36

Circulation-All cardiac arrests

Pulse rate

Pulse rate > 140

Systolic blood pressure

Neurology-Sudden fall in level of consciousness

(Fall in Glasgow Coma Scale score of > 2 points) Repeated or prolonged seizures

Hemorrhage

References

Bulechek, G. M., & McCloskey, J. C. (1992). Defining and validating nursing interventions. Nursing Clinics of North America, 27, 289-299.

Carpenito, L. J. (1997). Nursing diagnosis: Application to clinical practice (7th ed.). New York: Lippincott.

Gebbie, K., & Lavin, M. A. (1974). Classifying nursing diagnoses. American Journal of Nursing, 74, 250-253.

Joint Commission. (2008). Nursing sensitive performance measures. Retrieved on January 30, 2008, from www.jointcommission.org/ performancemeasurement/measurereservelibrary/nqf_nursing.htm

Kelly, M. A. (1985). Nursing diagnosis source book. East Norwalk, CT: Appleton-Century-Crofts.

Lash, A. A. (1978). A re-examination of nursing diagnosis. Nursing Forum, 4, 333-343.

Lunney, M. (1990). Accuracy of nursing diagnoses: Concept development. Nursing Diagnosis, 1,12-17.

Lunney, M. (1998). Accuracy of nurses’ diagnoses: Foundation of NANDA, NIC, and NOC. Nursing Diagnosis, 9, 83-85.

Maas, M. L., Hardy, M. A., & Craft, M. (1990). Some methodologic considerations in nursing diagnosis research. Nursing Diagnosis, 1, 24-30.

Meyer, G., & Lavin, M. A. (2005). Vigilance: The essence of nursing. Online Journal of Issues in Nursing, 23,1-15. Retrieved January 30, 2008, from http://nursingworld.org/mainmenucategories/ AN Amarketplace/ANAperiodicals/ojin/tableof contents/ volume82003/ num3sep30_2003/vigilancetheessenceofnursing.aspx

Mills, W. C. (1991). Nursing diagnosis: The importance of a definition. Nursing Diagnosis, 2, 3-8.

Muller-Staub, M., Lavin, M. A., Needham, L, & van Achterberg, A. T. (2006). Nursing diagnoses, interventions and outcomesapplication and impact on nursing practice: Systematic review. Journal of Advanced Nursing, 56, 514-531.

NANDA International. First task force to name and classify nursing diagnoses. Retrieved June 30, 2007, from http:// www.nanda.org/ html/historyl .html

Neal, M. C. (2007). Nursing diagnosis: Definitions and classification 2007-2008. Philadelphia: NANDA International.

Nightingale, F. (1969). Notes on nursing: What it is and what it is not. New York: Dover Publications. (Original work published in 1860).

Safar, P. (1974). Critical care medicine-quo vadis? Critical Care Medicine, 2,1-5.

Snyder, M., Egan, E. C., & Nojima, Y. (1996). Defining nursing interventions. Image, Journal of Nursing Scholarship, 28,137-141.

Thomas, C. L. (Ed.). (1993). Taber’s cyclopedic medical dictionary (18th ed.). Philadelphia: F. A. Davis.

U.S. National Library of Medicine. (2008). Nursing diagnosis citations. Retrieved June 30, 2007, from http://www. ncbi.nlm.nih.gov/sites/extrez

Elizabeth Wang, CRNA, MSN, is a Clinical CRNA, Kaiser Permanente Woodland Hills Medical Center, Woodland Hills, CA.

Author contact: [email protected]

Copyright Nursecom, Inc. Jul-Sep 2008

(c) 2008 Nursing Diagnosis. Provided by ProQuest LLC. All rights Reserved.

No Strictly in Our Dancing

A New fitness school is being launched to encourage more children to take up exercise.

Street Beatz Dance and Fitness Academy aims to provide a range of fitness and exercise classes to help children and adults become fitter.

With classes from street dance, Bollywood, salsa, cheerleading and contemporary dance, Street Beatz hopes to increase fitness levels among children in a fun way.

They are also launching a new class called Fit 4 Fun to encourage children aged from seven to 12 to take up exercise.

Leanne Hancock, who started Street Beatz with her friend Clare Moran, said: “With children, it’s all about finding something they like and want to do.

“A lot of children don’t want to do dance classes or football training and would rather play computer games, but we’ve discovered they’re quite happy to be playing team games or doing circuits for an hour.

“We can’t make children do something they don’t want to, but this lets them decide for themselves to try something they might enjoy.”

Leanne and Clare were both fitness coaches for East Riding Council, holding dance workshops and fitness classes.

However, their classes became so popular that they decided to strike out on their own and set up Street Beatz.

Leanne said: “Our classes were really popular and we had long waiting lists, so we decided to set up our own academy so we could reach more children.

“We have classes five nights a week and we had 100 children turn up on the first two nights.”

Street Beatz classes are held at St Nicholas Infants’ School in Holme Church Lane, at Beverley High School and at Bishop Burton College for children aged from five through to adults.

Anyone interested in taking part should call Leanne on 07795 210926.

(c) 2008 Hull Daily Mail (UK). Provided by ProQuest LLC. All rights Reserved.

Lew-Port School Board Told Cancer Study Results Inconclusive

By Paul Westmoore

A state study of cancer incidents released Tuesday for the towns of Lewiston and Porter, including the Lewiston-Porter School District campus, apparently turned up no conclusive results.

Keith Fox, a School Board member, told the board he briefly reviewed the 19-page report which covers studies of the Lake Ontario Ordnance Works, (LOOW), the Niagara Falls Storage Site, (NFSS), and the school campus, before last night’s board meeting and found nothing ominous.

“Frankly, I don’t think there’s anything to be very concerned about,” Fox said. He added the Health Department will be here soon to explain the report.

The public is invited to a meeting the department is holding on that study from 7 to 9 p.m. Sept. 29 in the Lewiston-Porter High School auditorium, where experts will answer questions about the cancer incidence investigation.

Interim Superintendent Don W. Rappold said at worst the report seemed to be “inconclusive.”

There has been concern for years in the two towns about the affect radiation and chemicals from weapons development here during World War II might have on incidents of cancer among the local population.

A press release from the Health Department on Tuesday said, “The study evaluated cancer incidence among people of all ages in each study area who were diagnosed with cancer from 1991-2000” to see if the number of cases arising were higher than should be expected.

Summarizing the findings, state officials said researchers found no unusual cancer patterns in the LOOW and NFSS locations.

The only exception was a high number of prostrate cancers in the LOOW area and the area near the Lewiston-Porter campus. The study noted, however, “The high number of prostrate cancers in these areas may be related to medical care practices such as prostrate screening.”

The study found statistically high numbers of several other cancers in the Lewiston-Porter campus area. That facet of the study was done because of concerns over children attending schools at Lew- Port. But those results also appeared to be inconclusive.

The study states, “The greater-than expected number of women with breast and bladder cancer [there] are not likely to be due to exposures received while the women were attending schools on campus because most of the cases were found in older women who went to school before the campus was built.”

The report said there also was an excess in cancers in children ages 10-14 living in this area.

“These children could have attended schools on the Lewiston- Porter campus, although interviews showed that not all of them had,” state health officials said.

The study also found “unusual numbers of testicular cancers in young men, and gonadal and germ cell tumors in children. However, health officials said, “Conclusions cannot be drawn about these high numbers and a relationship to exposures to any contaminants from the site because there is insufficient information about where these individuals went to school, or other possible risk factors they may have had.”

Health officials added that more recent data showed that “After 2000, the unusual numbers of childhood cancers in general and gonadal and germ cell tumors in particular did not continue.” They also said, “The possibility that the occurrence of the cancers was the result of chance can not be ruled out.”

e-mail: [email protected]

Originally published by NEWS NIAGARA BUREAU.

(c) 2008 Buffalo News. Provided by ProQuest LLC. All rights Reserved.

‘Underground Barber’ Opens Shop in Normal

By Bob Holliday

NORMAL – Davin Garrett started cutting the hair of his friends. Now, he’s opened a barber shop in Normal.

“I was cutting out of college dorms and was known as the underground barber’ and the name stuck on me,” he said.

Garrett’s new shop, at 315 W. Beaufort, Suite B, is appropriately called Underground Barber Shop. It is located near Illinois State University’s Watterson Towers.

Garrett had been cutting hair at another location in Bloomington but wanted more walk-in traffic.

Word of mouth provides a steady supply of customers, Garrett said. While appointments are preferred, he said walk-ins are welcome.

Garrett and another barber cut hair from 10 a.m. to 2 p.m. Monday; 9 a.m. to 7 p.m. Tuesday through Friday; and 9 a.m. to 6 p.m. Saturday. The shop is closed on Sunday.

Though college students are part of his customer base, Garrett said the pair cuts all ages.

A haircut for children 2 to 7 years old is $13, 8- to 17-year- olds pay $15 and adults are $17, Garrett said.

While there are only two barber chairs now, Garrett, whose family also runs Sly’s Barbecue in Normal, said the 1,100-square-foot barber shop has room for expansion.

(c) 2008 Pantagraph. Provided by ProQuest LLC. All rights Reserved.

Bad Batch of Vaccine Leads to Encephalitis Deaths

By THE ASSOCIATED PRESS

LUCKNOW, India Indias government sent thousands of ineffective vaccines to a northern Indian state, halting a planned immunization drive against a deadly outbreak of Japanese encephalitis that has killed more than 200 children since June, officials said. The mistake compounding delays in starting the immunizations raises chances that hundreds more children could die of the disease this year, health officials warned today. North Indias impoverished Uttar Pradesh state suffers from recurring annual outbreaks of the mosquito-borne disease, which causes high fevers and vomiting and sometimes comas and death. It is particularly deadly among children.

Japanese encephalitis can be prevented by a vaccine, but stocks sent by the federal government to the state showed in testing that they were unfit for human use, state Health Minister Anant Kumar Mishra told The Associated Press in Lucknow, the state capital. Over 1,000 people have been affected with encephalitis, and we are not sure when the fresh stock of vaccines will arrive, Mishra said. In the absence of vaccine we cannot start the vaccination drive. In 2005, more than 1,500 children were killed by the disease, but the numbers dropped sharply after the government started an annual vaccination drive in 2006. Last year, about 400 children were killed by Japanese encephalitis in Uttar Pradesh. Officials had hoped to keep the death toll relatively low this year. Uttar Pradeshs director general of health, Ishwar Sharan Srivastava, said the state had asked for the vaccines earlier in time for the monsoon seasons start in June but only received them last week. He said they needed up to 1 million vaccines. And Mishra said that of the 460,000 vaccines received, many had indicators that they had lost their potency. Officials from the federal Health Ministry said it was not immediately clear what happened.

(c) 2008 Charleston Daily Mail. Provided by ProQuest LLC. All rights Reserved.

Glen Burnie West: Quilters Ready for Big Bingo Event

By KATHLEEN SHATT For the Maryland Gazette

The Eternal Quilters and Friendship Quilters have joined forces once again to sponsor their biennial quilt bingo on Saturday at the Glen Burnie Moose Lodge, 1911 Crain Highway.

The theme of this year’s event is “Bedside Bingo.” Friendship quilter Lynne Kampe explained that all of the bingo prizes will be bed-sized quilts. The smallest quilt to be awarded is 50-by-70 inches.

Admission is $15 in advance, or $18 at the door, and includes 24 regular bingos, in addition to specials, a raffle quilt and raffle baskets.

Food and refreshments will be sold by the members of the lodge. The quilters will hold a “to go” sale of baked goods.

No one under the age of 18 will be admitted.

For details, call Mrs. Kampe at 410-766-6010.

Crop Walk 2008

Walkers are needed for this year’s North Anne Arundel County Crop Hunger Walk.

This year’s walk will begin at 1 p.m. Sept. 28. Participants will walk from Glen Burnie United Methodist Church, 5 Second Ave. S.E., to the Pasadena Crossroads Shopping Center and back along the Baltimore Annapolis Trail Park.

The Crop Walk raises money to fight hunger both locally and around the world. Twenty-five percent of the money raised will go to the North County Emergency Outreach Network.

CROP, originally an acronym for the Church Rural Overseas Project, began more than 50 years ago after World War II. The project is now run by Church World Service, a non-denominational religious organization which distributes emergency goods and self- help services to more than 80 countries, as well as throughout the United States.

For details, call Paul Shaffer at 410-987-8015 or send e-mail to [email protected]

North Glen

The North Glen Improvement Association will meet at 7 p.m. tonight at the community hall, 303 Wellham Ave.

The board of directors will convene at 6:30 p.m. before the general membership meeting.

For more information, call president Nancy Mason at 410-761-4894 or send e-mail to [email protected].

Corkran Middle

Corkran Middle School will host its annual back-to-school night, information fair and family supper tomorrow at the school, 7600 Quarterfield Road.

The family supper will be served from 5:15 to 6:15 p.m.

The cost of the meal is $1 and includes a slice of either cheese or pepperoni pizza, a bowl of salad, a soda and cookies.

During the dinner, the school will host its fourth annual information fair in the cafeteria. Information will be available on the International Baccalaureate program, college savings plans, health and wellness, and other services offered by the school and community organizations such as drug awareness and counseling, Giant Food and Market Day fundraisers, after-school programs, family counseling and youth recreation programs.

At 6:30 p.m. following the dinner, parents will be invited to report to their child’s homeroom classroom. The school’s Parent- Teacher-Student Organization will hold a brief meeting via the public address system. Parents will be welcome to visit their child’s classes.

For more information, call the school at 410-222-6493.

District 32 meeting

The District 32 Democratic Club will co-host a unity rally with several other local Democratic organizations from 6 to 8:30 p.m. tomorrow at the Fraternal Order of Police lodge, 1311 Generals Highway.

Guest speakers include County Councilmen Daryl Jones, Jamie Benoit and Josh Cohen, as well as representatives from the Barack Obama presidential campaign and local congressional campaigns.

Hot dogs and refreshments will be served.

New members and guests are welcome.

The rally will take the place of the club’s regularly scheduled meeting.

The club usually meets on the third Thursday of each month at the Ferndale Volunteer Fire Company hall, 4 S. Broadview Blvd. Membership dues cost $10.

For details, call president Tom Dixon at 410-672-2837.

Halloween dance

The sixth annual Halloween dance and bull roast to benefit the University of Maryland Children’s Oncology Unit will be held from 8 p.m. to midnight Oct. 25 at La Fontaine Bleue, 7514 Ritchie Highway.

The dance is held in memory of Travis McQuade, a 2-year-old toddler who died in 1994 of liver cancer. The event was initially organized by Travis’ aunt Karen Voelker and her colleagues at the Southdale office of Coldwell Banker Residential Brokerage.

The event raises funds for items to brighten the lives of pediatric patients at the hospital. It started by providing toys and has grown to include Nintendo games, Wii games and computers.

Travis’ dad, John McQuade, explained that the event has been therapy for him and his wife as they cope with the loss of their child.

The event will include a silent auction of sports memorabilia, bull roast and open bar, music by a disc jockey, costume contest, 50- 50 raffle, raffles for prizes and money wheels.

Mr. McQuade said the business community has been very generous in donating prizes which will be either raffled or auctioned.

Tickets are $45. Participants must be at least 21 years old.

For details, call Mr. McQuade at 410-303-5980.

Carry-out dinner

Ferndale United Methodist Church will host a carry-out dinner from 11:45 to 1:45 p.m. Sunday. Dinners may be picked up in the church fellowship hall, 117 Ferndale Road.

This month’s menu features meatloaf, mashed potatoes, succotash, roll and dessert. The cost is $8.

Walk-ins are welcome.

For more information, call Alice Neary at 410-766-4458 or the office at 410-761-2880.

Cruise night

The Lost in the 50s Custom Car Club hosts a cruise night from 6 to 10 p.m. every Saturday night in the parking lot at Marley Station mall, 7900 Ritchie Highway, through Nov. 1.

Admission is free.

Antique and customized cars, trucks and street rods from 1977 and older will be on display. There is room on the parking lot for up to 450 vehicles to be displayed.

New members of the club are welcome. Membership dues cost $20.

For details, call President Dennis Smith at 410-747-1256 or 410- 491-9969 or visit www.lostn50s.com.

Pascal Senior Center

Susan Brown will teach a 12-week session stamping class and a jewelry class beginning tomorrow at the Pascal Senior Center, 125 Dorsey Road.

The cost of each class is $12. Supply costs will vary depending on the projects worked on.

The stamping class will meet from 12:30 to 2 p.m. followed by the jewelry class from 2 to 3:30 p.m.

A DVD on the Canadian wilderness will be shown at 12:30 p.m. tomorrow.

A registered nurse will check glucose levels of diabetic patients from 9 a.m. to noon Friday at the center, 125 Dorsey Road. Blood pressures also will be checked.

Senior information specialist Wanda Swift will meet with seniors by appointment tomorrow. She will help seniors identify their needs, locate services and complete applications for assistance.

For details, call the center at 410-222-6680.

Yard sale

The Dundee and Associates Community Association will host its annual fall yard sale from 8 a.m. to 1 p.m. Oct. 18 at homes throughout the community.

Residents who would like to participate must register in advance to be included in the community map. There is a $5 fee to participate. On the day of the sale, registered participants will be given a special balloon to hang at their home. Maps also will be distributed showing the locations of participating homes.

The community is bordered by Oakwood Road, Oak Manor Drive, Crain Highway and Aquahart Roads.

In addition, the association will sponsor a 50-50 raffle drawing. The winning ticket will be drawn at noon Oct. 18.

For more information, call president Barbara Morgan at 410-768- 5430.

Quarter auction

A quarter action will be held Friday at 7 p.m. at the Ferndale Volunteer Fire Company hall, 4 S. Broadview Blvd., to benefit the charity HOPE Inc.

The doors will open at 6 p.m. for seating.

Admission is $4. Participants who bring two friends will receive free admission. Extra auction paddles will cost $2 each.

Food items will be sold.

Prizes have been donated by Arbonne, Cookie Lee, Creative Memories, DK Designs, Home Interiors, Pampered Chef, Party Lites, Purse Snickety and Tastefully Simple.

Door prizes also will be awarded and there will be a 50-50 raffle and two raffle baskets.

For more information, visit www.quarterauctiongroup.com.

Holy Name Society

The Holy Name Society at Holy Trinity Catholic Church will meet at 7:30 p.m. tomorrow in the Lipin Room at the Parish Center, 126 Dorsey Road.

For details, call 410-766-7079.

Flea market

St. Alban’s Episcopal Church will host its annual fall flea market from 9 a.m. to 1 p.m. Saturday at the church, 105 First Ave. S.W.

The event will include a white elephant table and homemade baked goods sale. Refreshments also will be sold. The event will be held rain or shine.

For more information, call the office at 410-766-1455 or Judy Smith at 410-761-5206.

Quarter auction

A Quarter Mania auction will be held tomorrow at the North Glen Community hall, 303 Wellham Ave.

The doors will open at 6:30 p.m. The auction will begin at 7 p.m.

Tickets cost $3.

Proceeds will benefit the Community of Christian Women faith retreat fund.

For more information, call 410-636-5322.

Singing meeting

The community is invited to a singing meeting, “Praising God in Song,” at 7:30 p.m. Friday and Saturday at the Glen Burnie Church of Christ, 2 Eastern Street. Good singing voices are not required.

Steve Garrett, an accomplished singer, will lead the services, Mr. Garrett also will deliver the lesson at the 10:30 a.m. Sunday service. He will bring some of the latest songs by Glenda Schales, some of which have not yet been published in book form.

Mr. Garrett has taught at singing schools with hymnal producer R.J. Stevens. He also has served as an evangelist for the Church of Christ in Columbia, Texas.

Visitors will not be asked to make a donation.

For more information, call 410-859-0511.

Clubs and organizations in the 21061 ZIP code area can call Kathleen Shatt at 410-766-8547, fax information to her at 410-766- 1520 or send e-mail to [email protected]. {Corrections:} {Status:}

(c) 2008 Maryland Gazette. Provided by ProQuest LLC. All rights Reserved.

Mum of Tragic Teen Bids to Raise Cancer Centre Cash Rosemary’s Girl Emily-Jane Lost Battle at Just 16

By SARAH SWAIN

A MUM who lost her teenage daughter to bone cancer is facing her fears – to help other youngsters battling the condition.

Teacher Rosemary Gold is preparing to take part in the Teenage Cancer Trust’s zipwire challenge across the River Clyde next month.

Her daughter EmilyJane died in January when she was just 16 after a two-year fight with the disease.

But Rosemary and psychiatric nurse husband Graham, 48, of Kirkintilloch, hope to make life easier for other teenagers with cancer by raising hundreds of pounds towards a new unit the charity is building at Yorkhill Hospital in Glasgow.

It will allow teenagers like Emily-Jane to be treated separate from young children.

Rosemary said: “I’m quite happy with heights although it will be different when I get up there. The zipline is 130ft high and 1000ft long!

“Emily-Jane would have done it and she’ll think it’s great that I am. She was really keen for them to have the unit.”

When Emily-Jane complained of a sore knee, doctors told her she had pulled a muscle – then that she had flat feet.

But when Rosemary, who is also mum to Juliet, 12, demanded an X- ray at Stobhill Hospital the diagnosis was far worse.

Emily-Jane had a cancerous tumour in her leg.

Rosemary, who is a P4 and 5 teacher at Auchinloch Primary School, near Lenzie, said: “We went through all the emotions. I don’t think I could speak to anybody except my husband for about a month. But Emily-Jane said: ‘Lets get through this.'” The Lenzie Academy pupil had chemotherapy at Yorkhill and a successful operation to remove her tumour and replaced her knee with titanium .

She battled back and soon swapped a wheelchair for crutches.

Despite her gruelling treatment, Emily-Jane passed six standard grades with top marks and got involved with the Teenage Cancer Trust .

But sadly the cancer spread to her lungs and shortly after her 16th birthday a year ago the family were given the awful news that nothing more could be done.

Rosemary said: “I found it more horrific than Emily-Jane. She said: ‘I’ll be fine.’ She had even started walking home from school with friends rather than getting me to pick her up.

“She just kept smiling through it all. Emily-Jane continued to go out and have visitors until the 13th of January. And on the 14th she stayed in bed and died in the early hours of Tuesday 15th.

She was talking to me on the Monday and said: “It all makes sense now. I’m ready. I said, what for? And she said: ‘to shine.'” The Teenage Cancer Trust needs to raise GBP350,000 towards the unit for 13 to 16-year-olds at Yorkhill, which it hopes to open next summer.

To sign up for the zipwire challenge on Sunday, October 5, call Catriona Stewart on 07860 757274.

To sponsor Rosemary visit www. justgiving. com/rosemarygold

Originally published by Newsquest Media Group.

(c) 2008 Evening Times; Glasgow (UK). Provided by ProQuest LLC. All rights Reserved.

Diabetes Spectrum Reports a Study Assessing the I-Port(R) Injection Port for Administration of Insulin

AUSTIN, Texas, Sept. 17 /PRNewswire/ — In a clinical trial comparing the i-port(R) (a small, disposable injection port about the size of a quarter) with standard injections in people with type 1 and type 2 diabetes, participants’ differences in glycosylated albumin was not significantly different. The new data appeared in an article published in the current issue (Summer, 2008) of Diabetes Spectrum, a peer-reviewed journal of the American Diabetes Association. Glycosylated albumin is a direct measure of short term glucose in blood protein. Based on these results, the authors conclude that the utility and efficacy of administering multiple doses of insulin through a single i-port(R) device is a viable alternative to standard injections. View the complete abstract and/or purchase the feature article at http://spectrum.diabetesjournals.org/cgi/content/abstract/21/3/197.

“Our study demonstrates that delivering insulin via the i-port(R) provides the same therapeutic benefits as standard injections,” said lead investigator Dr. Thomas Blevins of Texas Diabetes and Endocrinology in Austin, Texas. “This is especially significant for people with diabetes who struggle with adherence and need an alternative to the multiple daily skin punctures required by standard injections.”

The prospective, randomized, controlled, open-label crossover study enrolled 74 patients with diabetes being treated with daily insulin injections at five trial sites. Participants were randomly assigned to two of three injection treatment regimens including standard injection, injecting through a single i-port(R) device, and injecting through two separate i-port(R) devices with each regimen lasting three weeks. Patients using the single i-port(R) regimen injected both regular human or rapid-acting insulin and LANTUS(R) through the same device (separating the dose of LANTUS(R) from the regular human or rapid acting insulin by at least 60 minutes). Participants using the dual i-port(R) regimen injected each type of insulin through two separate devices. Participants were evaluated by measurements of glycosylated albumin and study questionnaires. The results were not significantly different between the three treatment regimens (P = 0.99 for standard injection vs. single i-port(R) and P = 0.97 for single i-port(R) vs. dual i-port(R)). Fifty of 72 participants (69.4%) reported that the i-port(R) was useful and helpful in the management of their diabetes.

ABOUT the i-port(R) Injection Port

The i-port(R) Injection Port is a prescription only device cleared by the FDA in September 2005, for use by people requiring multiple daily, subcutaneous injections of physician-prescribed medications, including insulin. The i-port(R) may be a helpful treatment delivery tool for anyone who wants to minimize the intrusion of daily injections.

The i-port(R) should not be worn for longer than 72 hours. The most serious risks when using the i-port(R) include infection and the potential for poor medication delivery if not properly applied. For people with diabetes, the poor medication delivery may result in abnormally high or low blood sugar levels. If you experience these or any other problems when using the i-port(R), tell your doctor.

About Patton Medical Devices

Headquartered in Austin, Texas, Patton Medical Devices is the manufacturer of the i-port(R) Injection Port. For people taking injection therapy who want to minimize the intrusion of injections on daily life, the i-port(R) is the only product of its kind conceived by a person with diabetes that offers a simple, convenient way to eliminate the need to puncture the skin with each dose of medication. The i-port(R) lets patients focus on living their lives instead of the challenges associated with the next shot. For more information about Patton Medical Devices, its products and services, visit http://www.i-port.com/ or http://www.pattonmd.com/.

   Contacts: Doug Hochstedler                  Nicole Carp             212-798-9724                      212-798-9753             [email protected]  [email protected]  

Patton Medical Device

CONTACT: Doug Hochstedler, +1-212-798-9724,[email protected], or Nicole Carp, +1-212-798-9753,[email protected]

Web Site: http://spectrum.diabetesjournals.org/cgi/content/abstract/21/3/197http://www.i-port.com/http://www.pattonmd.com/

HealthPartners and Wilson Tool Open Worksite Clinic

HealthPartners and Wilson Tool International today announced the opening of a new worksite clinic called HealthPartners Well@Work Wilson Tool. Located in Wilson Tool’s worldwide headquarters in White Bear Lake, Minn., the clinic serves the company’s 450 Minnesota-based employees and their families. It is the fourth worksite clinic HealthPartners has opened.

Staffed by a physician, a certified nurse practitioner and a wellness coach, the clinic offers most services provided by a traditional family practice clinic, including physical exams and screenings, lab tests, urgent care, work-related injury assessment, wellness counseling and evaluation. Clinic services are available to Wilson Tool employees and their families at no charge.

“We are pleased to offer this benefit to our employees,” said Brian Robinson, CEO, Wilson Tool Enterprises. “We pride ourselves on being a compassionate employer with a clear focus on the wellbeing of our employees and their families. High quality, on-site medical care will not only benefit our employees, it will help us maintain a high level of productivity and manage health care costs by promoting health and wellness and a lower overall level of absenteeism.”

“When healthcare services are proactive, easily accessible and appropriate, employees get the right care at the right time,” said Bob VanWhy, vice president of primary care for the HealthPartners Medical Group. “This promotes a healthier workforce and helps patients and employers manage costs.” VanWhy points to HealthPartners data showing the total cost of care in its worksite clinics is nine percent less than in traditional primary care clinics.

 Clinic hours:            Wed.         11 a.m. - 7 p.m. Thurs.       7:30 a.m. - 4 p.m. Fri.         6:30 a.m. - 3 p.m. 

A ribbon cutting ceremony will take place at Wilson Tool, 12909 Farnham Ave. N. White Bear Lake, Minn. on Thurs. Sept. 18 at 2:00 p.m.

About HealthPartners

HealthPartners family of care includes the HealthPartners Medical Group and Clinics, a 700 physician multi-specialty practice serving patients at more than 50 HealthPartners, RiverWay and North Suburban clinics and at Regions and Westfields hospitals. Founded in 1957, the HealthPartners (www.healthpartners.com) family of health care companies serve more than one million medical and dental health plan members nationwide and is the largest consumer-governed, nonprofit health care organization in the nation.

USAID’s Richard Greene Named Employee of the Year

To: NATIONAL EDITORS

Contact: USAID Press Office, +1-202-712-4320

WASHINGTON, Sept. 17 /PRNewswire-USNewswire/ — Richard Greene, Director of the Office of Health, Infectious Diseases, and Nutrition for the U.S. Agency for International Development (USAID) was named Federal Employee of the Year at the Partnership for Public Service annual gala event September 16. This award recognizes a federal employee whose professional contributions exemplify the highest attributes of public service. Greene was principally recognized for his work on the President’s Malaria Initiative (PMI) — an interagency initiative led by USAID with the Department of Health and Human Service’s Centers for Disease Control and Prevention (CDC) as the key partner.

Greene was chosen from nearly 500 nominees, representing two dozen federal agencies.The program pays tribute to America’s dedicated federal workforce, with the Service to America Medalsor “Sammies.” Honorees are chosen based on their commitment and innovation, as well as the impact of their work on addressing the needs of the nation.

“I am humbled and privileged,” said Greene of the honor. “The award represents the work and achievements of dedicated and talented staff at USAID headquarters, in overseas missions, and in CDC Atlanta that are responsible for these accomplishments. These include senior managers, malariaologists, entomologists, monitoring and evaluation experts, communication specialists and a host of others.”

Greene, who also runs USAID’s Office of Health, Infectious Diseases, and Nutrition, which manages programs in maternal and child health, nutrition, avian influenza, health systems, tuberculosis, and neglected tropical diseases, was asked to develop the plan and launch the President’s Malaria Initiative. His dedication and leadership were critical to the program’s early success. He led the day-to-day implementation of the plan, and he and his staff were credited with mobilizing programs and helping to launch services (and supporting systems) in record time while tailoring different approaches to fit the needs of each individual country.

In its first year, PMI reached more than 6 million people with insecticide-treated mosquito nets, spraying and therapeutic drugs. By the end of its second year, the program had reached more than 25 million people with malaria treatment or prevention measures, including more than 17 million people protected through indoor residual spraying.

Greene’s work on PMI is the pinnacle of a life spent in service to others around the globe. He began his career as a Peace Corps volunteer in the Ivory Coast in 1978. After taking a job with USAID in 1984, he spent 15 years overseas in places ranging from Sudan to Cameroon to Bangladesh. He eventually settled in as the head of USAID’s Office of Health, Infectious Diseases and Nutrition in the Bureau for Global Health, and he has put the agency on the cutting edge of addressing key global health issues, including: avian influenza, neglected tropical diseases, and maternal and child health programs.

“The President’s Malaria Initiative and these other efforts represent America at its best, exemplifying the generosity of the American people and our commitment to helping those most in need. In that same vein, Greene represents government at its best,” said Administrator Henrietta H. Fore. “He reminds us that when we come together in service of a common cause, we discover the best in ourselves and we can transform the lives of others across the globe.”

Other USAID Sammie award recipients include Mark Ward, Senior Deputy Assistant Administrator for the Asia and the Near East Bureau, who was presented the International Affairs Medal in 2006 for his leadership of the U.S. recovery and reconstruction efforts after the Asia tsunami in 2004 and the South Asia earthquake in 2005.

For more information about USAID and its global health programs, visit www.usaid.gov.

The American people, through the U.S. Agency for International Development, have provided economic and humanitarian assistance worldwide for nearly 50 years.

Public Information: 202-712-4810

SOURCE U.S. Agency for International Development

(c) 2008 U.S. Newswire. Provided by ProQuest LLC. All rights Reserved.

MPG Publishing Announces the Launch of SOBeFiT Magazine

MIAMI, Sept. 17 /PRNewswire/ — MPG Publishing announces the launch of SOBeFiT, the first publication in South Florida dedicated exclusively to providing expert advice to men and women on fitness, nutrition, health and sports. Set to bring readers across the nation South Florida’s renowned healthy living lifestyle, the publication will feature a column by NBA star Alonzo Mourning, alongside leading contributors and experts in the industry.

SOBeFiT will be published six times a year with its first issue released on December 24th, 2008. Distribution will include select U.S. cities in response to requests and orders already received from newsstand distribution companies and international fitness chains. In South Florida, the magazine will receive premier distribution via wholesalers such as Media Solutions, The News Group and Anderson News/Prologix. Distribution locations will include high-profile gyms, hospitals, doctor’s offices, malls, restaurants, high-end grocery stores and colleges. SOBeFiT is expected to reach more than 115,000 readers.

“SOBeFiT is proud to launch the first magazine that celebrates South Florida’s world renowned healthy living lifestyle and bring it to readers all over,” said Marta Montenegro, Publisher and Editor-In-Chief. “Our editorial content is exactly what our target readers are looking for — relevant and practical information that may be used in everyday life. The content contributed by well-known experts in the industry, combined with our mission of creating a national movement to building a healthier and more active way of life, is sure to make SOBeFiT a success.”

The magazine provides collectible ‘on the go’ exercises, healthy recipes and nutritional advice for both men and women that can be removed from the magazine and be utilized at home or at the gym. Original sections include Body Shop Express, showing readers proper form and technique while working out; Fit Gourmet, a gastronomical and nutritional tour of Florida’s favorite restaurants; LoCal Flavor, where SOBeFiT analyzes famous South Florida’s dishes and then deconstructs the recipes to come up with healthier, smarter alternatives that can be prepared in minutes; From A to Zo, Alonzo Mourning shares his insight on developing a truly health-conscious community; Coach’s Corner, top coaches offer expert advice on their sport; Time Bandits, a column devoted to the latest anti-aging techniques and procedures; and Menu Mates, where Charles Platkin, “The Diet Detective,” explores the best foods for him and for her when they are both trying to achieve a common objective.

The SOBeFiT content reflects South Florida’s commitment to a lifestyle that focuses on taking care of the body and mind, achieving a balanced state of well-being and a higher quality of life. SOBeFiT aims at empowering readers with practical and relevant content in four core areas:

   -- Fitness - SOBeFiT will be home to the most effective and innovative      workout techniques aimed at helping readers attain a healthier body and      mind;   -- Nutrition - the magazine will feature the very latest on the      nutritional front, advising readers on how to understand and balance      their food intake and consume nutritionally balanced diets;   -- Health - the magazine will focus on the essence of well-being backed by      information that relies on the most relevant national and regional      studies, as well as the opinions of highly qualified physicians,      medical specialists and researchers in a wide variety of fields;   -- Sports - SOBeFiT will thoroughly cover the wide variety of athletic      disciplines that can be practiced in the South Florida region,      providing exclusive in-depth advice on how to become more proficient at      them.    

Created in South Florida, SOBeFiT has assembled the most qualified team of advisors, contributors and industry leaders at the top of their game led by its CEO and Editor-In-Chief, Marta Montenegro. She is an avid athlete and marathoner with a diverse educational and professional background in journalism, finance, and exercise physiology and authored Forget Dieting! Exercise and Learn to Eat. She has been a frequent contributor to both local and national media outlets (including CNN) on topics ranging from nutrition, diet, and sports medicine to personal fitness, wellness, and conditioning. Marta is currently an Adjunct Professor of Clinical Exercise Physiology at Florida International University, where she earned her Master’s Degree in Exercise Physiology.

Among the qualified team of advisors and contributors are Dr. Richard Lopez, Associate Professor and Director of Florida International University’s programs in exercise and sports sciences. He has authored more than two dozen journal articles, scientific studies and book chapters on a wide array of topics in the field, with important contributions in the areas of geriatric sports medicine, exercise testing and prescription for special populations, and anabolic steroid and drug abuse among adolescents; Lisa Dorfman, Sports Nutritionist for the University of Miami since 2003, she is also a personal nutritionist for several professional athletes, including those in the NFL, MLB, PGA, USTA, and boxing; Dr. Keith Hechtman, a founding partner for UHZ Sports Medicine Institute and an orthopedic surgeon. He is also assistant team physician for professional local and national sports teams; and Charles Platkin, “The Diet Detective,” a nationally recognized local nutrition and public health advocate.

The first SOBeFiT cover will be unveiled at the launch event on October 14th, 2008 at 7 p.m. by Alonzo Mourning at Miami’s Four Seasons Hotel in Brickell and will be emceed by Dr. Sean Kenniff, CBS4’s Health Specialist. MPG Publishing Corp. will present Mourning with a check for $25,000 to benefit Alonzo Mourning Charities.

   For more information about SOBeFiT, log on to http://www.sobefitmagazine.com/.    About MPG Publishing  

SOBeFiT is the first title from MPG Publishing. Our parent company is ABA Capital Group, an investment holding firm formed in Spain in 2008. However, the company began in 1990 when Venezuelan entrepreneur, Enrique Auvert, and three other partners launched ABA Mercado de Capitales, the first broker dealer in western Venezuela. After promoting its first mutual fund in 1992, ABA shifted its focus towards investment banking with a market emphasis on private equity acquisitions. The early years of the current decade saw ABA concentrating its growth strategy on the acquisition of companies in the financial, oil, cattle and ranching, construction and capital goods sectors. By 2005, the group initiated an expansion outside of Venezuela upon becoming majority stockholder in Asesorias e Inversiones, a broker dealer in Colombia. That same year, ABA promoted ABA Global Fund SPC, a Cayman Islands private equity fund. Since then, the fund has been the vehicle for the group’s expansion in the United States, Panama, Colombia, Dominican Republic, Barbados and British Virgin Islands.

   Media Contacts:     Cindy Olivarez, BodenPR     T: 305.639.6770     T: 305.801.6676     [email protected]      Elizabeth Brito, BodenPR     T: 305.639.6770     [email protected]  

MPG Publishing

CONTACT: Cindy Olivarez, +1-305-639-6770, +1-305-801-6676,[email protected], or Elizabeth Brito, +1-305-639-6770, [email protected],both of BodenPR for MPG Publishing

Web site: http://www.sobefitmagazine.com/

Town Again Offers Guided Nature Walks

By Lisa Vernon-Sparks

COVENTRY — For local nature lovers, there is an open trail leading to the best hiking spots close to home.

The town Recreation Department is hosting its second-annual fall hiking series — guided nature walks through some of the community’s most pristine woods, parks and conservation areas.

The program is a part of a larger effort sponsored by the Greenways Alliance of Rhode Island to promote use of the state’s bike paths and trails. So far, fall hikes have been hosted in communities including Westerly, Lincoln, Pawtucket, Smithfield and South Kingstown.

In Coventry, the walks have been given in September every Sunday beginning at dusk, rain or shine. The hikes are free of charge, and are led by Recreation Director Guy L. Lefebvre. During the hikes, he discusses the background of the sites, how the town acquired those properties or conservation rights, how the property is maintained and being developed.

The hikes originate at the Coventry Community Center beginning at 5:45 p.m., when a bus departs for the site, and last about 1 1/2 hours. Lefebvre asks that everyone arrive at least 15 minutes earlier.

The next two trips this month include a hike this Sunday through the Neylon Conservation Area and the Coventry Greenway-Trestle Trail Path; the following Sunday, Sept. 28, will feature a walk through Foster Memorial Park followed by an evening stroll around Breezy Lake.

This is the second year the town has hosted the hikes. Last fall, the program drew about 25 participants. Lefebvre said the town is considering extending the series by a week, depending on interest.

“Our purpose is to advise people of what is out there close to home … what is available…and how to get in and get out of the trails. You have an opportunity for bird watching, getting some fresh air and learning about something in your community,” Lefebvre said. “It’s an education thing. Most often we find it’s certainly an eye opener for people.”

This Sunday’s walk along the Coventry-Greenway Trestle Trail, on Hill Farm Road, en route to the Neylon Property, will offer an update on the state Department of Environmental Management’s project to transform the gravel paths into bicycle and equestrian trails. The Neylon site is an 81-acre parcel owned by Gerald P. and Janice Neylon that surrounds the western side of Stump Pond near Whaley Hollow Road.

The town’s Land Trust acquired development rights to the Neylon property last year. The area is dominated by oak trees, blueberry bushes, trembling aspen, gray birch and red cedar. Marbled salamanders, box turtles and a family of bald eagles have been sighted there.

The following week, the hiking tours will take place in Foster Memorial Park, an 86-acre conservation parcel with lots of glacier deposits. This tour ends with a stroll to Breezy Lake, which is near Knotty Oak Road.

Hikers are encouraged to register at the recreation department by calling (401) 822-9107 in advance to reserve a seat on the bus, but it’s not required.

Coventry [email protected] / (401) 277-7156

Originally published by Lisa Vernon-Sparks, Journal Staff Writer.

(c) 2008 Providence Journal. Provided by ProQuest LLC. All rights Reserved.

Synvista Therapeutics Posts Letter to Stockholders on Web Site

MONTVALE, N.J., Sept. 17 /PRNewswire-FirstCall/ — Synvista Therapeutics, Inc. today announced that a Letter to Stockholders is now posted to the Company’s Web site http://www.synvista.com/. The text is as follows:

To Our Stockholders:

The team at Synvista Therapeutics has made tremendous progress in our efforts to deliver on the promise of personalized medicine, and to redefine the treatment of cardiovascular disease in diabetics as well as the treatment of other diseases in the general population. Since my last letter in August 2007, our clinical trials with SYI-2074 for the treatment of heart disease in diabetics had inconclusive results, and we opted not to move forward with the compound’s development in this indication. However, we have a robust pipeline on which we are building our business. We have:

   --  Advanced our Haptoglobin (Hp) diagnostic test.   --  Developed a test for Carboxy-methyl-lysine (CML), a biomarker of       advanced glycation end product (A.G.E.) formation, which is believed       to play a part in cardiovascular disease.   --  Initiated two Phase 2 trials with alagebrium for chronic heart       failure.   --  Advanced the development of a topical formulation for the use of       SYI-2074 in the treatment of psoriasis.   --  Chosen a lead Glutathione peroxidase mimetic generated in a discovery       collaboration with Provid Pharmaceuticals, that is now being evaluated       for its ability to restore reverse cholesterol transport and treat       atherosclerosis.   --  Strengthened our management team and board of directors with       appointments in research, development and marketing.     DIAGNOSTICS   

We believe that we have a clear development pathway for our immunoassay test to determine the 2-2 genotype of Hp and have validated the accuracy of a commercial kit, as presented at the 2008 Cardiovascular Biomarkers and Surrogate Endpoints Symposium in Bethesda, Maryland, on September 11, 2008. Our pre-IDE meeting with the U.S. Food and Drug Administration has been completed, and we are on track to submit a 510(k) application for marketing clearance of this kit in the fourth quarter of 2008. In preparation for marketing clearance, we are preparing to launch the test with a small, dedicated sales force in the U.S., initially focused on high prescribers in the Mid-Atlantic region. We are also preparing a CE mark submission to market the test through distributors in the EU.

Of particular significance, research first presented at the American Heart Association’s (AHA) Scientific Sessions November, 2007 in Orlando, Florida, and subsequently published in Arteriosclerosis, Thrombosis and Vascular Biology 2008 Feb;28(2):341-7. Epub 2007 Nov. 21, demonstrated that in patients with Diabetes Mellitus (DM) who had the Haptoglobin 2-2 (Hp2-2) genotype, supplementation with Vitamin E therapy decreased cardiovascular events. We believe that this provides a compelling disease management opportunity for payers who can recommend the use of our test to determine the appropriate use of Vitamin E and the potential reduction of heart attacks resulting in considerable healthcare savings.

In addition to these commercial and scientific advances for the Hp test, we have made considerable progress in the development of a test for CML, another proprietary cardiovascular risk marker. Last year, researchers published reports that CML may predict outcomes in patients with heart failure. Our product candidate alagebrium has been shown to affect CML levels in animal models and the marker is being tracked in our alagebrium Phase 2 programs involving a target of 260 patients. As a result of accumulating data on the connection between CML levels and cardiovascular outcomes and the progress of our alagebrium development program, we have begun to commercialize our CML assay. To date, a licensee has sold more than 6,000 research- use-only tests. We are preparing the kit for 510(k) submission in the first half of 2009.

THERAPEUTICS

We have initiated two Phase 2 studies with alagebrium. Alagebrium is a proposed breaker of A.G.E.s for the treatment of heart failure.

The BENEFICIAL study, which began in November 2007, is a 100-patient study in chronic heart failure (CHF) being conducted at a single site in The Netherlands. This study is designed to involve nine months of treatment and is designed to measure the effect of alagebrium on exercise tolerance in patients with CHF. The study objective is to improve maximal oxygen consumption (VO2max), which is highly correlated with an improvement in myocardial function in patients with CHF. It also examines the ability of alagebrium to breakdown A.G.E.s by tracking levels of CML. As of the time of this writing, the study is more than 50% enrolled and is on track for completion in late 2009.

The BREAK study, which enrolled the first of 160 patients in May 2008, is a randomized, double-blind, placebo-controlled study at approximately 25 U.S. sites intended to assess the effect of six months of oral treatment with 400mg (200mg twice daily) of alagebrium versus placebo in patients with diastolic heart failure. Diastolic heart failure is particularly common among people with diabetes, and our intent is that at least one-half of the subjects enrolled in this study will have diabetes. The primary efficacy measure of the BREAK study is improvement of exercise tolerance as assessed by the six-minute walk test, an accepted regulatory endpoint. In addition, there will be a number of secondary and tertiary measurements including the effect on CML. This study also is on track for completion in late 2009.

We have met with the FDA on these two studies and believe that our clinical endpoints are acceptable to them.

While we decided not to pursue the development of SYI-2074 in heart disease, we believe that the compound has characteristics that may make it a compelling treatment for psoriasis. We completed the formulation development for topical SYI-2074 in the third quarter of 2008, and we expect to begin patient enrollment in a 30-patient Phase 2 study in this area in October 2008.

We also have developed a new family of glutathione peroxidase mimetics with properties that may be more attractive than SYI-2074 in treating heart disease. We have selected the lead compound and have begun preclinical testing. We have shown that our new family of compounds can attenuate the loss of cholesterol efflux seen in select patients with diabetes. Higher levels of cholesterol efflux may correlate with reduced atherosclerosis.

LEADERSHIP

We welcomed several important additions to the Synvista management team in the past year. Carl Mendel, M.D., was appointed to the position of Vice President, Clinical Development and Chief Medical Officer and is responsible for the clinical-stage development of the Company’s lead products. Dr. Mendel brings 15 years of experience in the pharmaceutical industry, successfully directing development programs in metabolism, obesity, cardiovascular disease, abuse potential, oncology, virology and other therapeutic areas. David C. Tantillo joined us as Senior Director, Marketing and Sales, a newly created position and brings to Synvista nearly 20 years of broad-based industry experience. Mr. Tantillo is responsible for planning and implementing commercialization of the Company’s haptoglobin diagnostic test.

We strengthened our board of directors with the appointment of John F. Bedard, expanding our board to four members. Mr. Bedard brings 25 years of highly relevant experience, having successfully directed development and registration programs in various therapeutic areas, including cardiovascular and metabolic diseases, dermatology, gastroenterology and immunology.

We are very excited about the role Synvista has to play in fulfilling important, unmet medical needs in diabetic and other patients as we advance our pipeline through development and into commercialization.

Thank you for your continued interest in Synvista. I look forward to keeping you apprised of our progress.

   Sincerely,    Noah Berkowitz, M.D., Ph.D.   President and Chief Executive Officer    September 2008   About Synvista Therapeutics  

Synvista Therapeutics is a biopharmaceutical company developing diagnostics and drugs to diagnose, treat and prevent cardiovascular disease in people with diabetes. The Company has developed a clinical diagnostic test for Hp2-2 Diabetes. The genetic or protein form of this test can be used to identify diabetic patients at high risk for cardiovascular complications. These patients may benefit from a particular formulation of vitamin E. The Company is also developing a kit to measure CML (carboxy-methyllysine), another potential cardiovascular risk marker.

Synvista Therapeutics is developing oral antioxidant drugs to treat the HDL dysfunction seen in Hp2-2 Diabetes, a disease affecting almost 7 million patients in the United States. The Company is also developing alagebrium, a proposed breaker of advanced glycation endproducts (AGEs) for the treatment of systolic and diastolic heart failure. Diastolic heart failure represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database.

For more information, please visit the Company’s Web site at http://www.synvista.com/.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics’ diagnostic tests and product candidates, and other risks identified in Synvista Therapeutics’ filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption “Risk Factors” in Synvista Therapeutics’ Annual Report on Form 10-K for the year ended December 31, 2007. These filings are available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov/. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Synvista Therapeutics undertakes no obligation to publicly release the result of any revision to these forward- looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Synvista Therapeutics, Inc.

CONTACT: Synvista Therapeutics, Inc., +1-201-934-5000, [email protected];or Investor/Media Relations Contact: Investors: Kim Sutton Golodetz,[email protected], or Media: Jules Abraham, [email protected], both ofLippert/Heilshorn & Associates, +1-212-838-3777, for Synvista Therapeutics,Inc.

Web Site: http://www.synvista.com/

A Piece Of Mind

GORDONSVILLE, Va., Sept. 17 /PRNewswire/ — Vitamin B12 may protect the brain in old age and reduce risk of dementia, according to a new study by University of Oxford researchers. Published in the new issue of Neurology, the study determined people with higher blood levels of vitamin B12 were six times less likely to experience brain shrinkage compared with people with lower vitamin levels.

According to study author Anna Vogiatzoglou, MSc, University of Oxford, the study suggests consuming more vitamin B12 to prevent brain shrinkage may save memory.

“Research shows that vitamin B12 deficiency is a public health problem, especially among the elderly, so more vitamin B12 intake could help reverse this problem,” said Vogiatzoglou.

Doctors are prescribing Animi-3(R) to address nutritional deficiencies including vitamin B12 and other essential nutrients to deficient patients. Each capsule of Animi-3 contains 500 mg of omega-3, (350 mg of DHA), 1 mg of folic acid, 12.5 mg of B6, and 12 mcg of B12.

“This Oxford University study correlates with other clinical findings that point to specific nutrient deficiencies correlated with reduced brain function,” said Jack Schramm, President of PBM Pharmaceuticals, the makers of Animi-3. “Studies continue to highlight the role nutritional deficiencies of the Animi-3 nutrients play in those with diminished brain health.”

— Dr. Schaefer, M.D., Tufts University, has analyzed the relationship of DHA to dementia and Alzheimer’s disease. His observations from the Framingham Heart Study indicate top quartile plasma DHA levels (correlated with consuming 180 mg/day or more of DHA) are associated with a 50% decreased risk of dementia.

— Fernando Gomez-Pinilla, UCLA professor of neurosurgery and physiological science, identified nutrients beneficial in preventing mental disorders, including omega-3 (DHA), folic acid, and vitamins B6 and B12. Omega-3 deficiency has been associated with increased risk of attention-deficit disorder, dyslexia, dementia, depression, bipolar disorder, and schizophrenia.

— Dr. Jane Durga, Wageningen University, published findings from a double-blind, placebo-controlled study in The Lancet that determined cognitive function improved significantly in participants taking folic acid.

More information on Animi-3 ingredients is found on http://www.animi-3.com/ and on http://www.dhaandbvitamins.org/, a resource developed by specialists at Weill Cornell Medical College and other medical centers.

   Animi-3 is not intended to diagnose, treat, or cure any disease.   Source:   http://www.aan.com/press/index.cfm?fuseaction=release.view&release=652    Contact:  Joe Shields             Director of Public Relations             (800) 959-2066 ext. 1131             [email protected]  

PBM Pharmaceuticals, Inc.

CONTACT: Joe Shields, Director of Public Relations of PBMPharmaceuticals, Inc., +1-800-959-2066, Ext. 1131, [email protected]

Web site: http://www.pbmpharmaceuticals.com/http://www.dhaandbvitamins.org/http://www.animi-3.com/

UK Campaign Identifies “ËœNine Types Of Drinkers’

The UK government said it has identified nine types of heavy drinkers as it launches a new alcohol campaign.

Focus groups showed that heavy drinkers often fell into one of a number of categories, according to research by the Department of Health in England.

The categories range from de-stress and depressed drinkers to people who boozed because of boredom or to bond.

Experts said helping people to understand the reasons for their drinking habits was “very useful”.

Heavy drinkers””defined as consuming 35 units a week for women, 50 for men, which is twice the recommended limit””did so for a variety of reasons, researchers said.

De-stress drinkers were defined as people in pressured jobs who used alcohol to relax, while bonding drinkers could be anyone in society who had hectic social lives and lost track of their drinking.

The research is to aid a new drive by ministers to crack down on heavy drinkers and a pilot is being run in the north west of England over the coming months to specifically target heavy drinkers.

Over 900,000 households will receive leaflets in the mail highlighting the link between drinking and conditions such as cancer and liver disease.

The campaign is focusing on adults aged over 35 who fall into the nine drinking categories.

People will be given details about where they can go to get help along with information about disease risk.

Users can access a website where they can calculate their own individual risk from drinking and get access to a self-help manual. A telephone helpline will also be set up.

The plan will help the government attempt to reach 4,000 people in the region to reduce their drinking within a year.

Officials hope to roll it out to other parts of England if it is successful.

“These heavy drinkers were a tough one to crack,” said Public health minister Dawn Primarolo.

“This is a totally fresh approach to helping people understand the effects of their drinking habits and help them make changes for the better,” she added.
Alcohol Concern chief executive Don Shenker agreed this type of marketing is very useful.

“In order to get people to examine their drinking they need to become aware of why they are doing it and what motivates them.”

The Nine Types of Drinker

Depressed drinker: Life in a state of crisis eg recently bereaved, divorced or in financial crisis. Alcohol is a comforter and a form of self-medication used to help them cope

De-stress drinker: Pressurised job or stressful home life leads to feelings of being out of control and burdened with responsibility. Alcohol is used to relax, unwind and calm down and to gain a sense of control when switching between work and personal life. Partners often support or reinforce behaviour by preparing drinks for them

Re-bonding drinker: Relevant to those with a very busy social calendar. Alcohol is the “Ëœshared connector’ that unifies and gets them on the same level. They often forget the time and the amount they are consuming

Conformist drinker: Traditional guys who believe that going to the pub every night is “Ëœwhat men do’. Justify it as “Ëœme time’. The pub is their second home and they feel a strong sense of belonging and acceptance within this environment

Community drinker: Drink in fairly large social friendship groups. The sense of community forged through the pub-group. Drinking provides a sense of safety and security and gives their lives meaning. It also acts a social network

Boredom drinker: Typically single mums or recent divorcees with restricted social life. Drinking is company, making up for an absence of people. Drinking marks the end of the day, perhaps following the completion of chores

Macho drinker: Often feeling under-valued, disempowered and frustrated in important areas of their life. Have actively cultivated a strong “Ëœalpha male’ that revolves around their drinking “Ëœprowess’. Drinking is driven by a constant need to assert their masculinity and status to themselves and others

Hedonistic drinker: Single, divorced and/or with grown up children. Drinking excessively is a way of visibly expressing their independence, freedom and “Ëœyouthfulness’ to themselves. Alcohol used to release inhibitions

Border dependents: Men who effectively live in the pub which, for them, is very much a home from home. A combination of motives, including boredom, the need to conform, and a general sense of malaise in their lives

Boys & Girls Clubs of America to Launch ‘BE GREAT’ Advocacy Campaign

WASHINGTON, Sept. 17 /PRNewswire-USNewswire/ — America’s youth need help. From academic failure and gang violence to poverty, drugs and obesity, they face a daunting array of problems — with serious consequences and fewer safety nets at home and in the community.

   (Photo:  http://www.newscom.com/cgi-bin/prnh/20080917/DC33364 )   (Logo:  http://www.newscom.com/cgi-bin/prnh/20050921/CLW030LOGO )   

To address these issues and call America to action, Boys & Girls Clubs of America (BGCA), the nation’s largest youth development network, is kicking off a new integrated advocacy campaign called BE GREAT, led by national spokesperson and Academy Award-winning actor, Denzel Washington.

Other Club alumni joining Washington in the BE GREAT campaign include: Muhammad Ali, Swin Cash, Bill Clinton, Bill Cosby, Cuba Gooding, Jr., Michael Jordan, Queen Latifah, Mario Lopez, John Mellencamp, Edward James Olmos, Smokey Robinson, John Singleton, Ruben Studdard, Usher, Courtney Vance, Mark Wahlberg, and Kerry Washington.

“As someone whose life was changed dramatically by the Boys & Girls Club, I can think of no better organization to lead the country in addressing the pressing needs of today’s young people,” said Washington. “I also believe that as adults we must assume responsibility for many of the conditions that are preventing our young people from achieving their full potential.”

The BE GREAT campaign will be unveiled today after a Congressional Breakfast on Capitol Hill. At the breakfast, BGCA will announce the organization’s 2008 – 2009 National Youth of the Year, who will share her/his story about how the Boys & Girls Club has affected her/his life. Following the event, the new National Youth of the Year will personally deliver a report of recommendations to the offices of Senators John McCain and Barack Obama to convey the issues of most concern to America’s teens.

The BE GREAT campaign was developed after BGCA conducted an online survey of more than 1,100 teens earlier this year in which the young people said that education is the top issue facing America (33 percent). In the survey, another 67 percent reported knowing someone who had dropped out of high school.

In a BGCA-hosted national Teen Town Hall Meeting held earlier in Los Angeles, young Americans expressed concern about the rising level of teen pregnancy (20 percent) and 22 percent reported knowing students who regularly carried weapons to school.

   In response, BGCA's advocacy campaign urges Americans to:   --  Get involved in the life of a child by volunteering, serving on a       local board, or financially supporting local Boys & Girls Clubs;   --  Ask elected officials to call attention to the issues affecting young       people, and to direct more partnerships and resources toward       solutions;   --  Reconnect and re-engage, as alumni, with organizations such as Boys &       Girls Clubs that impacted their lives as youth;   --  Host a Teen Town Hall in their community (visit http://www.be-great.org/ for       tips.)    About Be Great  

To communicate its advocacy efforts, BGCA is launching a call-to-action plan built around the new BE GREAT campaign, which was developed by McCann Worldgroup, working on a pro bono basis. Public relations agency Weber Shandwick will provide pro bono media relations and event support. The Outdoor Advertising Association of America (OAAA) has selected BGCA as one of its official charities and will bring the BE GREAT campaign to audiences from coast-to-coast through billboards and other out-of-home venues including bus shelters, airports and shopping malls.

This integrated campaign positions BGCA as a recognized leader in youth development, with proven programs tackling tough issues like the high school dropout rate, childhood obesity and gangs.

“We are very excited about the BE GREAT campaign and the opportunity to position Boys & Girls Clubs of America as a true advocate for today’s young people,” said BGCA President and CEO Roxanne Spillett. “BE GREAT marks the first time we are bringing a full complement of BGCA alumni to illustrate the effectiveness of our generation-changing programs.”

BE GREAT is designed to increase public awareness and understanding about the positive impact of Clubs by focusing on celebrated alumni who are living proof that the programs work. Further evidence is found in the 2007 BGCA alumni survey conducted by Harris Interactive. Fifty-seven percent of alumni reported, “The Club saved my life,” another 28 percent credited Boys & Girls Clubs with keeping them in school.

BE GREAT also includes a new Web site (http://www.be-great.org/) where the general public can find useful resources and compelling stories about the diverse lives touched by Boys & Girls Clubs. The site will also include a Club locator to help visitors find a nearby Boys & Girls Club where every child is welcome and volunteer support is appreciated.

Additional campaign components include: TV/radio PSAs, print/outdoor ads, outreach to teens via BGCA’s “My Club My Life” Web site (http://www.myclubmylife.com/) and YouTube channel, an op-ed series addressing key issues facing young people, and PR/advocacy with issue-based events, PR tools and media templates to help local Clubs advocate on behalf of youth.

Boys & Girls Clubs of America urges the country’s political and business leaders to make the young people of America a priority and encourage every citizen to make a difference by supporting organizations such as Boys & Girls Clubs — ensuring that every child has a safe, supervised and structured environment during the critical after-school hours.

About Boys & Girls Clubs of America

Boys & Girls Clubs of America (http://www.bgca.org/) comprises a national network of some 4,300 neighborhood-based facilities, with 4.8 million youth served through Club membership and community outreach, in all 50 states and on U.S. military bases worldwide. Known as “The Positive Place for Kids,” the Clubs provide guidance-oriented character development programs on a daily basis for children 6-18 years old, conducted by a full-time professional staff. Key Boys & Girls Club programs emphasize leadership development, education and career exploration, financial literacy, health and life skills, the arts, sports, fitness and recreation, and family outreach. An estimated 30 million American youth have been served by Boys & Girls Clubs since the founding of BGCA in 1906. National headquarters are located in Atlanta.

Photo: http://www.newscom.com/cgi-bin/prnh/20050921/CLW030LOGOhttp://www.newscom.com/cgi-bin/prnh/20080917/DC33364http://photoarchive.ap.org/AP PhotoExpress Network: PRN8PRN Photo Desk, [email protected]

Boys & Girls Clubs of America

CONTACT: Shara Glickman, +1-202-585-2395, [email protected],for Boys & Girls Clubs of America; or Jan Still-Lindeman of Boys & Girls Clubsof America, +1-678-656-6252, [email protected]

Web Site: http://www.be-great.org/

DFB Sells Coria Labs to Valeant Pharmaceuticals

FORT WORTH, Texas, Sept. 17 /PRNewswire/ — H. Paul Dorman, Chairman and Chief Executive Officer of Fort Worth-based DFB Pharmaceuticals, Inc., today announced that DFB has signed a definitive agreement to sell its dermatology division Coria Laboratories, Ltd. to Valeant Pharmaceuticals International .

Under the terms of the agreement, Valeant will purchase all of the outstanding shares of Coria from DFB Pharmaceuticals, Inc., and other shareholders for $95 million, subject to certain adjustments. The transaction is expected to close following the required approval under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended.

“This merger is an exciting milestone in the evolution of the Coria business,” said Mr. Dorman. “Valeant has a commitment to the development and growth of its dermatology business, making it the ideal fit for Coria and its talented workforce here in Fort Worth as well as the field based sales representatives across the country. We see the combination of Coria with Valeant’s financial strength as a way to maximize the past success of Coria and provide an outstanding platform to create a leading dermatology franchise.”

The Coria transaction will add several marketed dermatology products to Valeant’s portfolio, including the CeraVe(R) Skin Care Line, Cloderm(R) Cream for the treatment of dermatoses, Akne-Mycin(R) and Atralin(TM) for the treatment of acne, and Salex(R) for the treatment of hyperkeratotic skin disorders, as well as Tetrix(TM) Cream for the treatment of hand dermatitis which is expected to be launched later this year. In addition, Coria has several products under development, including line extensions for the CeraVe(R) brand product line.

   Coria Laboratories was advised by William Blair & Company, L.L.C.    About Valeant  

Valeant Pharmaceuticals International is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at http://www.valeant.com/.

About Coria Laboratories, Ltd.

Coria Laboratories, Ltd. is a rapidly growing pharmaceutical company specializing in research, development and marketing of high-quality dermatology products for the treatment of diseases affecting the skin, hair, and nails. Coria Laboratories has a broad portfolio of branded prescription and over-the-counter dermatology products. For more information on Coria Laboratories, visit the web site at: http://www.corialabs.com/.

About DFB Pharmaceuticals, Inc.

DFB Pharmaceuticals, Inc. is a privately held Texas corporation that provides technology-driven pharmaceutical products, outsourcing services, and licensing opportunities through its affiliate partners to the healthcare industry worldwide. DFB’s business structure is organized by segments: Branded Pharmaceuticals, Biotechnology, and Pharmaceutical Services. The Branded Pharmaceuticals segment includes HEALTHPOINT, Ltd., active in the research, development, and marketing of branded pharmaceuticals, over-the-counter drugs, and biotech drugs for wound care indications since 1992; and Coria Laboratories, Ltd., focusing on dermatology and treatments of diseases that affect the skin, hair, and nails. Pharmaceutical Services includes DPT Laboratories, Ltd., a Contract Development and Manufacturing Organization (CDMO) and industry source for semi-solid and liquid development and manufacturing services for the world’s leading pharmaceutical, biotechnology, and healthcare companies. The Biotechnology segment encompasses Phyton Biotech, Inc., whose proprietary plant cell culture technology platform is used to develop and manufacture products with applications in the pharmaceutical and biotech industries; and Phyton’s German subsidiary, Phyton GmbH, which operates the world’s largest commercial cGMP manufacturing facility for plant cell fermentation. DFB is on the web at http://www.dfb.com/.

DFB Pharmaceuticals, Inc.

CONTACT: Michael A. Patterson, Chief Financial Officer of DFBPharmaceuticals, Inc., 1-800-441-8227

Web site: http://www.dfb.com/http://www.valeant.com/http://www.corialabs.com/

AmeriChoice and Baptist Memorial Health Care Sign Contract to Provide TennCare Services in West Tennessee

AmeriChoice by UnitedHealthcare and Baptist Memorial Health Care announced today that they have signed a definitive agreement to provide care and services to TennCare members in West Tennessee when the new program goes live on November 1, 2008.

AmeriChoice by UnitedHealthcare members will have access to care at all eight Baptist facilities in the state, including its flagship, Baptist Memorial Hospital-Memphis , Baptist Memorial Hospital for Women and Baptist Memorial Hospital-Desoto, just across the state line in Southaven, Miss.

Eric Paul, CEO of the AmeriChoice by UnitedHealthcare, said, “We are extremely pleased to be able to make the Baptist services available to our new members in West Tennessee. We share the same commitment to quality health care for TennCare beneficiaries, and our partnership reflects the significant commitment we both have made to the success of this vital program for the health of our state.”

“We are always glad to have the opportunity to provide quality health care services to our community,” said David Elliott, vice president of Baptist Memorial Health Care. “We are very supportive of the TennCare program, and this partnership will benefit our area greatly.”

About AmeriChoice by UnitedHealthcare

AmeriChoice by UnitedHealthcare will begin serving the TennCare Medicaid program in West Tennessee on November 1, 2008, becoming the only statewide risk based TennCare health plan. AmeriChoice by UnitedHealthcare is a unit of AmeriChoice, the UnitedHealth Group company that serves more than 2.2 million members of state health care programs in 22 states and the District of Columbia. AmeriChoice is a diversified health services company dedicated to helping states, localities, and other government agencies facilitate care for the economically impoverished, the medically underserved and those without the benefit of employer-funded health care coverage. For more information, visit www.americhoice.com.

About Baptist Memorial Health Care

One of the largest not-for-profit health care systems in the United States, Baptist Memorial Health Care offers a full continuum of care to communities throughout the Mid-South. The Baptist system, which consistently ranks among the top integrated health care networks in the nation, comprises 15 hospitals in West Tennessee, North Mississippi and East Arkansas; more than 3,100 affiliated physicians; home, hospice and psychiatric care; minor medical centers and clinics; a network of surgery, rehabilitation and other outpatient centers; and an education system highlighted by the Baptist College of Health Sciences. Baptist has more than 2,600 licensed beds systemwide, employs more than 12,000 people and has approximately 85,000 admissions annually. In fiscal year 2007, Baptist provided $429 million in community benefit to the communities it serves. For more information about Baptist, please visit www.baptistonline.org or call 800-4-BAPTIST.

Serbia, Russia Jockeying for Positions Prior to Gas Pipeline Talks – Daily

Text of report by Serbian newspaper Politika website on 12 September

[Report by Jasna Petrovic: “Sparks Flying Around South Stream”]

The statement by Yuriy Buligin, a representative of the Russian chamber of commerce, that the ratification of the natural gas and oil agreement by the Serbian Assembly does not also mean that the construction of South Stream will begin has once more raised the question of what the actual future is of that alternative gas pipeline, which is supposed to be an energy link between Russia and Europe. Buligin’s position is interpreted as an effort to occupy a better starting position on the eve of the resumption of Serbia’s negotiations with Gazprom concerning the construction of South Stream and the sale of a 51 per cent share of NIS [Naftna Industrija Srbije; Petroleum Industry of Serbia] to Gazpromneft.

Andrey Khripunov, the head of the Russian chamber of commerce, told Politika yesterday [11 September] that he is a little surprised by the statement by his colleague Yuriy Buligin and he emphasized that when the two sides sign the interstate agreement they will be obligated to abide by the terms of that document.

“The negotiations on the technical details of the oil and natural gas deal remain to be conducted. However, the price for NIS is stipulated under the agreement, and that must be honoured,” Khripunov stressed.

He believes that there is plenty of pressure on both sides, noting that the natural gas and oil agreement was signed in Moscow on the highest state level and that the obligations from the agreement relate both to NIS and to South Stream.

Nervousness between Belgrade and Moscow arose when the Serbian Government asked an auditing firm to prepare an appraisal of the market value of NIS, whereupon its capital was appraised at 2.2 billion euros, which was interpreted as an attempt by some ministers in the government to increase the originally agreed price of 400 million euros. The strongest objections to the price of 400 million euros that will accrue to the state came from the deputy prime minister and minister of economy, Mladjan Dinkic.

If, however, the entire deal were to end up falling through because of the increasing criticism being voiced by some experts who say that the natural gas arrangement with Russia is harmful to the Serbian economy, then major Serbian cities such as Uzice, Cacak, and Nis would have problems with their natural gas supply this winter and the price of that fuel would be significantly higher, says Sasa Ilic, the managing director of the public enterprise Srbijagas, who signed an agreement in Belgrade with Dmitriy Medvedev on establishing a joint venture for construction of the gas pipeline.

When asked to comment on Yuriy Buligin’s statements, Ilic says that he believes that the Russian representative said that because of the problems that some Russian companies have after they arrive in Serbia, and not because he thinks that that deal will come to naught. On the contrary, it is a fact that there has been much heavier investment of Russian capital in Serbia in recent years than capital coming from the West.

“With the signing of the interstate agreement and the ratification of the agreement not only with Serbia, but also with all the other countries through which South Stream will pass, Russia has made it clear who its priorities are in this deal, and so I doubt that Gazprom will now back away from this big deal, Ilic says categorically, adding that there is no truth to allegations that Russia is being given NIS as a gift in exchange for South Stream, because the feasibility study on the course of the gas pipeline is not yet complete.

Ilic, who is in almost daily contact with the Russian side, emphasizes that the next meetings will be an opportunity to define the route of the pipeline, its capacity, and the pace for completing the work, emphasizing that a South Stream route through Romania is not part of the plan.

“The public should know that the capacity of the gas pipeline does not depend on the Serbian negotiations, but rather on how much natural gas is needed by Hungary, Italy, Slovenia, Austria, and any other countries that will consume that gas. It is illogical for the Russian partner to say that the capacity of the gas pipeline passing through Serbia will be 30 billion cubic meters without there being an end consumer for that commodity,” the Srbijagas head explains.

It is realistic to expect that the capacity of the gas pipeline crossing Serbia will be greater than that of the one that crosses Greece to reach Italy, because the consumption of natural gas is much greater in the route that crosses Serbia. The agreement does mention at least 10 billion cubic meters of gas, which is five times more than current Serbian needs, Ilic notes.

In his opinion, what should be insisted on in the coming negotiations with Russia is that assurances be provided of a permanent, regular supply of all types of energy.

Zorana Mihajlovic-Milanovic, an energy adviser to former Deputy Prime Minister Miroljub Labus, agrees that the statements coming from both the Serbian and the Russian side are a way of fighting for the best terms achievable. The Russian side’s interest, she adds, is in there being no changes in the agreement, and they will try to achieve that any way they can. On the other hand, Serbia has realized that it can get more but that it can also lose, and now it should finally define its platform. The bad thing for both sides, however, is that messages are being sent to public opinion and the domestic political scene through the media.

She says that she does not believe that the deal might fall through after ratification, because it is in Serbia’s interest to have alternative routes for the supply of natural gas, but also technologically and environmentally modern refineries, which is an issue of energy security and development for at least the next two decades.

One thing that she regards as a certain obstacle and source of resistance is the way in which NIS is being privatized, because this is not a public procedure or a competitive bidding process through which the Russians are buying the Serbian fuel factory, she says.

[Box by “J.P.-D.S.”] Skundric: Russians Could Have Bypassed Serbia

The natural gas and oil deal ratified by the Assembly early in the week is an interstate agreement on a strategic partnership between Serbia and the Russian Federation from which everyone — both Serbia and Russia — benefits. The realization of that project gives Serbia a secure alternative route for the supply of natural gas for the next 40 to 50 years, Minister of Mining and Energy Petar Skundric said in an appearance at the Politika Business Club.

“If you look at this deal and compare only Serbia and Bulgaria, with which Russia has also signed an agreement on construction, you must not forget that the Russians had no other choice but to build the gas pipeline across Bulgaria, but they also could have bypassed Serbia and they decided in favour of our country,” says Minister Skundric (the entire interview will be published in the Sunday edition).

Since the Russians are insisting on a package deal, and thus the construction of the South Stream pipeline, the privatization of 51 per cent of NIS, and completion of the underground storage facility in Banatski Dvor, there is no way that the purchase agreement for the oil company can be signed without Serbia getting adequate guarantees that a gas pipeline of corresponding capacity will pass through Serbia.

Asked to comment on Yuriy Buligin’s statement that ratification of the agreement does not also mean that South Stream will be built, as well as suggestions by the LDP [Liberal Democratic Party] that the entire natural gas and oil deal should be re-examined by the Constitutional Court, Minister Skundric says that whenever certain interpretations are voiced, that is done with a specific goal and intention. But, he adds, this is something completely different, namely an interstate agreement that is to both side’s benefit. This agreement opens up new possibilities for Serbia in relation to the countries of the European Union, namely in the strategic sense.

He emphasized yesterday [11 September] that the price of electric energy will certainly not go up by the end of this year, noting that the price of electricity is not set by the Ministry of Mining and Energy, but rather by the Energy Agency.

[Box] American Warnings to Hungary

The American ambassador in Budapest, April Foley, said yesterday that Hungary should consider the possibility of discontinuing negotiations with Russia over the South Stream gas pipeline, adding that it would be beneficial to Hungary to think about the possibility of suspending negotiations with Moscow.

Hungary’s deputy minister of economy, Abel Garamhegyi, said that Budapest has no intention of suspending negotiations with Russia over that agreement, under which part of the South Stream natural gas pipeline would pass through Hungary.

Originally published by Politika website, Belgrade, in Serbian 12 Sep 08.

(c) 2008 BBC Monitoring European. Provided by ProQuest LLC. All rights Reserved.

New FDLI Book Provides Comprehensive Guidance on Off-Label Communication

To: NATIONAL EDITORS

Contact: Michael Levin-Epstein, Editor-in-Chief of FDLI, +1-202- 222-0897, [email protected]

WASHINGTON, Sept. 17 /PRNewswire-USNewswire/ — More than ever, physicians in the United States are prescribing drugs, biologics and devices to treat patients in ways that were not specifically approved by FDA. This treatment often is in response to patients’ increasing demand for access to drugs and devices that promise hope for treating diseases but that have not yet been approved by FDA for such uses.

There’s nothing illegal about this practice by physicians. But FDA rigorously regulates off-label communication, promotion and marketing by pharmaceutical, medical device and biotechnology firms. The bottom line: Although patients may use and physicians may prescribe off-label, manufacturers and distributors may not promote off-label except under the narrowest of circumstances.

Under the current federal regulatory scheme, the promotion of a product for a use that does not appear on the product’s labeling renders the product itself “misbranded,” and the adding of an unapproved use to the products labeling makes the product “adulterated.” Manufacturing, delivering, receiving, or introducing a medical product into the interstate commerce that is “misbranded” or “adulterated” is unlawful under federal law. Such conduct exposes the violator to injunction, product seizure, debarment, fines, civil penalties, and imprisonment. Criminal enforcement of these laws has been increasing at both the state and federal level.

FDA is still finalizing guidance in this area, especially on the issue of distributing journal articles describing off-label indications. So, experts concluded at the Food and Drug Law Institute’s annual Advertising and Promotion Conference in Washington, D.C., Sept. 9, companies should watch their step to avoid investigations that could lead to fines or even criminal prosecution.

Now, for the first time, the Food and Drug Law Institute (FDLI) has published a comprehensive guide for pharmaceutical firms, medical device companies, life science attorneys, sales and marketing staff, compliance officers, regulatory affairs specialists and consultants on how to comply with FDA regulations on off-label communications.

The 217-page book, Off-Label Communications: A Guide to Sales and Marketing Compliance,edited by Mark Carlisle Levy, a partner at Saul Ewing, LLP and Co-Chair of its Life Sciences Practice Group, in Philadelphia, PA, discusses specific problems arising from off- label use and promotion, while providing practical instruction on how to deal with them, including managing clinical trial disclosures; reimbursement; training and monitoring sales and marketing representatives; risk management; product liability litigation; ethical considerations and how the government is enforcing off-label sales and marketing compliance.

For more information about the book, visitwww.fdli.org.

Media:To obtain a review copy of Off-Label Communications: A Guide to Sales and Marketing Compliance,contact Michael Levin- Epstein, Editor-in-Chief, FDLI, (202) 222-0897; [email protected].

Founded in 1949, FDLI publishes the award-winning, peer-reviewed Food and Drug Law Journal;the bimonthly magazine Update; FDA Directory;and dozens of books and publications for attorneys, regulatory affairs practitioners, scientists, health care professionals, government employees and marketers in the food and drug field. For more information, visit www.fdli.org

SOURCE Food and Drug Law Institute

(c) 2008 U.S. Newswire. Provided by ProQuest LLC. All rights Reserved.

Solomon Islands Sending More Medical Students to Cuba

Text of report by Solomon Islands locally-owned newspaper website, Solomon Times Online on 15 September

[By Joy Basi]

Another 25 more students intending to study medicine will leave the country for Cuba at the end of the month. This was confirmed by the Ministry of Health’s under-secretary for health care, Dr Cedric Alependava in an interview last week.

“Under the agreement between the Cuban government and the Solomon Islands government there are 50 scholarship for 2007-2008 offered for Solomon Island students,” said Dr Alependava. He mentioned that the first part of the agreement had already been implemented, which is why the first lot of 25 students are currently studying medicine in Cuba.

According to Dr Alependava, the 25 students are quite successful in their studies and have completed their language training. The students are now into their academic studies.

The Ministry of Health is expecting another 25 students to leave at the end of the month.

He adds that the Ministry of Health and Medical Services has seen this agreement as a big bonus to the Solomon Islands, as already the Solomon Islands “is short of nearly 50- 60 doctors.”

According to Dr Alependava, the agreement will enable doctors to be relieved at times.

It has also been revealed that Malaita and Western Province are desperately in need of another 10 doctors and at least four more doctors for other smaller islands. The National Referral Hospital is also experiencing similar problems and is in dire need of 40 more doctors and additional anaesthetists. The hospital currently has only one anaesthetist.

Solomon Islands has only 59 doctors in total, working within the capital and in the provinces.

Dr Alependava also revealed that the Cuban government has given an additional 16 medical scholarships for 2009, which means that “after six yeas of studying we would have 66 new doctors to provide for the medical need of the country”.

Dr Alependava in conclusion thanked the Cuban government for the much needed assistance to the Solomon Islands.

Originally published by Solomon Times Online website, Honiara, in English 15 Sep 08.

(c) 2008 BBC Monitoring Asia Pacific. Provided by ProQuest LLC. All rights Reserved.

Women’s Sexual Health Foundation Announces Inaugural Media Award To Recognize an Outstanding Journalist

CINCINNATI, Sept. 17 /PRNewswire-USNewswire/ — Recognizing the challenges of covering women’s sexual health and education in consumer media, The Women’s Sexual Health Foundation (TWSHF) (http://www.twshf.org/) has announced its first ever Media Award. To be presented annually, the award will recognize an outstanding media professional whose work has broadened the knowledge and understanding of women’s sexual health disorders and related women’s health concerns. Media professionals eligible for nomination may work in any consumer media — print, television, radio or internet. The award recipient will be formally announced at the Foundation’s conference, Women’s Education: Reclaiming Healthy Intimacy, Passion and Pleasure (http://www.twshf.org/), on April 4, 2009, in New York City, which is also hosted by the Columbia University College of Physicians and Surgeons.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080917/DC32925LOGO )

TWSHF listens to thousands of women each year who want and need factual information to help them make important decisions related to their sexual health. Healthcare professionals also want to be informed about the latest research based information so they can facilitate productive dialogue with their patients. The media plays an important role having the power to help or hinder these valuable exchanges.

“We rely on the media to help us reach women and healthcare professionals,” comments Lisa Martinez (http://www.twshf.org/bio_lmartinez.html), TWSHF’s founder and director. “While we have seen the topic sullied with sensationalism and the facts distorted with innuendos, there are outstanding reporters who write about women’s sexual health in an accurate, balanced and sensitive way. Those are the journalists we seek to honor.”

Nominations will be accepted until November 15, 2008, and may be submitted to [email protected] with Media Award in the subject line. Include the following information with each submission:

— Nominee’s name & contact information – day and evening phone numbers, email address

— Nominator’s name & contact information – day and evening phone numbers, email address

— Five hundred (500) word, or less, essay explaining what the nominee has done professionally to broaden the knowledge and understanding of women’s sexual health disorders and related women’s health concerns.

The journalist to be honored will be chosen by a panel of TWSHF board members. The recipient will be notified by February 1, 2009.

TWSHF, an international non-profit organization, has numerous resources for the public and healthcare professionals at http://www.twshf.org/, including educational brochures and The Women’s Sexual Health Journal.

Photo: http://www.newscom.com/cgi-bin/prnh/20080911/DC32925LOGOhttp://photoarchive.ap.org/PRN Photo Desk, [email protected]

The Women’s Sexual Health Foundation

CONTACT: Lisa Martinez, +1-513-638-2810, or Robyn Carey Allgeyer,+1-513-207-8227 both of The Women’s Sexual Health Foundation

Web Site: http://www.twshf.org/

HealthMedia(R) Overcoming(TM) Insomnia Showing Eye-Opening Results

ANN ARBOR, Mich., Sept. 17 /PRNewswire/ — HealthMedia, Inc., the pioneer in applying advanced technology to emulate a health coaching session via the web — without the coach — for wellness, disease management, behavioral health, medication adherence, and aging well has released the latest data from the HealthMedia(R) Overcoming(TM) Insomnia program. Overcoming Insomnia, a scalable, low-cost solution to a condition that costs health plans and employers an estimated $100 billion annually, helps individuals change negative thoughts and behaviors that interfere with sleep, develop healthy sleep habits, and improve the quality of sleep. The company’s latest user outcome data shows:

   -- A productivity savings of $2,235/year per participant   -- 90 percent are satisfied with the program (rating it good, very good or      excellent)   -- 70 percent found it easier to stay asleep during the night after 90      days   -- 63 percent experienced improvement in overall quality of sleep after 30      days    

A recent initiative with customers resulted in a 40 percent increase in program participation in just two months. With its data, the company is formulating a profile of a typical program user that employers and health plans can use to reach out to their populations. Initial data shows that the typical user works full time, has experienced insomnia for over a year, sleeps an average of six hours per night, and is motivated to manage his/her insomnia. Users of the Overcoming Insomnia program reported experiencing the following results:

   -- 36 percent reduction in difficulty falling asleep   -- 35 percent decrease in difficulty staying asleep   -- 31 percent increase in confidence to manage insomnia   -- 30 minute increase in average nightly sleep time   -- 27 percent reduction in fatigue levels   -- 18 percent reduction in anxiety    

“Outcomes data and user feedback for this product are beyond impressive,” said HealthMedia President and CEO Ted Dacko. “They show an average productivity savings of more than $2,235 per user, per year.”

A recent case study conducted by a major U.S. corporation with over 30,000 employees proves that a computer-based cognitive behavioral therapy (CBT) solution can be an effective, efficient, and inexpensive way to treat insomnia. The study revealed that 30 percent of employees were getting six hours of sleep or less per night, had an average productivity impairment of more than 23 percent, and were responsible for a $9.4 million company loss in productivity — all due to insomnia. After taking the HealthMedia online program, productivity impairment in users dropped nearly seven percentage points. This improvement equates to productivity savings of more than $3,250 per employee, per year.

“About 44 percent of U.S. adults are not getting enough sleep, and many of our members are in that group,” said Donald R. Fischer, MD, senior vice president and chief medical officer at Highmark Inc. “Getting adequate sleep is a big factor in their work day and overall health. On average, people who are chronically tired are at risk for health problems such as obesity, depression, and risky behaviors such as smoking, drinking and physical inactivity. We are pleased that our members are participating in HealthMedia’s Overcoming Insomnia program and having a greater hand in their health.”

Despite the pervasive nature of the problem, 90 percent of those who suffer from insomnia receive no medical treatment. In a new Consumer Reports survey released last week, 44 percent of respondents say they aren’t sleeping at night and according to the National Institutes of Health, as many as 70 million Americans may be dealing with sleep problems.

HealthMedia(R) Overcoming(TM) Insomnia is an individually tailored CBT program that includes sleep scheduling, stimulus control, changing negative sleep thoughts, and changes in lifestyle. In spite of its effectiveness, CBT is often unavailable to consumers due to the small number of professionals trained in the approach.

   Studies have shown that that those who suffer from insomnia:   -- Are responsible for $2,800 in higher direct-per patient costs   -- Are hospitalized at twice the rate of good sleepers   -- Lead to an additional $13.8 billion of primary care visits   -- Miss work twice as often   -- Have a significantly higher rate of work-related accidents, and have      2.5 times more serious work errors    

Until now, medication has been the most frequent treatment of choice for insomnia, and carries a national annual price tag of $2.1 billion for prescriptions and $376 million for over-the-counter sleep aids.

“Medication treats the symptom, not the cause, and because of an increased awareness of potential medication side affects and dependence; market demand is growing for safer treatment options that can address condition contributors like behavior and co-morbid chronic health problems,” said Dacko.

About HealthMedia, Inc.

HealthMedia, Inc. is the world’s innovator in combining advanced technology and behavioral science to effectively emulate a health coach via the web. HealthMedia applies its revolutionary Fusion(TM) technology to address the five most problematic pain points facing the health industry today: participation, scalability, cost, efficacy, and return on investment. HealthMedia’s suite of interventions provides automated web-based coaching for wellness, disease management, behavioral health, and medication adherence with proven outcomes, increased compliance, reduced medical utilization, and increased productivity — boosting profitability for health plans, employers, pharmaceutical companies, and behavioral health organizations. Clients include Community First Health Plans, Daiichi Sankyo, Fresh & Easy Neighborhood Market, Inc., Johnson & Johnson, Kaiser Permanente, GlaxoSmithKline and nine Blue Cross Blue Shield organizations across the United States. HealthMedia partners include APS Healthcare, Corphealth, Health Dialog, RedBrick Health Corporation, SHPS, StayWell Custom Communications, and Wellsource. For more information, visit http://www.healthmedia.com/

Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Ted Dacko http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=78153

HealthMedia, Inc.

CONTACT: Caren Kenney of HealthMedia, Inc., +1-508-942-4407,[email protected]

Web site: http://www.healthmedia.com/

Nationwide Survey Shows Infertility Patients Prefer ENDOMETRIN(R) Compared With Other Progesterone Supplements

PARSIPPANY, N.J., Sept. 17 /PRNewswire/ — Results of a nationwide survey of infertility patients undergoing an assisted reproductive technology treatment (ART), such as in vitro fertilization, revealed that patients prefer ENDOMETRIN(R) (progesterone) Vaginal Inserts to progesterone-in-oil (PIO) injections, and to all other vaginal progesterone supplements. The reasons cited most frequently for their preference included easy, convenient and pain-free administration.

Adequate progesterone support is considered extremely important for a successful pregnancy. Since natural progesterone production may be compromised by ART, progesterone supplements are used extensively for luteal phase and early pregnancy support. There are several forms: oral, injection, and vaginal — tablet inserts, vaginal capsules, suppositories and gels.

“The survey confirms what we hear all the time from patients — that when they reach the final stage of their IVF treatment, the last thing they want is another series of shots or inconvenient treatments,” said Christine Stroup, RN. “Our patients are very pleased with ENDOMETRIN because it’s simple to use and very convenient.”

“I’ve tried just about every progesterone treatment available, and was so happy to find one that didn’t hurt, like shots, and wasn’t messy, like gels and suppositories,” said Victoria Knapp, IVF patient. “After all those cycles of treatment I went through, it was a relief to find one that was so simple to use.”

The Evaluation of Attitudes and Satisfaction with Endometrin Survey of 212 patients was commissioned by Ferring Pharmaceuticals Inc. to compare patient satisfaction with ENDOMETRIN, the most recent progesterone supplement to enter the market, with all other progesterone supplements.

   Key Survey Findings    --  More than 90 percent of patients would recommend ENDOMETRIN to a       friend undergoing infertility treatment, 84 percent would request it       for their next treatment cycle, and 93 percent found the dosing       regimen easy to fit into their daily routine.  When asked to describe       it in three words, the most common were: "easy, convenient, painless       and comfortable."    --  The vast majority found the vaginal inserts more convenient (87       percent), comfortable (89 percent), and easier to administer (95       percent) compared with injections, taken by 154 respondents.  Of the       women who needed a partner to administer the shots, most (65 percent)       said their partner felt anxious about it.    --  Of the 62 women who used the capsules administered vaginally, most       said ENDOMETRIN was more convenient (74 percent), comfortable (nearly       70 percent), and easier to administer (83 percent).    --  Patients found suppositories, made by the pharmacy, awkward to       administer without an applicator.  Of the 83 women who used them,       nearly 90 percent said they melted or leaked, and more than half said       they caused irritation.    --  Nearly 80 percent of the 26 gel users said gel created build-up,       nearly 50 percent found gel messy to administer and more than       one-third said it caused irritation.    --  While 20 of the 40 women who used the oral form preferred the       administration convenience of ENDOMETRIN and 13 preferred the oral       supplement, the oral form is widely considered less effective than       other options.    Methodology  

Nurses at more than 60 designated fertility centers across the country selected qualified patients who had used or were about to start ENDOMETRIN in an IVF or ovulation induction cycle. Patients must also have used a different progesterone supplement in a previous or current cycle. The survey reflects the patient’s most recent treatment cycle. The majority of the 212 patients were 40-years-old or younger; nearly 40 percent had been in fertility treatment for more than two years.

About ENDOMETRIN

ENDOMETRIN administered as a progesterone vaginal insert is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment for infertile women.

Only physicians thoroughly familiar with infertility treatment should prescribe ENDOMETRIN. In clinical trials (n=808), adverse reactions that occurred at a rate greater than or equal to two percent included: uterine spasm (3% to 4%) and vaginal bleeding (3%). Vaginal irritation, itching, burning or discomfort, urticaria, and peripheral edema were reported at an incidence of less than two percent. ENDOMETRIN is expected to have adverse reactions to other drugs containing progesterone (breast tenderness, bloating, mood swings, irritability, and drowsiness).

About Ferring Pharmaceuticals

Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, manufactures and markets the largest family of fertility treatments of any manufacturer in the U.S. The Company markets MENOPUR(R) (menotropins for injection, USP), BRAVELLE(R) (urofollitropin for injection, purified), REPRONEX(R) (menotropins for injection, USP), NOVAREL(R) (chorionic gonadotropin for injection, USP) and ENDOMETRIN in the U.S. to infertility specialists and their patients. Ferring also offers the Q?CAP(TM), the first and only needle-free reconstitution device, for use with its fertility treatments.

Ferring’s line of orthopaedic and urology products includes EUFLEXXA(R) (1% sodium hyaluronate) hyaluronic acid for pain from osteoarthritis in the knee and PROSED(R)/DS for the relief of discomfort of the lower urinary tract. Other products include: ACTHREL(R) (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing’s syndrome; and DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis.

The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/ gynecology and infertility. For more information, call 888-337-7464 or visit http://www.ferringusa.com/ or http://www.ferringfertility.com/.

Contact Andrea Preston for full prescribing information for ENDOMETRIN.

Ferring Pharmaceuticals

CONTACT: Andrea Preston, Kovak-Likly Communications, +1-203-762-8833,[email protected]

Web Site: http://www.ferringfertility.com/http://www.ferringusa.com/

DOR BioPharma Forms orBec(R) European Medical Advisory Board

DOR BioPharma, Inc. (DOR or the Company) (OTCBB: DORB), a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against certain bioterrorism agents, announced today the formation of a European Medical Advisory Board (MAB) to provide medical/clinical strategic guidance to the Company as it relates to the ongoing development of orBec(R) for the treatment of gastrointestinal Graft-versus-Host disease (GI GVHD).

The MAB will play a crucial advisory role in the design of future clinical studies and associated interactions with the European Medicines Evaluation Agency (EMEA). The European MAB is made up of physicians with extensive backgrounds in the field of allogeneic hematopoietic cell transplantation (HCT), the clinical setting in which GI GVHD occurs. DOR’s new MAB members are from a diverse array of European countries, and will bring a unique European perspective to the strategic development of orBec(R). The MAB will be chaired by George B. McDonald, MD, Professor of Medicine at the University of Washington, Member at the Fred Hutchinson Cancer Research Center, inventor of orBec(R) and a consultant to DOR.

Dr. McDonald stated, “I am pleased with the caliber of the orBec(R) Medical Advisory Board we have selected from key European countries. This experienced and respected group of leading hematopoietic cell transplant oncologists has been assembled based on their substantial practice and research contributions in the transplant field in their own institutions. Their collective research efforts have had a clinical impact worldwide. We are very much looking forward to their productive involvement with the orBec(R) program in Europe.”

“We are very excited to be able to attract key European opinion leaders to participate in the development of orBec(R) as members of our Medical Advisory Board,” stated Christopher J. Schaber, PhD, President and Chief Executive Officer of DOR. “The formation of a European Board, in concert with the North American Medical Advisory Board established last year, will provide us with critical medical guidance to continue the development of orBec(R) so that we may make it available to the patients who so desperately require a therapeutic option. The availability of orBec(R) in Europe under named patient protocols is an important step forward in the treatment for GI GVHD.”

The orBec(R) European MAB Members

George B. McDonald, MD, is a Professor of Medicine at the University of Washington, School of Medicine, and a Member at the Fred Hutchinson Cancer Research Center, where he is head of the Gastroenterology/Hepatology Section. He also serves as the head of the Program in Complications of Cancer Treatment that has as its goals the reduction of morbidity from cancer treatment, improved survival, and prevention of late sequelae of cancer treatment. Dr. McDonald’s research is focused on gastrointestinal and hepatobiliary complications of HCT, specifically problems involving the toxicity of high-dose myeloablative regimens that are used to prepare patients for transplant and acute and chronic GVHD involving the gastrointestinal tract and liver. He has recently developed and validated a new method of assessing the severity of acute GVHD, called the acute GVHD Activity Index, an accurate predictor of transplant-related mortality. He was the lead investigator on the clinical trials that pioneered the use of topical corticosteroid therapy with oral beclomethasone dipropionate for GI GVHD.

Dietger Niederwieser, MD, is the Head of the Department of Hematology and Oncology at the University of Leipzig in Leipzig, Germany. Professor Niederwieser is the current President of the European Group for Blood and Marrow Transplantation (EBMT). He has been active with EBMT for the past 20 years, previously serving as the Chairman of the Chronic Leukemia Working Party. He has published more than 300 papers focusing on topics such as the immunology of stem cell transplantation (SCT), minor histocompatibility antigens, graft-versus-tumour reactions, reduced intensity conditioning SCT, standardization of procedures and donor-transmitted diseases. Prof. Niederwieser was trained in Internal Medicine and Haematology at Innsbruck in Austria, and received specialized training on clinical SCT and pathophysiology of GVHD in Basel, Switzerland and Seattle, Washington, USA. He has received a number of awards including the doctor honoris causa of the University of Thessaloniki and the title of Cavaliere della Repubblica Italiana from the Presidente della Repubblica Italiana Napolitano.

Jane Apperley, MD, is the Chair of the Department of Hematology at the Imperial College and the Chief of Service for Clinical Hematology at the Imperial College Healthcare NHS Trust in London, England. She qualified in Medicine from the University of Birmingham and after initial specialization in internal medicine she completed specialist training in hematology in Birmingham, London, Cambridge and Boston. Her particular interests are the biology and management of chronic myeloid leukemia, which has led naturally to an extensive experience in SCT and more recently to the use of signal transduction inhibitors in this disease. Professor Apperley is the past-President of both the EBMT and the British Society of Blood and Marrow Transplantation and serves on the Advisory Board of the CIBMTR CLINT (Facilitating International Prospective Clinical Trials in Stem Cell Transplantation).

Andrea Bacigalupo, MD, is the Head of the Department of Hematology at Ospedale San Martino in Genoa, Italy, where he has served in various capacities since 1974. Dr. Bacigalupo’s BMT work began in 1976 in Genoa on allogeneic BMT. He has worked for many years within the EBMT since 1983, and has served as President. He is a member of the International Society for Experimental Hematology and the Societa’ Italiana Ematologia. Dr. Bacigalupo has published more than 300 articles in peer-reviewed journals. His research interests lie in bone marrow transplantation, leukemia, graft versus leukemia, aplastic anemia, in vitro growth of progenitor cells, growth factors, CMV, data management, and patient oriented computer-based monitoring.

Jose Antonio Perez Simon, MD, PhD, is an Attending Physician in the Bone Marrow Transplant Unit in the University Hospital in Salamanca, Spain, and leads the Cellular Therapy Laboratory of the Department of Hematology in the area of Immunology of Bone Marrow Transplantation. He completed his clinical training in BMT at the Fred Hutchinson Cancer Research Center and his laboratory training at the Karolinska Institute. He has multiple peer-review publications and his major contributions have been in the field of GVHD both in the clinical setting as well as in the basic research.

Hans Haegglund, MD, PhD, is an Associate Professor of Hematology and Internal Medicine Specialist in the Department of Hematology at the Karolinska University Hospital in Huddinge, Sweden. Dr Haegglund completed a post-doc position at the Fred Hutchinson Cancer Research Center. He has multiple peer-review publications in the field of SCT, lymphoma and acute lymphoblastic leukemia. He is a committee member of the Swedish Hematology Association and the national acute lymphoblastic leukemia group.

About orBec(R)

orBec(R) represents a first-of-its-kind oral, locally acting therapy tailored to treat the gastrointestinal manifestation of GVHD, the organ system where GVHD is most frequently encountered and highly problematic. orBec(R) is intended to reduce the need for systemic immunosuppressive drugs to treat GI GVHD. BDP is a highly potent, topically active corticosteroid that has a local effect on inflamed tissue. BDP has been marketed in the US and worldwide since the early 1970s as the active pharmaceutical ingredient in a nasal spray and in a metered dose inhaler for the treatment of patients with allergic rhinitis and asthma. orBec(R) is formulated for oral administration as a single product consisting of two tablets; one tablet is intended to release BDP in the proximal portions of the GI tract, and the other tablet is intended to release BDP in the distal portions of the GI tract.

In addition to issued patents and pending worldwide patent applications held by or exclusively licensed to DOR, orBec(R) also benefits from orphan drug designations in the US and in Europe for the treatment of GI GVHD, which provide for seven and 10 years of post-approval market exclusivity, respectively.

About GI GVHD

GI GVHD is a debilitating and painful disease. It is a common disorder among immuno-compromised cancer patients after receiving allogeneic stem cell or bone marrow transplants. Unlike organ transplants where the patient’s body may reject the organ, in GVHD it is the donor cells that begin to attack the patient’s body — most frequently the gastrointestinal tract, liver and skin. Patients with mild-to-moderate GI GVHD typically develop symptoms of anorexia, nausea, vomiting and diarrhea. If left untreated, GI GVHD can progress to ulcerations in the lining of the GI tract, and in its most severe form, can be fatal.

About Allogeneic Bone Marrow/Stem Stem Cell Transplantation (HSCT)

HSCT is considered a potentially curative option for many leukemias as well as other forms of blood cancer. In an allogeneic HSCT procedure, hematopoietic stem cells are harvested from a closely matched relative or unrelated person, and are transplanted into the patient following either high-dose chemotherapy or intense immunosuppressive conditioning therapy. The curative potential of allogeneic HSCT is now partly attributed to the so-called graft-versus-leukemia or graft-versus-tumor effects of the newly transplanted donor cells to recognize and destroy malignant cells in the recipient patient.

The use of allogeneic HSCT has grown substantially over the last decade due to advances in human immunogenetics, the establishment of unrelated donor programs, the use of cord blood as a source of hematopoietic stem cells and the advent of non-myeloablative conditioning regimens (“mini-transplants”) that avoid the side effects of high-dose chemotherapy. Based on the latest statistics available, it is estimated that there are more than 12,000 HSCT procedures annually in the US and a comparable number in Europe. Estimates as to the current annual rate of increase in these procedures are as high as 20%. High rates of morbidity and mortality occur in this patient population. Clinical trials are also underway testing allogeneic HSCT for treatment of some metastatic solid tumors such as breast cancer, renal cell carcinoma, melanoma and ovarian cancer. Allogeneic transplants have also been used as curative therapy for several genetic disorders, including immunodeficiency syndromes, inborn errors of metabolism, thalassemia and sickle cell disease. The primary toxicity of allogeneic HSCT, however, is GVHD. In GVHD, the newly transplanted donor cells damage cells in the recipient’s gastrointestinal tract, liver and skin.

About DOR BioPharma, Inc.

DOR BioPharma, Inc. (DOR) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR’s lead product, orBec(R) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of bone marrow transplantation. DOR filed a New Drug Application for orBec(R) with the FDA for the treatment of acute GI GVHD and received a not approvable letter in which the FDA has requested data from a confirmatory Phase 3 clinical trial to demonstrate the safety and efficacy of orBec(R). orBec(R) is currently the subject of an NIH-supported, Phase 2, randomized, double-blind, placebo-controlled trial in the prevention of acute GVHD. Oral BDP may also have application in treating other gastrointestinal disorders characterized by severe inflammation. Additionally, DOR has a Lipid Polymer Micelle (LPM(TM)) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.

Through its Biodefense Division, DOR is developing biomedical countermeasures pursuant to the Project BioShield Act of 2004. DOR’s biodefense products in development are recombinant subunit vaccines designed to protect against the lethal effects of exposure to ricin toxin, botulinum toxin and anthrax. DOR’s ricin toxin vaccine, RiVax(TM), has been shown to be well tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers.

For further information regarding DOR BioPharma, Inc., please visit the Company’s website located at www.dorbiopharma.com.

This press release contains forward-looking statements that reflect DOR BioPharma, Inc.’s current expectations about its future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,””believes,””intends,” or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. DOR cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec(R), particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that it will be able to secure partnerships or obtain financing within the next nine months to meet operating expenses and to conduct its upcoming confirmatory Phase 3 trial of orBec(R), that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec(R) for gastrointestinal GVHD include the risks that: the FDA’s requirement that DOR conduct additional clinical trials to demonstrate the safety and efficacy of orBec(R) will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; DOR is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec(R) may not gain market acceptance if it is eventually approved by the FDA; and others may develop technologies or products superior to orBec(R). These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR’s most recent reports on Forms 10-Q and 10-KSB. Unless required by law, DOR assumes no obligation to update or revise any forward-looking statements as a result of new information, future events.

 Company Contact:  Evan Myrianthopoulos Chief Financial Officer (609) 538-8200 www.dorbiopharma.com  DOR BioPharma, Inc. 850 Bear Tavern Road, Suite 201 Ewing, NJ 08628  

SOURCE: DOR BioPharma, Inc.

Three Rivers Pharmaceuticals(R), LLC Obtains Additional Commercial Rights to Infergen(R) From Amgen Inc.

CRANBERRY TOWNSHIP, Pa., Sept. 17 /PRNewswire/ — Three Rivers Pharmaceuticals, LLC announced today that it has signed a definitive license agreement with Amgen Inc. to expand its commercial rights to the hepatitis C drug Infergen. Three Rivers Pharmaceuticals will obtain commercial rights to Infergen in all markets except Japan. In addition, Three Rivers Pharmaceuticals will obtain commercial rights to China effective March 31, 2009. Three Rivers Pharmaceuticals currently has commercial rights to Infergen in the United States and Canada.

“The expansion of commercial rights to Infergen compliments Three Rivers Pharmaceuticals strategy to continue to grow its hepatitis C franchise,” stated Patrick Kerrish RPh., MBA Three Rivers Pharmaceuticals’ Executive Vice President of Business Development.

Three Rivers Pharmaceuticals will seek marketing partners to assist with the commercialization of Infergen outside of the United States. Interested marketing partners should contact Patrick Kerrish at [email protected] .

Infergen, or consensus interferon, is a unique, bio-optimized, selective and highly potent type 1 interferon alpha originally developed by Amgen and launched in the United States in 1997. Infergen is indicated for the treatment of chronic HCV infection in patients 18 years of age or older with compensated liver disease who have anti-HCV serum antibodies and /or the presence of HCV RNA.

Important Safety Information

Physicians and patients can obtain additional prescribing information regarding Infergen, including the product’s safety profile and the box warning for all interferon alphas regarding neuropsychiatric, autoimmune, ischemic and infectious disorders, by visiting http://www.infergen.com/ .

About Three Rivers Pharmaceuticals

Three Rivers Pharmaceuticals is a privately held company headquartered in Cranberry Township, Pennsylvania that focuses on specialized therapies including hepatitis C therapies. With its unique experience and understanding of the complex challenges of treating chronic, difficult diseases, Three Rivers is a valuable partner in the healthcare community.

The company’s mission is to develop, manufacture, and market the highest quality branded and generic drug products for patients with serious diseases. Three Rivers Pharmaceuticals focuses on the specialized therapies because of its extensive knowledge and experience in this area. More information about the company can be found at http://www.3riverspharma.com/ .

Three Rivers Pharmaceuticals, LLC

CONTACT: Patrick Kerrish of Three Rivers Pharmaceuticals,+1-724-778-6013, [email protected]

Web site: http://www.3riverspharma.com/http://www.infergen.com/

Listening to Resveratrol

By Kent, David M

IN MY CAMBRIDGE, Massachusetts, neighborhood, competing restaurants have promoted opposing gastronomic and life strategies. The motto at Jae’s, a “nouvelle” Pan-Asian cafe specializing in presenting small, stylized foods on oversized white plates, was “Eat at Jae’s. Live forever!” The sign next door at Jake and Earl’s take- out grill read “Eat BBQ. Die Happy!” Although neither establishment survived long, the stark choice that together they presented- between a savory, greasy gluttony and a long life-conforms to some deeply rooted and more enduring puritanical logic. Indeed, until recently the only approach researchers had found to effectively extend lifespan-whether in a single-celled organism or a mammal-was through severe caloric restriction. Countless people have accordingly taken up caloric-restriction diets in the hope that it will work in humans too. Though this tactic is unproven, my friends who have tried it assure me that, at the very least, their lives will certainly seem longer. Biotechnology, however, presently promises to offer us a more palatable means of attaining a longer life than perpetual semi-starvation.

Calorie deprivation appears to slow aging through the activation of members of a family of enzymes called sirtuins, which belong to a larger group called deacetylases. These enzymes appear to reduce cell death by protecting cells against reactive oxygen species and DNA damage. Perhaps the most seminal work in this area came from David A. Sinclair’s laboratory at Harvard, which described a group of compounds, including resveratrol (famously in red wine), that stimulate the activity of sirtuins across a variety of species. Resveratrol also has been found to increase lifespan in a variety of laboratory animals, including simple worms, fruit flies and short- lived fish. More recently, Sinclair and his colleagues reported that resveratrol can improve health and survival in mice fed a high- calorie diet (perhaps of Jake and Earl’s BBQ).

Not surprisingly, these findings led to a spike in the sale of red wine (which apparently has such small amounts of active resveratrol as to be biologically inert at drinkable doses) as well as over-the-counter nonalcoholic wine-derived dietary supplements (of variable activity). In order to develop and bring to market more potent-and patentable-alternatives, Sinclair helped to create a company, called Sirtris. In June of this year, only four years after it was founded, Sirtris was bought by the pharmaceutical giant GlaxoSmithKline for a tidy $720 million. Who can doubt that commercially available life-extending compounds are around the corner? Even if the effects in humans are less dramatic than those of resveratrol in yeast (60 percent increase in replicative lifespan) or than in the overfed mouse (15 percent increase in lifespan), it seems that we are on the cusp of a dramatic shift in medicine, one for which we may not be fully prepared.

Life’s Natural Limits

In the July 1980 issue of the New England Journal of Medicine, James F. Fries proposed an influential model of health and illness based on the observation that there appear to be, even in the absence of disease, natural limits to the human lifespan. According to this view, aging is a natural and inevitable part of life. It is marked by a decline in organ function that begins in our 30s and eventually reaches a critical state in which even small perturbations in homeostasis cannot be tolerated. The benefits of modern medicine, it follows, would be confined to preventing premature death and compressing sickness toward the end of life, not fundamentally prolonging our natural lifespan.

Fries supported his model with a set of curves that plot survival against age over the 20th century (see the graph on page 360). As the curves show, improvements in medicine and public health have increased average life expectancy at birth enormously (close to 30 years), whereas the life expectancy of an 80-year-old has hardly increased at all (about two years). This “rectangularization” of the life expectancy function lends support to Fries’s concept of fundamental limits on the human lifespan, and suggests that-at least for richer segments of the population-life expectancy is approaching those limits. Therefore, according to Fries, in the future we should expect diminishing returns in mortality gains for new treatments of infectious diseases, cardiovascular diseases, cancer and the like. Medical innovation, he argued, should concentrate instead on living better, by “compressing” morbidity to the very end of life, not on living longer.

However, discoveries in more basic sciences, such as our developing understanding of sirtuin activators, suggest that this model may be at least half wrong. There may be natural limits to the mortality gains we should expect from disease-specific therapies, as Fries suggested. But by influencing the basic mechanisms underlying aging, medical innovations of the 21st century may yet increase the human lifespan in ways he did not foresee. Indeed, since the remaining frontier for mortality reduction is largely at the end of life, aging itself will have to be addressed and the shape of progress must be altered if there are to be any mortality gains from our huge investment in medical science and technology. Thus, a new set of curves, extending life expectancy beyond the frontier at the far right of the survival function, could well describe gains in life expectancy in the coming 100 years.

Immortality’s Cost

We may be on the brink of an important and unrecognized change in medical technology development, one that raises important questions about the future of medicine and human health.

How will we test the efficacy and safety of new life-prolonging technologies?

Currently our drug development and approval systems aim at disease-specific treatments. Indeed, the Food and Drug Administration approves medications only for specific indications, and “mortality,” a universal condition, would seem unlikely to qualify under the current system. Further, if senescence begins in one’s 30s but the outcome (that is, death) can be measured only in one’s 70s or 80s, how will researchers be able to perform timely clinical trials in humans? Sinclair and others hoping to commercialize anti-aging elixirs have devised a strategy of testing agents for the treatment of age-related diseases, such as specific forms of cancer, Alzheimer’s disease and heart disease. Yet Sinclair also reports that he started taking resveratrol in his 30s-a reasonable course for an anti-aging agent-but such use will remain “off-label” unless we create a new system, including reliable surrogate outcomes, to test and approve such compounds for this purpose.

How much will life-prolonging therapies cost-and who will pay?

Health insurance is based on the principle of risk pooling. Because nobody can be certain that they will remain healthy, the disease-free are willing to share the cost burden with the sick, who often are unable to handle the expense of their own care. This approach works with disease-oriented treatments in which risks are pooled across those people who could and those who actually do develop an illness. But if resveratrol-like drugs are recommended for everybody over 30 at risk for mortality (a universal condition), there would be no risk pooling; insurance premiums for everybody would just go up by the drugs’ cost (plus an administrative fee).

Although drug pricing strategies remain a deeply held trade secret among pharmaceutical companies, there is little doubt that there will be consumers willing to pay very high prices for life- prolonging elixirs, even for drugs with a relatively small incremental benefit. The optimal pricing strategy for such agents might put them well out of reach of the poor and possibly also some of the middle class. Since multiple cellular pathways are probably involved in aging, there are sure to be multiple medicines in our antiaging cocktail. The rich have always lived longer and healthier lives than the poor, and new lifespan-extending technologies could widen this gap.

Should access to resveratrol and other such agents be an entitlement? Many societies see access to health care to cure diseases and rescue patients from premature death as a matter of equity. What ethical attitude will we take toward 21st-century medical technologies aimed at challenging the limits of our natural lifespan?

How will lifespan-prolonging therapies affect population growth and demographic structure, and what will be the consequences?

In the past century, disease-specific medicine reduced mortality at all ages, including the economically productive years between one’s 20s and 60s. But the rectangularization of the mortality curve implies that life-prolonging therapies will add years only at the end of life. Unless there is a shift in the retirement age, 21st- century medical innovation will have an even more dramatic effect on the dependency ratio (a measure of the portion of a population composed of those either too old or too young to work). Maintaining retirement as a widespread option at around 65, already an economic stretch, undoubtedly will become untenable. The price of longer life will almost certainly be a longer work life. Society’s Demands

There are many who would argue that significant extension of the human lifespan remains a pipe dream. Aging, they argue, is an over- determined process of cellular entropy, a ubiquitous force with so much empirical evidence that it has its own law of thermodynamics. There are too many cellular pathways that would have to be halted or reversed in order to alter aging. But if we were mice, this inevitable process would culminate in two years, not 85 years; if we were dogs in about 12 years. The extreme elasticity of aging is evident in the range of lifespans among our mammalian cousins.

Indeed, the plasticity of lifespan across species is not mere accident, but a consequence of one of the central levers of evolution. In his 1977 book Ontogeny and Phylogeny, Steven J. Gould provides a persuasive account of how changes in the timing of developmental events have manifold consequences on size, form and life history, such that small alterations in the regulatory genes governing these processes may be a central mechanism of evolution. seen in this way, lifespan is a fundamental part of the identity of an organism. It is a well-accepted rule that natural selection among complexly social animals favors delayed development; this delay permits the expansion of the central nervous system necessary for complex social life and a prolonged apprenticeship before sexual maturation. Such trends among social animals have reached an extreme in humans: we exhibit delayed sexual maturation, long gestation, reduced number of offspring and long and intense parental support.

As social complexity has increased through cultural evolution, our need for increased differentiation and specialization has outstripped even our extreme biological adaptations. In my own field of medicine, it is typical for training and apprenticeship to extend well into the fourth decade of life. Recently, in vitro fertilization has been enthusiastically adopted into our culture to allow women to defer childbearing beyond their natural period of fertility, permitting women to more fully participate and compete in the workplace. Among most people I know, technology-assisted pregnancy in one’s fifth decade is seen as more normal than pregnancy in one’s late teens, a time where natural fertility is near its peak. Given their early, yet unmistakable, signs of talent and ambition, and the ever-increasing complexity of the global society and market in which they’ll need to find their place, my own daughters (ages two and six) might well opt to defer childbearing until well after they are 40. Indeed, should they choose to do so, I am certain that they will have the technology to enable this choice, and perhaps also anti-aging agents that would still permit them to dance at their own grandchildren’s weddings.

In this way, resveratrol-like agents may truly be medicines for the 21st century, permitting humans to tinker with the clock of our own development. Through such means we may be able to adjust our life history to meet the demands of an emerging society that changes in ways that seem beyond our control. Judging from our past behavior, it is hard to imagine that science or the marketplace will pause very long to consider the important questions raised by the possibility of life-prolonging pharmaceuticals. It seems hardly a fair fight when the potential and uncertain consequences to society are pitted against the urgent, deeply rooted, biologically programmed desires and demands of the individuals of which it is composed.

Could the famous ingredient of red wine herald a new era in medicine?

Bibliography

Fries, J. F. 1983. The compression of morbidity. The Millbank Memorial Fund Quarterly 61:397-419.

Fries, J. F. 1980. Aging, natural death and the compression of morbidity. The New England Journal of Medicine 303:130-135.

Wood, J., et al 2004. Sirtuin activators mimic calorie restriction and delay aging in metazoans. Nature 430:686-689.

David M. Kent is an associate professor of medicine at Tufts Medical Center and an associate professor of clinical research at the Sackler School for Graduate Biomedical Sciences of Tufts University. Address: Tufts Medical Center, 800 Washington St #63, Boston MA 02111. Internet: [email protected]

Copyright Sigma XI-The Scientific Research Society Sep/Oct 2008

(c) 2008 American Scientist. Provided by ProQuest LLC. All rights Reserved.